

**Instructions for the  
Capital Assessments and Stress Testing information collection  
(Reporting Form FR Y-14A)**

**DRAFT**

This Report is required by law: section 165 of the Dodd-Frank Act (12 U.S.C. § 5365) and section 5 of the Bank Holding Company Act (12 U.S.C. § 1844). Public reporting burden for this information collection is estimated to vary from approximately 10 to 987 hours per response, with an average of 159 hours per response, including time to gather and maintain data in the required form and to review instructions and complete the information collection. Comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing the burden, may be sent to Secretary, Board of Governors of the Federal Reserve System, 20th and C Streets, NW, Washington, DC 20551, and to the Office of Management and Budget, Paperwork Reduction Project (7100-0341), Washington, DC 2050

## Contents

GENERAL INSTRUCTIONS.....	4
<b>WHO MUST REPORT .....</b>	5
<b>WHERE TO SUBMIT THE REPORTS .....</b>	6
<b>WHEN TO SUBMIT THE REPORTS .....</b>	6
<b>HOW TO PREPARE THE REPORTS: .....</b>	8
Schedule A—Summary.....	11
<b>A.1 INCOME STATEMENT, BALANCE SHEET, AND CAPITAL .....</b>	11
A.1.a— <i>Income Statement</i> .....	12
A.1.b— <i>Balance Sheet</i> .....	27
A.1.c— <i>Risk-Weighted Assets (RWA)</i> .....	41
A.1.c.1— <i>Standardized RWA</i> .....	41
A.1.c.2— <i>Advanced RWA</i> .....	48
A.1.d— <i>Capital</i> .....	49
<b>A.2 RETAIL .....</b>	65
A.2.a— <i>Retail Balance and Loss Projections</i> .....	65
A.2.b— <i>Retail Repurchase Projections</i> .....	70
<b>A.3 AFS/HTM SECURITIES .....</b>	73
A.3.a— <i>Projected OTTI for AFS Securities and HTM by Security</i> .....	75
A.3.b— <i>High-Level OTTI Methodology and Assumptions for AFS and HTM Securities by Portfolio</i> .....	75
A.3.c— <i>Projected OTTI for AFS and HTM Securities by Portfolio</i> .....	75
A.3.d— <i>Projected OCI and Fair Value for AFS and Impaired HTM</i> .....	76
A.3.e— <i>Actual AFS and HTM Fair Market Value Sources by Portfolio</i> .....	76
<b>A.4 TRADING .....</b>	77
<b>A.5 COUNTERPARTY CREDIT RISK (CCR)</b> .....	79
<b>A.6 BHC OR IHC OPERATIONAL RISK SCENARIO INPUTS AND PROJECTIONS</b> .....	80
<b>A.7 PRE-PROVISION NET REVENUE (PPNR) .....</b>	82
A.7.a— <i>PPNR Projections Sub-schedule</i> .....	85
A.7.b— <i>PPNR Net Interest Income (NII) Sub-schedule</i> .....	101
A.7.c— <i>PPNR Metrics</i> .....	110
Schedule B—Scenario.....	123
Schedule C—Regulatory Capital Instruments .....	126
Schedule D—Regulatory Capital Transitions.....	149
<b>D.1—CAPITAL COMPOSITION .....</b>	151
<b>D.2—EXCEPTION BUCKET CALCULATOR .....</b>	161
<b>D.3—ADVANCED RISK-WEIGHTED ASSETS.....</b>	164
<b>D.4—STANDARDIZED RISK-WEIGHTED ASSETS .....</b>	171
<b>D.5—LEVERAGE EXPOSURE .....</b>	177
<b>D.6—PLANNED ACTIONS .....</b>	182
<i>Additional Information Required for Each Planned Action</i> .....	182

<b><i>Column Instructions</i></b> .....	<b>182</b>
Schedule E—Operational Risk.....	185
<b>E.1—BHC OR IHC LEGAL RESERVES REPORTING</b> .....	<b>185</b>
<b>E.2—MATERIAL RISK IDENTIFICATION</b> .....	<b>185</b>
<b>E.3—OPERATIONAL RISK SCENARIOS</b> .....	<b>185</b>
Schedule F – Business Plan Changes.....	185
Schedule G – Retail Repurchase Exposures .....	189
Appendix A: Supporting Documentation.....	194

## GENERAL INSTRUCTIONS

The Capital Assessments and Stress Testing Report (FR Y-14A report) collects detailed data on quantitative projections of balance sheet assets and liabilities, income, losses, and capital across a range of macroeconomic scenarios and qualitative information on methodologies used to develop internal projections of capital across scenarios. It applies to bank holding companies (BHCs) with total consolidated assets of \$50 billion or more and intermediate holding companies (IHCs) foreign banking organizations (collectively referred to as "BHCs").

The FR Y-14A report is comprised of a Summary, Scenario, Regulatory Capital Instruments, Regulatory Capital Transitions, Operational Risk, Business Plan Changes, and Retail Repurchase Exposure schedules, each with multiple supporting sub-schedules. The number of schedules a BHC or IHC must complete is subject to materiality thresholds and certain other criteria. For instance, large and noncomplex firms<sup>1</sup> are not required to complete certain sub-schedules. BHCs and IHCs report projections on the FR Y-14A schedules across supervisory scenarios provided by the Federal Reserve (supervisory baseline, adverse and severely adverse), as well as BHC or IHC defined scenarios (BHC baseline and BHC stress). One or more of the macroeconomic scenarios includes a market risk shock that the BHCs or IHCs will assume when making trading and counterparty loss projections. The Federal Reserve will provide details about the macroeconomic scenarios to the BHCs and IHCs.

BHCs and IHCs are also required to submit qualitative information supporting their projections, including descriptions of the methodologies used to develop the internal projections of capital across scenarios and other analyses that support their comprehensive capital plans. Further information regarding the qualitative and technical requirements of required supporting documentation is provided in individual schedules as appropriate, as well as in Appendix A: Supporting Documentation.

As noted, this document includes requirements and supervisory expectations related to supporting documentation for all BHCs and IHCs subject to the Y-14 reporting requirements. That supporting documentation is intended to help to ensure that BHCs and IHCs subject to Y-14 reporting requirements provide accurate and comprehensive information for their Y-14 reports. In certain cases, particularly as outlined in Appendix A, this document describes additional expectations for certain capital planning practices to help support BHCs' and IHCs' Y-14 reporting. However, this document is not intended to describe the full set of expectations for capital planning. The full set of capital planning expectations have been consolidated in two Federal Reserve supervisory letters, SR Letters 15-18 and 15-19, issued in December 2015. Importantly, those two SR letters clarify that the capital planning expectations for LISCC<sup>2</sup> and large and complex firms<sup>3</sup> (as defined in those letters) are higher than the expectations for Large and Noncomplex Firms (as defined in those

---

<sup>1</sup> A large and noncomplex firm is a BHC or a U.S. intermediate holding company subsidiary of a foreign banking organization (IHC) with total consolidated assets of at least \$50 billion but less than \$250 billion; total consolidated nonbank assets of less than \$75 billion, and is not a U.S. GSIB.

<sup>2</sup> A LISCC firm is a BHC that is subject to the Federal Reserve's Large Institution Supervisory Coordinating Committee (LISCC) framework.

<sup>3</sup> A large and complex firm is a BHC, other than a LISCC firm, with total consolidated assets of \$250 billion or more, or nonbank assets of \$75 billion or more.

letters).<sup>4</sup> A BHC or IHC should refer to SR Letter 15-18 or SR Letter 15-19, as applicable, for the capital planning expectations applicable to that BHC or IHC (depending on the BHC's or IHC's size and complexity), as this document applies to all BHCs and IHCs subject to Y-14 reporting. To the extent that this document references expectations that may not be applicable to a large and noncomplex firm pursuant to SR Letter 15-19, a large and noncomplex firm will not be held to those expectations but should instead refer to the expectations in SR Letter 15-19.

## **Who Must Report**

### **A. Reporting Criteria**

BHCs and IHCs with total consolidated assets of \$50 billion or more, as defined by the capital plan rule (12 CFR 225.8), are required to submit the Capital Assessment and Stress Testing report (FR Y-14A/Q/M) to the Federal Reserve. The capital plan rule defines total consolidated assets as the average of the company's total consolidated assets over the course of the previous four calendar quarters, as reflected on the BHC's or IHC's Consolidated Financial Statement for Bank Holding Companies (FR Y-9C). Total assets shall be calculated based on the due date of the bank or intermediate holding company's most recent FR Y-9C. If the BHC or IHC has not filed an FR Y-9C for each of the four most recent quarters, the average of the BHC's or IHC's total consolidated assets in the most recent consecutive quarters as reported quarterly on the BHC's or IHC's FR Y-9C should be used in the calculation.

Separate annual schedules must be reported for each scenario as required, unless otherwise specified in the schedule or sub-schedule instructions (for example for historical data collections on the Retail Repurchase sub-schedule, for which only the baseline scenario is required). Certain data elements within the annual schedules are subject to materiality thresholds. The instructions to these data schedules provide details on how to determine whether a BHC or IHC must submit a specific schedule, sub-schedule, or data element.

All annual schedules are required to be reported by all BHCs and IHCs with the exception of certain sub-schedules of the Summary schedule, which should be filed as described below:

***Securities OTTI methodology, Securities Market Value Source, Securities OTTI by Security, Retail Repurchase, Trading, Counterparty, and Advanced RWA sub-schedules (Summary Schedule):***  
Large and noncomplex firms are not required to complete these subschedules.

***CCR schedule and Trading and CCR sub-schedules (Summary Schedule):*** BHCs and IHCs with greater than \$500 billion in total consolidated assets who are subject to the amended market risk rule (12 CFR Parts 208, Appendix E and 225 Appendix E) must submit this schedule and sub-schedules. Additionally, the Board or the Director of the Division of Banking Supervision and Regulation of the Federal Reserve Board, acting under delegated authority, may require any company to complete the CCR schedule and sub-schedule under 12 CFR 252.144(b)(2).must submit this schedule and sub-schedules.

---

<sup>4</sup> SR Letter 15-18 sets forth capital planning expectations for BHCs and IHCs that are subject to the Federal Reserve's Large Institution Supervisory Coordinating Committee (LISCC) framework and Large and Complex Firms. SR Letter 15-19 sets forth capital planning expectations for Large and Noncomplex Firms, as defined in the capital plan rule.

## **B. Exemptions**

BHCs and IHCs that do not meet the reporting criteria listed above are exempt from reporting. The following institutions are also exempt:

BHCs, IHCs, savings and loan holding companies (SLHCs) and state member banks (SMBs) with average total consolidated assets of greater than \$10 billion but less than \$50 billion subject to the final rule on annual company-run stress tests (12 CFR 252(h)) are not required to file this report. However, institutions meeting this threshold should review the reporting requirements and instructions for the Annual Company-Run Stress Test Projections (FR Y-16) on the Board's public website.

SLHCs are currently not required to comply with FR Y-14A reporting requirements. Further information regarding reporting for SLHCs will be provided in the future.<sup>5</sup>

## **Where to Submit the Reports**

All BHCs and IHCs subject to these reporting requirements must submit completed reports electronically via the IntraLinks website. BHCs and IHCs will be provided information on how to transmit data to the FR Y-14 IntraLinks Collaboration website. Requests for access to the IntraLinks site should be sent to [ccar.support@ccar.frb.org](mailto:ccar.support@ccar.frb.org).

For requirements regarding the submission of qualitative supporting information, please see Appendix A: Supporting Documentation, in addition to instructions associated with each schedule for which supporting documentation might be required.

## **When to Submit the Reports**

BHCs and IHCs must file the FR Y-14A schedules annually or semi-annually according to the appropriate time schedules described below. All schedules will be due on or before the end of the submission date (unless that day falls on a weekend (subject to timely filing provisions)). Early submission, including submission of schedules on a flow basis prior to the due date, aids the Federal Reserve in reviewing and processing data and is encouraged.

If the submission date falls on a weekend or holiday, the data must be received on the first business day after the weekend or holiday. No other extensions of time for submitting reports will be granted.

---

<sup>5</sup> SLHCs would not be subject to Dodd-Frank annual company-run stress testing requirements until the next calendar year after the SLHCs become subject to regulatory capital requirements.

Schedules and Sub-Sub-schedules	Data as-of-date	Submission Date to Federal Reserve
<b>Semi-annual Schedules</b>		
<b>Summary, Macro Scenario</b>	<ul style="list-style-type: none"> <li>• Data as-of December 31st.</li> <li>• Data as-of June 30th.</li> </ul>	<ul style="list-style-type: none"> <li>• Data are due April 5th of the following year.</li> <li>• Data are due October 5th of the same year.</li> <li>• Adjusted summary schedule submission: The Federal Reserve will notify companies at least 14 calendar days in advance of the date on which it expects companies to submit any adjusted capital actions.</li> </ul>
<b>Retail Repurchase Exposures</b>	<ul style="list-style-type: none"> <li>• Data as-of December 31st.</li> <li>• Data as-of June 30th.</li> </ul>	Data are due seven days after the FR Y-9C reporting schedule: Reported data (52 calendar days after the calendar quarter-end for December and 47 calendar days after the calendar quarter-end for June).
<b>Annual Schedules</b>		
<b>Regulatory Capital Transitions, Operational Risk and Business Plan Changes schedules</b>	<ul style="list-style-type: none"> <li>• Data as-of December 31st.</li> </ul>	<ul style="list-style-type: none"> <li>• Data are due April 5th of the following year.</li> </ul>
<b><u>CCAR Market Shock exercise</u></b> <b>Summary schedule</b> <ul style="list-style-type: none"> <li>• <b>Trading Risk</b></li> <li>• <b>Counterparty</b></li> </ul>	Data as-of a specified date in the first quarter. As-of-date would be communicated by Federal Reserve <sup>6</sup>	Data are due April 5th
<b>Regulatory Capital Instruments</b>	<ul style="list-style-type: none"> <li>• Data as-of December 31st.</li> </ul>	<ul style="list-style-type: none"> <li>• Original submission: Data are due April 5th of the following year.</li> <li>• Adjusted submission: The Federal Reserve will notify companies at least 14 calendar days in advance of</li> </ul>

<sup>6</sup> As outlined in Sections 252.144 (Annual Stress Tests) of Regulation YY (12 CFR 252), the as-of date will be between January 1st and March 1st of that calendar year and will be communicated to the BHCs by March 1st of the calendar year. BHCs are permitted to submit the CCR schedule and the Trading and CCR sub-schedules of the Summary schedule as-of another recent reporting date prior to the supplied as-of date as appropriate.

		<p>the date on which it expects companies to submit any adjusted capital actions.</p> <ul style="list-style-type: none"> <li>• Incremental submission: At the time the firm seeks approval for additional capital distributions (see 12 CFR 225.8(g)) or notify the Federal Reserve of its intention to make additional capital distributions under the de minimis exception (see 12 CFR 225.8(g)(2)).</li> </ul>
--	--	---

## **How to Prepare the Reports:**

### **A. Applicability of GAAP**

BHCs and IHCs are required to prepare and file the FR Y-14A schedules in accordance with U.S. generally accepted accounting principles (GAAP) and these instructions. The financial records of the BHCs and IHCs should be maintained in such a manner and scope to ensure the FR Y-14A is prepared in accordance with these instructions and reflects a fair presentation of the BHCs' or IHCs' financial condition and assessment of performance under stressed scenarios.

### **B. Rules of Consolidation**

Please reference the FR Y-9C General Instructions for a discussion regarding the rules of consolidation.

### **C. Projections**

Many schedules collect data on a “projection horizon”, which includes one quarter of actual data followed by at least nine quarters of projected data. Where projections are required, the following applies:

- The “projection horizon” refers to the nine quarters starting with the first quarter of the reporting year (e.g., from the first quarter of 2013 through the first quarter of 2015).
- Column headings refer to PQ1 through PQ9. PQ stands for projected quarter. PQ1 through PQ9 are nine quarterly projections over which the planning horizon extends.
- In some cases, the projected quarters will extend beyond the nine-quarter planning horizon (as is the case of projected future losses charged to the repurchase reserve), necessitating PQ10 or more.

### **D. Technical Details**

The following instructions apply generally to the FR Y-14A schedules, unless otherwise specified. For further information on the technical specifications for this report, please see the Technical Instructions.

- Do not enter any information in gray highlighted or shaded cells, including those with embedded formulas. Only non-shaded cells should be completed by institutions.
- Ensure that any internal consistency checks are complete prior to submission.
- Report dollar values in millions of US dollars (unless specified otherwise).
- Dates should be entered in an YYYYMMDD format (unless specified otherwise).
- Report negative numbers with a minus (-) sign.
- Report data as an integer (unless specified otherwise)

- An amount, zero or null should be entered for all items, except in those cases where other options such as “not available” or “other” are specified. If information is not available or not applicable and no such options are offered, the field should be left blank.
- Report income and loss data on a quarterly basis, and not on a cumulative or year-to-date basis.

#### **E. Other Instructional Guidance**

BHCs should review the following published documents (in the order listed below) when determining the precise definition to be used in completing the schedules. Where applicable, references to the FR Y-9C have been provided in the FR Y-14A instructions and templates noting associations between the reporting series.

- The FR Y-14A instructions;
- The FR Y-14 Q/M instructions;
- The latest available FR Y-9C instructions published on the Federal Reserve’s public web site: <http://www.federalreserve.gov/reportforms>

For purposes of completing certain FR Y-14A schedules, BHCs and IHCs should also consult the following references for relevant guidance:

- The most recent CapPR Instructions
- The most recent CCAR Instructions

#### **F. Confidentiality**

As these data will be collected as part of the supervisory process, they are subject to confidential treatment under exemption 8 of the Freedom of Information Act (5 U.S.C. 552(b)(8)). In addition, commercial and financial information contained in these information collections may be exempt from disclosure under Exemption 4.5 (U.S.C. 552(b)(4)). Disclosure determinations would be made on a case-by-case basis.

#### **G. Amended Reports**

The Federal Reserve will require the filing of amended reports if previous submissions contain significant errors. In addition, a reporting institution must file an amended report when it or the Federal Reserve discovers significant errors or omissions subsequent to submission of a report. Failure to file amended reports on a timely basis may subject the institution to supervisory action.

If resubmissions are required, institutions should contact the appropriate Reserve Bank, as well as the FR Y-14 mailbox at [info@ccar.frb.org](mailto:info@ccar.frb.org), and resubmit data via the Intralinks website.

#### **H. Questions and Requests for Interpretations**

BHCs should submit any questions or requests for interpretations by e-mail to [info@CCAR.frb.org](mailto:info@CCAR.frb.org).

#### **I. Attestation**

For Bank Holding Companies that are part of the Federal Reserve’s Large Institution Supervision Committee portfolio,<sup>7</sup> the Capital Assessments and Stress Testing (FR Y-14A/Q/M) data submission must be signed by the chief financial officer or an equivalent senior officer. By signing the cover page of this report, the authorized officer acknowledges that any knowing and willful misrepresentation or omission of a material fact on this report constitutes fraud in the inducement and may subject the

---

<sup>7</sup> <http://www.federalreserve.gov/bankinforeg/large-institution-supervision.htm>

officer to legal sanctions provided by 18 USC 1001 and 1007. Material weaknesses in internal controls or material errors or omissions in the data submitted must be reported through the respondent's designated Federal Reserve System contacts as they are identified.

The cover page for the FR Y-14A/Q/M attestation should be submitted with the FR Y-14A submission for the FR Y-14A, FR Y-14Q and FR Y-14M reports as of December 31, 2016. The cover page for the FR Y-14Q/M and FR Y-14A semi-annual (as-of June 30) attesting to conformance to instructions and materially correctness of the data should be submitted with all other semi-annual, quarterly and monthly submissions in 2017. Effective December 31, 2017, there will a new FR Y-14A cover page (including internal controls throughout the year for the FR Y-14Q/M) to be submitted with the annual FR Y-14A submission. The FR Y-14Q/M cover page should continue to be submitted quarterly and monthly with the FR Y-14Q and FR Y-14M submission, respectively, and for the FR Y-14A semi-annual submission as-of June 30.

*A signed version of the attestation cover page should be submitted concurrently with the report submission electronically in Intralinks, and respondents must maintain in their files a signed attestation cover page.*

## **Schedule A—Summary**

### **General Instructions**

This document contains instructions for the FR Y-14A Summary schedule. The schedule includes data collection sub-schedules related to the following:

1. Income Statement, Balance Sheet, and Capital Statements;
2. Retail;
3. Securities;
4. Trading;
5. Counterparty Credit Risk;
6. Operational Risk; and
7. Pre-Provision Net Revenue (PPNR).

The bank holding company (BHC) or intermediate holding company (IHC) should submit a **separate** Summary schedule for **each** scenario.

A BHC or IHC that decides the supervisory baseline scenario is appropriate for its BHC or IHC baseline scenario should still submit an FR Y-14A for each scenario. The two submissions would differ in that the supervisory baseline FR Y-14A would contain a completed Capital - CCAR and Capital - DFAST; the BHC or IHC baseline submission would not contain a completed Capital - DFAST.

Under the BHC baseline, supervisory baseline, supervisory adverse, and supervisory severely adverse scenarios, BHCs and IHCs should report the FR Y-14A summary schedule's worksheets, other than "Capital - DFAST" where applicable, assuming planned capital actions.

Under the BHC stress scenario, BHCs and IHCs should report the FR Y-14A summary schedule's worksheets assuming alternative capital actions. The BHC stress scenario submission would not contain a completed Capital - DFAST.

Each year the Board provides each BHC and IHC with the opportunity to adjust its planned capital actions based on the preliminary results of CCAR. A BHC or IHC that uses this opportunity and submits adjusted planned capital actions must submit an updated FR Y-14A Summary schedule Capital - CCAR worksheet under the BHC Baseline, Supervisory Adverse, and Supervisory Severely Adverse scenarios. This submission would be labeled the "Adjusted" submission. The Board will notify companies of the date on which it expects companies to submit planned capital actions at least 14 calendar days prior to the expected deadline for submitted planned capital actions. Incremental capital actions would be submitted at the time the firm wishes to seek approval for additional capital distributions (see 12 CFR 225.8(g)) or notify the Federal Reserve of its intention to make additional capital distributions under the de minimis exception of the capital plan rule (see 12 CFR 225.8(g)(2)).

### **Supporting Documentation**

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

#### **A.1 Income Statement, Balance Sheet, and Capital**

### **A.1.a—Income Statement**

The Income Statement sub-schedule collects projections for the main components of the income statement. Federal Reserve Micro Data Reference Manual (MDRM) codes are provided in the 'Notes' column for many of the line items.<sup>8</sup> Where applicable, use the definitions for the FR Y-9C line items corresponding to the MDRM code. For each scenario used, input the loan loss projections for the various line items in this sub-schedule. The BHC or IHC should include losses tied to the relevant balances reported on the Balance Sheet sub-schedule. Losses associated with held for investment loans accounted for at amortized cost should be reported in the appropriate line items under the "Losses Associated With Loans Held for Investment Accounted for at Amortized Cost" section and any losses due to changes in the fair value of assets that are held for sale or held for investment under the fair value option should be reported in the appropriate line items under the "Losses Associated With Loans Held for Sale and Loans Accounted for Under the Fair Value Option" section.

For Corporate and CRE loans, if an MDRM number is not provided, use the same definitions as provided in the FR Y-14Q Corporate and Commercial Real Estate schedules. For credit card loans, use the same definitions as provided in the FR Y-14M Credit Card schedule. The Repurchase Reserve/Liability for Mortgage Reps and Warrants line items are included to provide information on the expected evolution of any reserve or accrued liability that has been established for losses related to sold or government- insured mortgage loans (first or second lien). Losses charged to this reserve can occur through contractual repurchases, settlement agreement, or litigation loss, including losses related to claims under securities law or fraud claims; it is likely that most losses charged to this reserve will come through contractual repurchases or settlements. Quarterly reserve/accrued liability levels and quarterly provisions and net charge-offs to the reserve/accrued liability should be reported as forecast under the applicable scenario. To ensure consistency across the sheets of each FR Y-14A summary workbook, the Provisions during the quarter line is linked to the PPNR Projections Sub-schedule rows where BHCs and IHCs are expected to report any provisions to the Repurchase Reserve/Liability for Mortgage Reps and Warrants. For the same reason, the Net charges during the quarter line is linked to Table G.3 in the Retail Repurchase Sub-schedule.

#### **Line items 1 through 43 LOSSES ASSOCIATED WITH LOANS HELD FOR INVESTMENT AT AMORTIZED COST:**

##### **Line item 1 Real estate loans (in domestic offices)**

This item is a shaded cell and is derived from the sum of items 2, 5, 8 and 14.

##### **Line item 2 First lien mortgages (including HELOANS)**

This item is a shaded cell and is derived from the sum of items 3 and 4.

##### **Line item 3 First lien mortgages**

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, excluding closed-end

---

<sup>8</sup> Each MDRM code is associated with a specific line item (data cell) on the FR Y-9C report. See <http://www.federalreserve.gov/reportforms/mdrm/> for a list of MDRM codes and data descriptions.

first lien home equity loans (reported in item 4).

**Line item 4 First lien home equity loans (HELOANS)**

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end first lien home equity loans.

**Line item 5 Second/junior lien mortgages**

This item is a shaded cell and is derived from the sum of items 6 and 7.

**Line item 6 Closed-end junior loans**

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties.

**Line item 7 Home equity lines of credit (HELOCS)**

Report losses associated with loans held for investment accounted for at amortized cost on the amount outstanding under revolving, open-end lines of credit secured by 1 to 4 family residential properties.

**Line item 8 Commercial real estate (CRE) loans**

This item is a shaded cell and is derived from the sum of items 9, 10, and 11.

**Line item 9 Construction**

Report losses associated with loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2).

**Line item 10 Multifamily**

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d).

**Line item 11 Nonfarm, nonresidential**

This item is a shaded cell and is derived from the sum of items 12 and 13.

**Line item 12 Owner-occupied**

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1).

**Line item 13 Non-owner-occupied**

Report losses associated with loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2).

**Line item 14 Loans secured by farmland**

Report losses associated with loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

**Line item 15 Real estate loans (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 16, 17, 18 and 24.

**Line item 16 First lien mortgages (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, not held in domestic offices.

**Line item 17 Second/junior lien mortgages (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on all loans secured by second/junior (i.e., other than first) liens on 1 to 4 family residential properties, not held in domestic offices.

**Line item 18 Commercial real estate (CRE) loans (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 19, 20, and 21.

**Line item 19 Construction (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), not held in domestic offices.

**Line item 20 Multifamily (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), not held in domestic offices.

**Line item 21 Nonfarm, nonresidential (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 22 and 23.

**Line item 22 Owner-occupied (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1), not held in domestic offices.

**Line item 23 Non-owner-occupied (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2), not held in domestic offices.

**Line item 24 Loans secured by farmland (Not in domestic offices)**

Report losses associated with loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

**Line item 25 C&I Loans**

This item is a shaded cell and is derived from the sum of items 26, 27 and 28.

**Line item 26 C&I Graded**

Report losses associated with loans held for investment accounted for at amortized cost on all graded commercial and industrial (C&I) loans. Report only loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes losses associated with domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

**Line item 27 Small Business (Scored/Delinquency Managed)**

Report losses associated with loans held for investment accounted for at amortized cost on small business loans. Report all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

**Line item 28 Business and Corporate Card**

Report losses associated with loans held for investment accounted for at amortized cost on loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude losses associated with corporate card or charge card loans included in Line item 26 (C&I Graded Loans).

**Line item 29 Credit Cards**

Report losses associated with loans held for investment accounted for at amortized cost on loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 30 Other Consumer**

This item is a shaded cell and is derived from the sum of items 31, 32, 33 and 34.

**Line item 31 Auto Loans**

Report losses associated with loans held for investment accounted for at amortized cost on auto loans, as defined in the FR Y-9C, Schedule HC-C, item 6(c).

**Line item 32 Student Loans**

Report losses associated with loans held for investment accounted for at amortized cost on student loans.

**Line item 33 Other (consumer) loans backed by securities (non-purpose lending)**

Report losses associated with loans held for investment accounted for at amortized cost on other

consumer loans that are backed by securities (i.e., non-purpose lending).

**Line item 34 Other (consumer)**

Report losses associated with loans held for investment accounted for at amortized cost on all other consumer loans not reported in items 31, 32 or 33.

**Line item 35 Other Loans**

This item is a shaded cell and is derived from the sum of items 36, 37, 38, 39 and 40.

**Line item 36 Loans to Foreign Governments**

Report losses associated with loans held for investment accounted for at amortized cost on loans to foreign governments, as defined in the FR Y-9C, Schedule HC-C, item 7. Exclude losses associated with loans to foreign governments included in Line item 27 (Small Business Loans).

**Line item 37 Agricultural Loans**

Report losses associated with loans held for investment accounted for at amortized cost on agricultural loans, as defined in the FR Y-9C, Schedule HC-C, item 3. Exclude losses associated with agricultural loans included in Line item 27 (Small Business Loans).

**Line item 38 Loans for Purchasing or Carrying Securities (secured or unsecured)**

Report losses associated with loans held for investment accounted for at amortized cost on loans for purchasing or carrying securities (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(1). Exclude losses associated with loans for purchasing or carrying securities included in Line item 27 (Small Business Loans).

**Line item 39 Loans to Depositories and Other Financial Institutions**

Report losses associated with loans held for investment accounted for at amortized cost on loans to depositories and other financial Institutions (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, and 9.a. Exclude losses associated with loans to depositories and other financial institutions included in Line item 27 (Small Business Loans).

**Line item 40 All Other Loans and Leases**

This item is a shaded cell and is derived from the sum of items 41 and 42.

**Line item 41 All Other Loans (exclude consumer loans)**

Report losses associated with loans held for investment accounted for at amortized cost on all other loans (excluding consumer loans), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(2). Exclude losses associated with all other loans included in Line item 27 (Small Business Loans).

**Line item 42 All Other Leases**

Report losses associated with loans held for investment accounted for at amortized cost on all other leases (excluding consumer leases), as defined in the FR Y-9C, Schedule HC-C, item 10.b. Exclude losses associated with all other leases included in Line item 27 (Small Business Loans).

**Line item 43 Total Loans and Leases**

Report the sum of items 1, 15, 25, 29, 30 and 35.

**Line items 44 through 57 LOSSES ASSOCIATED WITH HELD FOR SALE LOANS AND LOANS ACCOUNTED FOR UNDER THE FAIR VALUE OPTION:**

**Line item 44 Real estate loans (in domestic offices)**

This item is a shaded cell and is derived from the sum of items 45, 46, 47 and 48.

**Line item 45 First Lien Mortgages**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all closed-end loans secured by first liens on 1 to 4 family residential properties, including closed-end first lien home equity loans.

**Line item 46 Second/Junior Lien Mortgages**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties.

**Line item 47 Commercial real estate (CRE) loans**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all construction, multifamily, and nonfarm nonresidential loans, as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2).

**Line item 48 Loans secured by farmland**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

**Line item 49 Real estate loans (not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 50, 51 and 52.

**Line item 50 Residential Mortgages (not in domestic offices)**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by 1 to 4 family residential properties, including both first lien and second/junior lien loans, not held in domestic offices.

**Line item 51 Commercial real estate (CRE) loans (not in domestic offices)**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all construction, multifamily, and nonfarm nonresidential loans, as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2), not held in domestic offices.

**Line item 52 Loans secured by farmland (not in domestic offices)**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

**Line item 53 C&I Loans**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all commercial and industrial loans, as defined in items 26, 27 and 28.

**Line item 54 Credit Cards**

Report losses associated with held for sale loans and loans accounted for under the fair value option on loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 55 Other Consumer**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all other consumer loans, as defined in items 31, 32, 33 and 34.

**Line item 56 All Other Loans and Leases**

Report losses associated with held for sale loans and loans accounted for under the fair value option on all other loans and leases, as defined in items 36, 37, 38, 39, 41 and 42.

**Line item 57 Total Loans and Leases**

This item is a shaded cell and is derived from the sum of items 44, 49, 53, 54, 55 and 56.

**Line items 58 through 63 TRADING ACCOUNT:****Line item 58 Trading Mark-to-market (MTM) Losses**

Line item 58 must equal the sum of the totals reported in item 10 on the Trading Schedule, with the sign reversed.

**Line item 59 Trading Issuer Default Losses**

Line item 59 must equal item 1 on the Counterparty Risk Schedule.

**Line item 60 Counterparty Credit MTM Losses (CVA losses)**

Line item 60 must equal item 2 on the Counterparty Risk Schedule.

**Line item 61 Counterparty Default losses**

Line item 61 must equal item 3 on the Counterparty Risk Schedule.

**Line item 62 Total Trading and Counterparty losses**

This item is a shaded cell and is derived from the sum of items 58, 59, 60, and 61. BHCs should include Schedule A.5 – Counterparty Credit Risk worksheet item 4 “Other Counterparty Losses” in item 65 “Other Losses” on this worksheet.

**Line items 63 through 67 OTHER LOSSES:****Line item 63 Goodwill Impairment**

Report losses associated with goodwill impairment, as defined in the FR Y-9C, Schedule HC, item 10(a). Under GAAP (ASC 350-20-35-30), "Goodwill of a reporting unit shall be tested for impairment between annual tests if an event occurs or circumstances change that would more likely than not

reduce the fair value of a reporting unit below its carrying amount." However, it is acceptable for purposes of this exercise to provide annual estimates as long as the resulting quarterly capital projections would not differ materially from those generated using quarterly impairment projections.

**Line item 64 Valuation Adjustment for firm's own debt under fair value option (FVO)**

Report losses associated with the valuation adjustment for the firm's own debt under the fair value option (FVO).

**Line item 65 Other losses**

Report all other losses not reported in items 1 through 65. Describe these losses in the supporting documentation.

**Line item 66 Total Other Losses**

Report the sum of all other losses included in items 63, 64, and 65.

**Line item 67 Total Losses**

Report the sum of items 43, 57, 62 and 66.

**Line items 68 through 116 ALLOWANCE FOR LOAN AND LEASE LOSSES (ALLL):**

**Line item 68 ALLL prior quarter**

Report the total allowance for loan and lease losses as of the end of the prior quarter.

**Line item 69 Real Estate Loans (in Domestic Offices)**

Report the sum of items 70, 74, and 78.

**Line item 70 Residential Mortgages (in Domestic Offices)**

Report the sum of the allowance for loan and lease losses included in items 71, 72, and 73.

**Line item 71 First Lien Mortgages (in Domestic Offices)**

Report the allowance for loan and lease losses for all loans secured by first liens on 1 to 4 family residential properties, including first lien home equity loans, held in domestic offices.

**Line item 72 Closed-end Junior Liens (in Domestic Offices)**

Report the allowance for loan and lease losses for all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties, held in domestic offices.

**Line item 73 HELOCs (in Domestic Offices)**

Report the allowance for loan and lease losses for revolving, open-end lines of credit secured by 1 to 4 family residential properties, held in domestic offices.

**Line item 74 CRE Loans (in Domestic Offices)**

Report the sum of the allowance for loan and lease losses included in items 76, 77 and 78.

**Line item 75 Construction (in Domestic Offices)**

Report the allowance for loan and lease losses for construction, land development, and other land

loans (as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2)), held in domestic offices.

**Line item 76 Multifamily (in Domestic Offices)**

Report the allowance for loan and lease losses for loans secured by multifamily (5 or more) residential properties (as defined in the FR Y-9C, Schedule HC-C, item 1(d)), held in domestic offices.

**Line item 77 Nonfarm, Non-residential (in Domestic Offices)**

Report the allowance for loan and lease losses for loans secured by nonfarm nonresidential properties (as defined in the FR Y-9C, Schedule HC-C, items 1(e)(1) and 1(e)(2), held in domestic offices.

**Line item 78 Loans Secured by Farmland (in Domestic Offices)**

Report the allowance for loan and lease losses for loans secured by farmland (as defined in the FR Y-9C, Schedule HC-C, item 1(b)), held in domestic offices.

**Line item 79 Real Estate Loans (Not in Domestic Offices)**

Report the sum of items 81, 82 and 83.

**Line item 80 Residential Mortgages (Not in Domestic Offices)**

Report the allowance for loan and lease losses for all loans secured by 1 to 4 family residential properties, including both first lien and second/junior lien loans, not held in domestic offices.

**Line item 81 CRE Loans (Not in Domestic Offices)**

Report the allowance for loan and lease losses for all construction, multifamily, and nonfarm nonresidential loans (as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2)), not held in domestic offices.

**Line item 82 Farmland (Not in Domestic Offices)**

Report the allowance for loan and lease losses for all loans secured by farmland (as defined in the FR Y-9C, Schedule HC-C, item 1(b)), not held in domestic offices.

**Line item 83 C&I Loans**

Report the sum of items 85, 86 and 87.

**Line item 84 C&I Graded**

Report the allowance for loan and lease losses for all graded commercial and industrial (C&I) loans. Report the associated allowance only for loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes the allowance for loan and lease losses for all domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

**Line item 85 Small Business (Scored/Delinquency Managed)**

Report the allowance for loan and lease losses for small business loans. Report the associated allowance for all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding

corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

**Line item 86 Business and Corporate Card**

Report the allowance for loan and lease losses for loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude the allowance for loan and lease losses related to corporate card or charge card loans included in Line item 85 (C&I Graded Loans).

**Line item 87 Credit Cards**

Report the allowance for loan and lease losses for loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 88 Other Consumer**

Report the allowance for loan and lease losses for all other consumer loans, as defined in items 31, 32, 33 and 34.

**Line item 89 All Other Loans and Leases**

Report the allowance for loan and lease losses for all other loans and leases, as defined in items 36, 37, 38, 39, 41 and 42.

**Line item 90 Unallocated**

Report any unallocated portion of the allowance for loan and lease losses.

**Line item 91 Provisions during the quarter**

Report the provision for loan and lease losses during the quarter, as defined in the FR Y-9C, Schedule HI, item 4.

**Line item 92 Real Estate Loans (in Domestic Offices)**

Report the sum of items 93, 97, and 101.

**Line item 93 Residential Mortgages (in Domestic Offices)**

Report the sum of the provision for loan and lease losses included in items 94, 95, and 96.

**Line item 94 First Lien Mortgages (in Domestic Offices)**

Report the provision for loan and lease losses for all loans secured by first liens on 1 to 4 family residential properties, including first lien home equity loans, held in domestic offices.

**Line item 95 Closed-end Junior Liens (in Domestic Offices)**

Report the provision for loan and lease losses for all closed-end loans secured by junior (i.e., other

than first) liens on 1 to 4 family residential properties, held in domestic offices.

**Line item 96 HELOCs (in Domestic Offices)**

Report the provision for loan and lease losses for revolving, open-end lines of credit secured by 1 to 4 family residential properties, held in domestic offices.

**Line item 97 CRE Loans (in Domestic Offices)**

Report the sum of the provision for loan and lease losses included in items 98, 99, and 100.

**Line item 98 Construction (in Domestic Offices)**

Report the provision for loan and lease losses for construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), held in domestic offices.

**Line item 99 Multifamily (in Domestic Offices)**

Report the provision for loan and lease losses for loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), held in domestic offices.

**Line item 100 Nonfarm, Non-residential (in Domestic Offices)**

Report the provision for loan and lease losses for loans secured by nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, items 1(e)(1) and 1(e)(2), held in domestic offices.

**Line item 101 Loans Secured by Farmland (in Domestic Offices)**

Report the provision for loan and lease losses for loans secured by farmland as defined in the FR Y-9C, Schedule HC-C, item 1(b), held in domestic offices.

**Line item 102 Real Estate Loans (Not in Domestic Offices)**

Report the sum of items 104, 105 and 106.

**Line item 103 Residential Mortgages (Not in Domestic Offices)**

Report the provision for loan and lease losses for all loans secured by 1 to 4 family residential properties, including both first lien and second/junior lien loans, not held in domestic offices.

**Line item 104 CRE Loans (Not in Domestic Offices)**

Report the provision for loan and lease losses for all construction, multifamily, and nonfarm nonresidential loans, as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1) and 1.e.(2), not held in domestic offices.

**Line item 105 Farmland (Not in Domestic Offices)**

Report the provision for loan and lease losses for all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

**Line item 106 C&I Loans**

Report the sum of items 107, 108, and 109.

**Line item 107 C&I Graded**

Report the provision for loan and lease losses for all graded commercial and industrial (C&I) loans.

Report the associated provision only for loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes the provision for loan and lease losses for all domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

**Line item 108 Small Business (Scored/Delinquency Managed)**

Report the provision for loan and lease losses for small business loans. Report the associated provision for all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b of schedule HC-C of the FR Y-9C excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

**Line item 109 Business and Corporate Cards**

Report the provision for loan and lease losses for loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude the provision for loan and lease losses related to corporate card or charge card loans included in Line item 107 (C&I Graded Loans).

**Line item 110 Credit Cards**

Report the provision for loan and lease losses for loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 111 Other Consumer**

Report the provision for loan and lease losses for all other consumer loans, as defined in items 31, 32, 33 and 34.

**Line item 112 All Other Loans and Leases**

Report the provision for loan and lease losses for all other loans and leases, as defined in items 36, 37, 38, 39, 41 and 42.

**Line item 113 Unallocated**

Report any unallocated portion of the provision for loan and lease losses.

**Line item 114 Net charge-offs during the quarter**

Report charge-offs net of recoveries during the quarter, as defined in the FR Y-9C, Schedule HI-B, Part I, item 9, Column A minus Column B.

**Line item 115 Other ALLL Changes**

Report other changes to the allowance for loan and lease losses, as defined in the FR Y-9C, Schedule HI-B, Part II, item 6, minus Schedule HI-B, Part II, item 4.

**Line item 116 ALLL, current quarter**

Report the sum of items 68, 91 and 115, minus item 114.

**Line items 117 through 120 PRE-PROVISION NET REVENUE (PPNR):****Line item 117 Net interest income**

Line item 117 must equal item 13 on the PPNR Submission Sub-schedule.

**Line item 118 Noninterest income**

Line item 118 must equal item 26 on the PPNR Submission Sub-schedule.

**Line item 119 Noninterest expense**

Line item 119 must equal item 38 on the PPNR Submission Sub-schedule.

**Line item 120 Pre-provision Net Revenue**

Report the sum of items 117 and 118, minus item 119.

**Line items 121 through 135 CONDENSED INCOME STATEMENT:****Line item 121 Pre-provision Net Revenue**

Report the value for item 120.

**Line item 122 Provisions during the quarter**

Report the value for item 91.

**Line item 123 Total Trading and Counterparty Losses**

Report the value for item 62.

**Line item 124 Total Other Losses**

Report the value for item 66.

**Line item 125 Other Income Statement (I/S) Items**

Report other income statement items that the institution chooses to disclose. Describe these items in the supporting documentation.

**Line item 126 Realized Gains (Losses) on available-for-sale securities, including OTTI**

Report realized gains (losses) on available-for-sale securities, as defined in the FR Y-9C, Schedule HI, item 6.b. For the projected quarters, this amount represents projected other-than-temporary impairment losses on available-for-sale securities and realized gains and losses on available-for-sale securities. Gains and losses from sales of available-for-sale securities, other than OTTI, should not be allowed unless there is an existing contractual or legal obligation to sell a security or a security has

already been sold.

**Line item 127 Realized Gains (Losses) on held-to-maturity securities, including OTTI**

Report realized gains (losses) on held-to-maturity securities, as defined in the FR Y-9C, Schedule HI, item 6.a. For the projected quarters, this amount represents projected other-than-temporary impairment losses on held-to-maturity securities and realized gains and losses on held-to-maturity securities. Gains and losses from sales of held-to-maturity securities, other than OTTI, should not be allowed unless there is an existing contractual or legal obligation to sell a security or a security has already been sold.

**Line item 128 Income (loss) before taxes and extraordinary items**

Report the sum of items 121, 125, 126, and 127, minus items 122, 123, and 124.

**Line item 129 Applicable income taxes (foreign and domestic)**

Report all applicable income taxes, both foreign and domestic, as defined in the FR Y-9C, Schedule HI, item 9.

**Line item 130 Income (loss) before extraordinary items and other adjustments**

Report the amount of item 128 minus item 129.

**Line item 131 Extraordinary items and other adjustments, net of income taxes**

Report all extraordinary items and other adjustments, net of income taxes, as defined in the FR Y-9C, Schedule HI, item 11.

**Line item 132 Net income (loss) attributable to BHC or IHC and minority interests**

Report the sum of item 130 and item 131.

**Line item 133 Net income (loss) attributable to minority interests**

Report net income (loss) attributable to minority interests, as defined in the FR Y-9C, Schedule HI, item 13.

**Line item 134 Net income (loss) attributable to BHC or IHC**

Report the amount of item 132 minus item 133.

**Line item 135 Effective Tax Rate (%)**

Report the amount of item 132 divided by item 133, multiplied by 100.

**Line items 136 through 139 REPURCHASE RESERVE/LIABILITY FOR MORTGAGE REPS AND WARRANTIES:**

**Line item 136 Reserve, prior quarter**

Report the amount of any reserve or accrued liability that was established in the prior quarter for losses related to sold or government-insured mortgage loans (first or second lien).

**Line item 137 Provisions during the quarter**

Report the amount of provisions during the quarter to the repurchase reserve/liability for mortgage

representations and warranties.

**Line item 138 Net charges during the quarter**

Report the amount of net charges (charges less recoveries) during the quarter to the repurchase reserve/liability for mortgage representations and warranties. Losses charged to this reserve can occur through contractual repurchases, settlement agreement, or litigation loss, including losses related to claims under securities law or fraud claims.

**Line item 139 Reserve, current quarter**

Report the sum of items 136 and 137 minus item 138.

## **A.1.b—Balance Sheet**

For each scenario used, input the loan balance projections in the various line items in this sub-schedule. Balance projections for loans held in the loans held for investment portfolio should be reported in the appropriate line items in the “Loans Held for Investment at Amortized Cost” and balances for held for sale or held for investment under the fair value option should be reported in the appropriate line items in the “Loans Held for Sale and Loans Accounted for Under the Fair Value Option” section. MDRM codes are provided within the ‘Notes’ column for many of the line items. When applicable, the definition of the BHC’s or IHC’s projections should correlate to the definitions outlined by the corresponding MDRM code within the FR Y-9C report. Domestic refers to portfolios in the domestic US offices (as defined in the FR Y-9C report), and International refers to portfolios outside of the domestic US offices.

Explain any M&A and divestitures included and how they are funded (liabilities, asset sales, etc.)

### **Line items 1 through 3 SECURITIES**

#### **Line item 1 Held to Maturity (HTM)**

Report the amount of held-to-maturity securities, as defined in the FR Y-9C, Schedule HC, item 2.a.

#### **Line item 2 Available for Sale (AFS)**

Report the amount of available-for-sale securities, as defined in the FR Y-9C, Schedule HC, item 2.b.

#### **Line item 3 Total Securities**

This item is a shaded cell and is derived from the sum of items 1 and 2.

#### **Line item 4 Securitizations (investment grade)**

Investment grade means that the entity to which the Board-regulated institution is exposed through a loan or security, or the reference entity with respect to a credit derivative, has adequate capacity to meet financial commitments for the projected life of the asset or exposure. Such an entity or reference entity has adequate capacity to meet financial commitments if the risk of its default is low and the full and timely repayment of principal and interest is expected.

#### **Line item 5 Securitizations (non-investment grade)**

Securitizations that do not meet the investment grade definition above.

### **Line items 6 through 51 TOTAL LOANS AND LEASES:**

#### **Line item 6 Real estate loans (in domestic offices)**

This item is a shaded cell and is derived from the sum of items 7, 10, 13 and 19.

#### **Line item 7 First lien mortgages (including HELOANS)**

This item is a shaded cell and is derived from the sum of items 8 and 9.

**Line item 8 First lien mortgages**

Report loans secured by first liens on 1 to 4 family residential properties, excluding closed-end first lien home equity loans (reported in item 7).

**Line item 9 First lien home equity loans (HELOANS)**

Report all closed-end first lien home equity loans.

**Line item 10 Second/junior lien mortgages**

This item is a shaded cell and is derived from the sum of items 11 and 12.

**Line item 11 Closed-end junior loans**

Report all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b).

**Line item 12 Home equity lines of credit (HELOCS)**

Report the amount outstanding under revolving, open-end lines of credit secured by 1 to 4 family residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1).

**Line item 13 Commercial real estate (CRE) loans**

This item is a shaded cell and is derived from the sum of items 14, 15, and 16.

**Line item 14 Construction**

Report construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2).

**Line item 15 Multifamily**

Report loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d).

**Line item 16 Nonfarm, non-residential**

This item is a shaded cell and is derived from the sum of items 17 and 18.

**Line item 17 Owner-occupied**

Report loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1).

**Line item 18 Non-owner-occupied**

Report nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2).

**Line item 19 Loans secured by farmland**

Report all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

**Line item 20 Real estate loans (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 21, 22, 23 and 29.

**Line item 21 First lien mortgages (Not in domestic offices)**

Report all closed-end loans secured by first liens on 1 to 4 family residential properties, not held in domestic offices.

**Line item 22 Second/junior lien mortgages (Not in domestic offices)**

Report all loans secured by second/junior (i.e., other than first) liens on 1 to 4 family residential properties, not held in domestic offices.

**Line item 23 Commercial real estate (CRE) loans (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 24, 25, and 26.

**Line item 24 Construction (Not in domestic offices)**

Report construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), not held in domestic offices.

**Line item 25 Multifamily (Not in domestic offices)**

Report loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), not held in domestic offices.

**Line item 26 Nonfarm, non-residential (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 27 and 28.

**Line item 27 Owner-occupied (Not in domestic offices)**

Report loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1), not held in domestic offices.

**Line item 28 Non-owner-occupied (Not in domestic offices)**

Report nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2), not held in domestic offices.

**Line item 29 Loans secured by farmland (Not in domestic offices)**

Report all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

**Line item 30 C&I Loans**

This item is a shaded cell and is derived from the sum of items 31, 32, 33 and 34.

**Line item 31 C&I Graded**

Report all graded commercial and industrial (C&I) loans. Report only loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

**Line item 32 Small Business (Scored/Delinquency Managed)**

Report all "scored" or "delinquency managed" U.S. small business loans for which a commercial

internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

**Line item 33 Corporate Card**

Report loans extended under corporate credit cards. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude corporate card loans included in Line item 31 (C&I Graded Loans).

**Line item 34 Business Card**

Report loans extended under business credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level).

**Line item 35 Credit Cards**

This item is a shaded cell and is derived from the sum of items 36 and 37.

**Line item 36 Charge Cards**

Report loans extended under consumer general purpose or private label credit cards that have terms and conditions associated with a charge card. Instead of having a stated interest rate, charge cards have an annual fee and an interchange fee. Also customers must pay off the loan within the billing cycle, which is typically one month. General purpose charge cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student card if applicable. Private label charge cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 37 Bank Cards**

Report loans extended under consumer general purpose or private label credit cards that have terms and conditions associated with a bank card. A bank card will have a stated interest rate and a minimum payment amount due within the billing cycle. General purpose bank cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label bank cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 38 Other Consumer**

This item is a shaded cell and is derived from the sum of items 39, 40, 41 and 42.

**Line item 39 Auto Loans**

Report all auto loans, as defined in the FR Y-9C, Schedule HC-C, item 6(c).

**Line item 40 Student Loans**

Report all student loans.

**Line item 41 Other (consumer) loans backed by securities (non-purpose lending)**

Report other consumer loans that are backed by securities (i.e., non-purpose lending).

**Line item 42 Other (consumer)**

Report all other consumer loans not reported in items 39, 40 or 41.

**Line item 43 Other Loans**

This item is a shaded cell and is derived from the sum of items 44, 45, 46, 47 and 48.

**Line item 44 Loans to Foreign Governments**

Report all loans to foreign governments, as defined in the FR Y-9C, Schedule HC-C, item 7. Exclude loans to foreign governments included in Line item 32 (Small Business Loans).

**Line item 45 Agricultural Loans**

Report all agricultural loans, as defined in the FR Y-9C, Schedule HC-C, item 3. Exclude agricultural loans included in Line item 32 (Small Business Loans).

**Line item 46 Loans for Purchasing or Carrying Securities (secured or unsecured)**

Report all loans for purchasing or carrying securities (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(1). Exclude loans for purchasing or carrying securities included in Line item 32 (Small Business Loans).

**Line item 47 Loans to Depositories and Other Financial Institutions**

Report all loans to depositories and other financial Institutions (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, and 9.a. Exclude loans to depositories and other financial institutions included in Line item 32 (Small Business Loans).

**Line item 48 All Other Loans and Leases**

This item is a shaded cell and is derived from the sum of items 49 and 50.

**Line item 49 All Other Loans (exclude consumer loans)**

Report all other loans (excluding consumer loans), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(2). Exclude all other loans included in Line item 32 (Small Business Loans).

**Line item 50 All Other Leases**

Report all other leases (excluding consumer leases), as defined in the FR Y-9C, Schedule HC-C, item 10.b. Exclude all other leases included in Line item 32 (Small Business Loans).

**Line item 51 Total Loans and Leases**

Report the sum of items 6, 20, 30, 35, 38 and 43.

**Line items 52 through 94 LOANS HELD FOR INVESTMENT AT AMORTIZED COST:**

**Line item 52 Real estate loans (in domestic offices)**

This item is a shaded cell and is derived from the sum of items 53, 56, 59 and 65.

**Line item 53 First lien mortgages (including HELOANS)**

This item is a shaded cell and is derived from the sum of items 54 and 55.

**Line item 54 First lien mortgages**

Report loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, excluding closed-end first lien home equity loans (reported in item 53).

**Line item 55 First lien home equity loans (HELOANS)**

Report loans held for investment accounted for at amortized cost on all closed-end first lien home equity loans.

**Line item 56 Second/junior lien mortgages**

This item is a shaded cell and is derived from the sum of items 57 and 58.

**Line item 57 Closed-end junior loans**

Report loans held for investment accounted for at amortized cost on all closed-end loans secured by junior (i.e., other than first) liens on 1 to 4 family residential properties.

**Line item 58 Home equity lines of credit (HELOCS)**

Report loans held for investment accounted for at amortized cost on the amount outstanding under revolving, open-end lines of credit secured by 1 to 4 family residential properties.

**Line item 59 Commercial real estate (CRE) loans**

This item is a shaded cell and is derived from the sum of items 60, 61, and 62.

**Line item 60 Construction**

Report loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2).

**Line item 61 Multifamily**

Report loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d).

**Line item 62 Nonfarm, nonresidential**

This item is a shaded cell and is derived from the sum of items 63 and 64.

**Line item 63 Owner-occupied**

Report loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1).

**Line item 64 Non-owner-occupied**

Report loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2).

**Line item 65 Loans secured by farmland**

Report loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b).

**Line item 66 Real estate loans (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 67, 68, 69 and 75.

**Line item 67 First lien mortgages (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on all closed-end loans secured by first liens on 1 to 4 family residential properties, not held in domestic offices.

**Line item 68 Second/junior lien mortgages (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on all loans secured by second/junior (i.e., other than first) liens on 1 to 4 family residential properties, not held in domestic offices.

**Line item 69 Commercial real estate (CRE) loans (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 70, 71, and 72.

**Line item 70 Construction (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on construction, land development, and other land loans, as defined in the FR Y-9C, Schedule HC-C, items 1(a)(1) and 1(a)(2), not held in domestic offices.

**Line item 71 Multifamily (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on loans secured by multifamily (5 or more) residential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(d), not held in domestic offices.

**Line item 72 Nonfarm, nonresidential (Not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 73 and 74.

**Line item 73 Owner-occupied (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on loans secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(1), not held in domestic offices.

**Line item 74 Non-owner-occupied (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on nonfarm nonresidential real estate loans that are not secured by owner-occupied nonfarm nonresidential properties, as defined in the FR Y-9C, Schedule HC-C, item 1(e)(2), not held in domestic offices.

**Line item 75 Loans secured by farmland (Not in domestic offices)**

Report loans held for investment accounted for at amortized cost on all loans secured by farmland, as defined in the FR Y-9C, Schedule HC-C, item 1(b), not held in domestic offices.

**Line item 76 C&I Loans**

This item is a shaded cell and is derived from the sum of items 77, 78 and 79.

**Line item 77 C&I Graded**

Report loans held for investment accounted for at amortized cost on all graded commercial and industrial (C&I) loans. Report only loans "graded" or "rated" using the reporting entity's commercial credit rating system, as it is defined in the reporting entity's normal course of business. This includes domestic and international business and corporate credit card or charge card loans for which a commercially graded corporation is ultimately responsible for repayment of credit losses incurred.

**Line item 78 Small Business (Scored/Delinquency Managed)**

Report loans held for investment accounted for at amortized cost on small business loans. Report all "scored" or "delinquency managed" U.S. small business loans for which a commercial internal risk rating is not used or that uses a different scale than other corporate loans reported in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a, 4.b, 7, 9.a, 9.b.1, 9.b.2, 10.b, excluding corporate and small business credit card loans included in the FR Y-9C, Schedule HC-C, line 4.a.

**Line item 79 Business and Corporate Card**

Report loans held for investment accounted for at amortized cost on loans extended under business and corporate credit cards. Business cards include small business credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as applicant. Report at the control account level or the individual pay level (not at the sub-account level). Corporate cards include employer-sponsored credit cards for use by a company's employees. Exclude corporate card or charge card loans included in Line item 77 (C&I Graded Loans).

**Line item 80 Credit Cards**

Report loans held for investment accounted for at amortized cost on loans extended under consumer general purpose or private label credit cards. General purpose credit cards are credit cards that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity, co-brand cards in this category, and student cards if applicable. Private label credit cards are credit cards, also known as proprietary credit cards, tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil & gas cards in this loan type, and student cards if applicable.

**Line item 81 Other Consumer**

This item is a shaded cell and is derived from the sum of items 82, 83, 84 and 85.

**Line item 82 Auto Loans**

Report loans held for investment accounted for at amortized cost on auto loans, as defined in the FR Y-9C, Schedule HC-C, item 6(c).

**Line item 83 Student Loans**

Report loans held for investment accounted for at amortized cost on student loans.

**Line item 84 Other (consumer) loans backed by securities (non-purpose lending)**

Report loans held for investment accounted for at amortized cost on other consumer loans that are backed by securities (i.e., non-purpose lending).

**Line item 85 Other (consumer)**

Report loans held for investment accounted for at amortized cost on all other consumer loans not reported in items 82, 83 or 84.

**Line item 86 Other Loans and Leases**

This item is a shaded cell and is derived from the sum of items 87, 88, 89, 90 and 91.

**Line item 87 Loans to Foreign Governments**

Report loans held for investment accounted for at amortized cost on loans to foreign governments, as defined in the FR Y-9C, Schedule HC-C, item 7. Exclude loans to foreign governments included in Line item 78 (Small Business Loans).

**Line item 88 Agricultural Loans**

Report loans held for investment accounted for at amortized cost on agricultural loans, as defined in the FR Y-9C, Schedule HC-C, item 3. Exclude agricultural loans included in Line item 78 (Small Business Loans).

**Line item 89 Loans for Purchasing or Carrying Securities (secured or unsecured)**

Report loans held for investment accounted for at amortized cost on loans for purchasing or carrying securities (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(1). Exclude loans for purchasing or carrying securities included in Line item 78 (Small Business Loans).

**Line item 90 Loans to Depositories and Other Financial Institutions**

Report loans held for investment accounted for at amortized cost on loans to depositories and other financial institutions (secured or unsecured), as defined in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, and 9.a. Exclude loans to depositories and other financial institutions included in Line item 78 (Small Business Loans).

**Line item 91 All Other Loans and Leases**

This item is a shaded cell and is derived from the sum of items 92 and 93.

**Line item 92 All Other Loans (exclude consumer loans)**

Report loans held for investment accounted for at amortized cost on all other loans (excluding consumer loans), as defined in the FR Y-9C, Schedule HC-C, item 9.b.(2). Exclude all other loans included in Line item 78 (Small Business Loans).

**Line item 93 All Other Leases**

Report loans held for investment accounted for at amortized cost on all other leases (excluding consumer leases), as defined in the FR Y-9C, Schedule HC-C, item 10.b. Exclude all other leases included in Line item 78 (Small Business Loans).

**Line item 94 Total Loans and Leases**

Report the sum of items 52, 66, 76, 80, 81 and 86.

**Line items 95 through 111 HELD FOR SALE LOANS AND LOANS ACCOUNTED FOR UNDER THE FAIR VALUE OPTION:****Line item 95 Real estate loans (in domestic offices)**

This item is a shaded cell and is derived from the sum of items 96, 97, 98 and 99.

**Line item 96 First Lien Mortgages**

This item is a shaded cell and is derived as item 7 minus item 53.

**Line item 97 Second/Junior Lien Mortgages**

This item is a shaded cell and is derived as item 10 minus item 56.

**Line item 98 Commercial real estate (CRE) loans**

This item is a shaded cell and is derived as item 13 minus item 59.

**Line item 99 Loans secured by farmland**

This item is a shaded cell and is derived as item 19 minus item 65.

**Line item 100 Real estate loans (not in domestic offices)**

This item is a shaded cell and is derived from the sum of items 101, 102 and 103.

**Line item 101 Residential Mortgages (not in domestic offices)**

This item is a shaded cell and is derived as the sum of items 21 and 22 minus items 67 and 68.

**Line item 102 Commercial real estate (CRE) loans (not in domestic offices)**

This item is a shaded cell and is derived as item 23 minus item 69.

**Line item 103 Loans secured by farmland (not in domestic offices)**

This item is a shaded cell and is derived as item 29 minus item 75.

**Line item 104 C&I Loans**

This item is a shaded cell and is derived as item 30 minus item 76.

**Line item 105 Credit Cards**

This item is a shaded cell and is derived as item 35 minus item 80.

**Line item 106 Other Consumer**

This item is a shaded cell and is derived as item 38 minus item 81.

**Line item 107 All Other Loans and Leases**

This item is a shaded cell and is derived as item 41 minus item 86.

**Line item 108 Total Loans and Leases Held for Sale and Loans and Leases Accounted for under the Fair Value Option**

This item is a shaded cell and is derived from the sum of items 95, 100, 104, 105, 106 and 107.

**Line item 109 Unearned Income on Loans**

Report all unearned income on loans, as defined in the FR Y-9C, Schedule HC-C, item 11, Column A.

**Line item 110 Allowance for Loan and Lease Losses**

This item is a shaded cell and is carried over from item 117 of the Income Statement Sub-schedule.

**Line item 111 Loans and Leases (Held for Investment and Held for Sale) Net of Unearned Income and Allowance for Loan and Lease Losses**

This item is a shaded cell and is derived as item 51 minus items 109 and 110.

**TRADING**

**Line item 112 Trading Assets**

Report trading assets, as defined in the FR Y-9C, Schedule HC, item 5.

**Line items 113 through 117 INTANGIBLES:**

**Line item 113 Goodwill**

Report goodwill, as defined in the FR Y-9C, Schedule HC, item 10.a.

**Line item 114 Mortgage Servicing Rights**

Report all mortgage servicing rights, as defined in the FR Y-9C, Schedule HC-M, item 12.a.

**Line item 115 Purchased Credit Card Relationships and Nonmortgage Servicing Rights**

Report all purchased credit card relationships and nonmortgage servicing rights, as defined in the FR Y-9C, Schedule HC-M, item 12.b.

**Line item 116 All Other Identifiable Intangible Assets**

Report all other identifiable intangible assets, as defined in the FR Y-9C, Schedule HC-M, item 12.c.

**Line item 117 Total Intangible Assets**

This item is a shaded cell and is derived from the sum of items 113, 114, 115 and 116.

**Line items 118 through 131 OTHER (Assets):**

**Line item 118 Cash and cash equivalent**

Report cash and cash equivalent, as defined in the FR Y-9C, Schedule HC, items 1.a., 1.b.(1), 1.b.(2).

**Line item 119 Federal Funds Sold**

Report federal funds sold in domestic offices, as defined in the FR Y-9C, Schedule HC, item 3.a.

**Line item 120 Securities Purchased under Agreements to Resell**

Report securities purchased under agreements to resell, as defined in the FR Y-9C, Schedule HC, item 3.b.

**Line item 121 Premises and Fixed Assets**

Report all premises and fixed assets, as defined in the FR Y-9C, Schedule HC, item 6.

**Line item 122 Other Real Estate Owned (OREO)**

This item is a shaded cell and is derived from the sum of items 123, 124 and 125.

**Line item 123 Commercial**

Report the net book value of all other real estate owned in the form of, or for which the underlying real estate consists of, commercial real estate.

**Line item 124 Residential**

Report the net book value of all other real estate owned in the form of, or for which the underlying real estate consists of, residential real estate.

**Line item 125 Farmland**

Report the net book value of all other real estate owned in the form of, or for which the underlying real estate consists of, farmland.

**Line item 126 Collateral Underlying Operating Leases for Which the Bank is the Lessor**

This item is a shaded cell and is derived from the sum of items 127 and 128.

**Line item 127 Autos**

Report the carrying amount of automobiles rented to others under operating leases, net of accumulated depreciation. The amount reported should only reflect collateral rented under operating leases and should not include collateral subject to capital/financing type leases.

**Line item 128 Other**

Report the carrying amount of any equipment or other assets (other than automobiles) rented to others under operating leases, net of accumulated depreciation. The amount reported should only reflect collateral rented under operating leases and should not include collateral subject to capital/financing type leases.

**Line item 129 Other assets**

Report all other assets, as defined in the FR Y-9C, Schedule HC, sum of items 8, 9 and 11, minus item 126 (above).

**Line item 130 Total Other (assets)**

This item is a shaded cell and is derived from the sum of items 118-122, 126, and 129.

**Line item 131 Total Assets**

This item is a shaded cell and is derived from the sum of items 3, 111, 112, 117 and 130.

**Line items 132 through 142 LIABILITIES:****Line item 132 Deposits in Domestic Offices**

Report all deposits in domestic offices, as defined in the FR Y-9C, Schedule HC, items 13.a.(1) and 13.a.(2).

**Line item 133 Deposits in Foreign Offices**

Report all deposits in foreign offices, as defined in the FR Y-9C, Schedule HC, items 13.b.(1) and 13.b.(2).

**Line item 134 Deposits**

This item is a shaded cell and derived from the sum of items 132 and 133.

**Line item 135 Federal Funds Purchased and Repurchase Agreements**

Report all federal funds purchased and repurchase agreements, as defined in the FR Y-9C, Schedule HC, items 14.a and 14.b.

**Line item 136 Trading Liabilities**

Report all trading liabilities, as defined in the FR Y-9C, Schedule HC, item 15.

**Line item 137 Other Borrowed Money**

Report other borrowed money, as defined in the FR Y-9C, Schedule HC, item 16.

**Line item 138 Subordinated Notes and Debentures**

Report subordinated notes and debentures, as defined in the FR Y-9C, Schedule HC, item 19.a.

**Line item 139 Subordinated Notes Payable to Unconsolidated Trusts Issuing TruPS and TruPS Issued by Consolidated Special Purpose Entities**

Report all subordinated notes payable to unconsolidated trusts issuing trust preferred securities, and trust preferred securities issued by consolidated special purpose entities, as defined in the FR Y-9C, Schedule HC, item 19.b.

**Line item 140 Other liabilities**

Report other liabilities, as defined in the FR Y-9C, Schedule HC, item 20.

**Line item 141 Memo: Allowance for off-balance sheet credit exposures**

Report the allowance for off-balance sheet credit exposures, as defined in the FR Y-9C, Schedule HC-G, item 3.

**Line item 142 Total Liabilities**

Report the sum of items 134 through 140.

**Line items 143 through 151 EQUITY CAPITAL:**

**Line item 143 Perpetual Preferred Stock and Related Surplus**

Report all perpetual preferred stock and related surplus, as defined in the FR Y-9C, Schedule HC, item 23.

**Line item 144 Common Stock (Par Value)**

Report the par value of common stock, as defined in the FR Y-9C, Schedule HC, item 24.

**Line item 145 Surplus (Exclude All Surplus Related to Preferred Stock)**

Report surplus (excluding surplus related to preferred stock), as defined in the FR Y-9C, Schedule HC, item 25.

**Line item 146 Retained Earnings**

Report all retained earnings, as defined in the FR Y-9C, Schedule HC, item 26.a.

**Line item 147 Accumulated Other Comprehensive Income (AOCI)**

Report accumulated other comprehensive income (AOCI), as defined in the FR Y-9C, Schedule HC, item 26.b.

**Line item 148 Other Equity Capital Components**

Report other equity capital components, as defined in the FR Y-9C, Schedule HC, item 26.c.

**Line item 149 Total BHC or IHC Equity Capital**

Report the sum of items 143 through 148.

**Line item 150 Noncontrolling (Minority) Interests in Consolidated Subsidiaries**

Report all noncontrolling (minority) interests in consolidated subsidiaries, as defined in the FR Y-9C, Schedule HC, item 27.b.

**Line item 151 Total Equity Capital**

Report the sum of items 149 and 150.

**Line item 152 Unused Commercial Lending Commitments and Letters of Credit**

Report all unused commercial lending commitments and letters of credit, as defined in the FR Y-9C, Schedule HC-L, items 1.c.(1), 1.c.(2), 1.e.(1), 1.e.(2), 1.e.(3), 2, 3, and 4.

## **A.1.c—Risk-Weighted Assets (RWA)**

### **A.1.c.1—Standardized RWA**

All BHCs and IHCs are required to complete the “Standardized RWA” sub-schedule for all reporting quarters ~~starting January 1, 2015~~.

For reporting quarters starting January 1, 2018, advanced approaches firms must apply a 250 percent risk-weight to mortgage servicing assets (MSAs), deferred tax assets arising from temporary differences that could not be realized through net operating loss carrybacks, and significant investments in the capital of unconsolidated financial institutions in the form of common stock that are not deducted from capital. For all reporting quarters, a non-advanced approaches firm must apply a 100 percent risk weight to any amounts of MSAs, deferred tax assets arising from temporary differences that could not be realized through net operating loss carrybacks, and significant investments in the capital of unconsolidated financial institutions in the form of common stock that are not deducted from capital, and continue to apply the 2017 risk weights under the capital rules to amounts of non-significant investments in the capital of unconsolidated financial institutions and significant investments in the capital of unconsolidated financial institution not in the form of common stock that are not deducted from capital.

BHCs and IHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC or IHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital requirements during the forecast period, then the BHC or IHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to 78 Federal Register 62250, October 11, 2013 and 78 Federal Register 76521, December 18, 2013 for details of the requirements.

### **Standardized Approach Credit Risk**

#### **Line item 1 Cash and balances due from depository institutions**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 1.

#### **Securities**

#### **Line item 2a Held-to-maturity (excluding securitizations):**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 2a.

#### **Line item 2b Available-for-sale (excluding securitizations):**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 2b.

#### **Line item 3 Federal funds sold**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 3a.

#### **Loans and leases on held for sale**

#### **Line item 4a Residential mortgage exposures**

Report the risk-weighted asset amount consistent with the definition for the FR Y-9C, Part II, Line item 4a.

**Line item 4b High Volatility Commercial Real Estate**

Report the risk-weighted amount consistent with the definition for the FR Y-9C, HC-R, Part II, Line item 4b.

**Line item 4c Exposures past due 90 days or more or on nonaccrual**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line item 4c.

**Line item 4d All other exposures**

Report the risk-weighted asset amount consistent with the definition for the FR Y-9C, HC-R, Part II, Line item 4d.

**Loans and leases, net of unearned income**

**Line item 5a Residential mortgage exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5a.

**Line item 5b High Volatility Commercial Real Estate**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5b.

**Line item 5c Exposures past due exposures 90 days or more or on nonaccrual**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5c.

**Line item 5d All other exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5d.

**Line item 6 Trading assets (excluding securitizations that receive standardized charges)**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 7.

**Line item 7a All other assets**

Report the risk-weighted asset amount consistent with the definition of Y-9C, HC-R, Part II, line item 8.

**Line item 7b Separate account bank-owned life insurance**

Report the risk-weighted asset amount consistent with the definition of Y-9C, HC-R, Part II, line item 8a.

**Line item 7c Default fund contributions to central counterparties**

Report the risk-weighted asset amount consistent with the definition of Y-9C, HC-R, Part II, line item 8b.

**On-balance sheet securitization exposures**

**Line item 8a Held-to-maturity**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9a.

**Line item 8b Available-for-sale**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9b.

**Line item 8c Trading assets that receive standardized charges**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9c.

**Line item 8d All other on-balance sheet securitization exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9d.

**Line item 9 Off-balance sheet securitization exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 10.

**Line item 10 RWA for Balance Sheet Asset Categories (sum of items 1 through 8d)**

This item is shaded and is derived from other items in the schedule, no input required.

**Derivatives and Off-Balance Sheet Items**

**Line item 11 Financial standby letters of credit**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 12.

**Line item 12 Performance standby letters of credit and transaction related contingent items**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 13.

**Line item 13 Commercial and similar letters of credit with an original maturity of one year or less**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 14.

**Line item 14 Retained recourse on small business obligations sold with recourse**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 15.

**Line item 15 Repo-style transactions**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 16.

**Line item 16 All other off-balance sheet liabilities**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 17.

**Line item 17a Unused commitments: Original maturity of one year or less, excluding ABCP conduits**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 18a.

**Line item 17b Unused commitments: Original maturity of one year or less to ABCP conduits**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 18b.

**Line item 17c Unused commitments: Original maturity exceeding one year**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 18c.

**Line item 18 Unconditionally cancelable commitment**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 19.

**Line item 19 Over-the-counter derivatives**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 20.

**Line item 20 Centrally cleared derivatives**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 21.

**Line item 21 Unsettled transactions (failed trades)**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 22.

**Line item 22 RWA for Assets, Derivatives and Off-Balance-Sheet Asset Categories**

This item is a shaded cell and is derived from the sum of items 9 through 21.

**Line item 23 RWA for purposes of calculating the allowance for loan and lease losses (ALLL)  
1.25 percent threshold**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 26.

**Market Risk**

Line items 24 through 40 are applicable only to BHCs and IHCs that are subject to the market risk capital rule. If a BHC or IHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0.

**Line item 24 Value-at-risk (VaR)-based capital requirement**

Report the risk-weighted amount consistent with the definition for FFIEC 102 Line Item 4.

**Line item 25 Stressed VaR-based capital requirement**

Report the risk-weighted amount consistent with the definition for FFIEC 102 Line Item 7.

**Specific risk add-on**

**Line item 26 Debt Positions**

Report the risk-weighted amount consistent with the definition for FFIEC 102 Line Item 8

**Line item 27 Equity positions**

Report the risk-weighted amount consistent with the definition of FFIEC 102 Line Item 9.

**Line item 28 Capital requirements for securitization positions using the Simplified Supervisory Formula Approach (SSFA) or applying a specific risk-weighting factor of 1250 percent.**

Report the risk-weighted amount consistent with the definition of FFIEC 102 Line Item 10.

**Line item 29 Standardized measure of specific risk add-ons (sum of items 26, 27, and 28)**

This item is the derived sum of line item 26, 27, and 28. The risk-weighted amount should be consistent with the definition for the FFIEC 102 Line item 14.

**Item 30 is not applicable to an institution that does not calculate a modeled measure of incremental risk.**

**Line item 30 Incremental risk charge requirement**

Report the risk-weighted amount consistent with the definition for FFIEC 102 Line Item 18.

**Line item 31 Modeled comprehensive risk measure**

Report the risk-weighted amount consistent with the definition for FFIEC 102 Line Item 19.

**Line item 32 Standardized measure of specific risk add-ons for net long correlation trading positions**

Report the risk-weighted amount consistent with the definition of FFIEC 102 Line Item 26.

**Line item 33 Standardized measure of specific risk add-ons for net short correlation trading positions**

Report the risk-weighted amount consistent with the definition of FFIEC 102 Line Item 34

**Line item 34 Standardized measure of specific risk add-ons (greater of item 32 or 33)**

This item is derived as the greater of Line Item 32 or 33.

**Line item 35 Surcharge for modeled correlation trading positions (item 34 multiplied by 0.08)**

This item is derived as product of line item 34 multiplied by 0.08. This item should be consistent

with the risk-weighted amount for FFIEC 102 Line Item 37.

**Line item 36 Comprehensive risk capital measure requirement**

Report the risk-weighted amount consistent with the definition for FFIEC 102 Line Item 42. Only if a BHC or IHC has received supervisory approval of its comprehensive risk model effectiveness, report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 48.

**De minimis positions and other adjustments**

**Line item 37 Capital requirement for all de minimis exposures**

Report the risk-weighted amount consistent with the definition of FFIEC 102 Line Item 52

**Line item 38 Additional capital requirement**

Report the risk-weighted amount consistent with the definition of FFIEC 102 Line Item 53.

**Line item 39 Sum of items 37 and 38**

This item is derived as sum of item 37 and item 38. The risk-weighted amount should be consistent with the definition of FFIEC 102 Line Item 54.

**Market risk-weighted assets**

**Line item 40 Standardized market risk-weighted assets: Sum of items 24, 25, 29, 30 (if applicable), 36 (if applicable), and 39**

This item is derived as the sum of items 24, 25, 29, 30 (if applicable), 36 (if applicable), and 39.

**Line item 41 Risk-weighted assets before deductions for excess allowance of loan and lease losses and allocated risk transfer risk reserve**

This item is a shaded cell and is derived from the sum of items 22 and 40.

**Line item 42 Less: Excess allowance for loan and lease losses**

Report the asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 29.

**Line item 43 Less: Allocated transfer risk reserve**

Report the asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 30.

**Line item 44 Total risk-weighted assets**

This item is a shaded cell and is derived from item 41 minus the sum of items 42 and 43.

**Memoranda Items - Derivatives**

Report all memoranda items lines 45 through 48g.

**Line item 45 Current credit exposure across all derivative contracts covered by the regulatory capital rules**

Report the total current credit exposure amount for all interest rate, foreign exchange rate and gold, credit (investment grade reference assets), credit (non-investment grade reference assets), equity, precious metals (except gold), and other derivative contracts covered by the regulatory capital rules after considering applicable legally enforceable bilateral netting agreements. Banking organizations

that are subject to Subpart F of the regulatory capital rules should exclude all covered positions subject to these guidelines, except for foreign exchange derivatives that are outside of the trading account. Foreign exchange derivatives that are outside of the trading account and all OTC derivatives continue to have a counterparty credit risk capital charge and, therefore, a current credit exposure amount for these derivatives should be reported in this item.

**Line item 46 Notional principal amounts of over-the-counter derivative contracts**

This item is a shaded cell and is derived from the sum of lines 47a through 47g.

Report in the appropriate sub-item the notional amount or par value of all OTC derivative contracts, including credit derivatives that are subject to the regulatory capital rules. Such contracts include swaps, forwards, and purchased options.

**Line item 47a Interest rate**

Report interest rate contracts that are subject to the regulatory capital rules.

**Line item 47b Foreign exchange rate and gold**

Report foreign exchange contracts and the remaining maturities of gold contracts that are subject to the regulatory capital rules.

**Line item 47c Credit (investment grade reference asset)**

Report credit derivative contracts where the reference entity meets the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

**Line item 47d Credit (non-investment grade reference asset)**

Report credit derivative contracts where the reference entity does not meet the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

**Line item 47e Equity**

Report equity derivative contracts that are subject to the regulatory capital rules.

**Line item 47f Precious metals (except gold)**

Report other precious metals contracts that are subject to the regulatory capital rules. Report all silver, platinum, and palladium contracts.

**Line item 47g Other**

Report other contracts that are subject to the regulatory capital rules. For contracts with multiple exchanges of principal, notional amount is determined by multiplying the contractual amount by the number of remaining payments (e.g., changes of principal) in the derivative contract.

**Line item 48 Notional principal amounts of centrally cleared derivative contracts**

This item is a shaded cell and is derived from the sum of lines 48a through 48g.

Report in the appropriate sub-item the notional amount or par value of all centrally cleared derivative contracts, including credit derivatives that are subject to the regulatory capital rules. Such contracts include swaps, forwards, and purchased options.

**Line item 49a Interest rate**

Report interest rate contracts that are subject to the regulatory capital rules.

**Line item 49b Foreign exchange rate and gold**

Report foreign exchange contracts and the remaining maturities of gold contracts that are subject to the regulatory capital rules.

**Line item 49c Credit (investment grade reference asset)**

Report credit derivative contracts where the reference entity meets the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

**Line item 49d Credit (non-investment grade reference asset)**

Report credit derivative contracts where the reference entity does not meet the definition of investment grade as described in 12 CFR 217.2 of the regulatory capital rule.

**Line item 49e Equity**

Report equity derivative contracts that are subject to the regulatory capital rules.

**Line item 49f Precious metals (except gold)**

Report other precious metals contracts that are subject to the regulatory capital rules. Report all silver, platinum, and palladium contracts.

**Line item 49g Other**

Report other contracts that are subject to the regulatory capital rules. For contracts with multiple exchanges of principal, notional amount is determined by multiplying the contractual amount by the number of remaining payments (e.g., changes of principal) in the derivative contract.

**A.1.c.2—Advanced RWA**

*Please note that for purposes of CCAR 2017, BHCs and IHCs are NOT required to fill out the “Advanced RWA” sub-schedule. Large and noncomplex firms are not required to complete this subschedule.*

| BHCs and IHCs subject to subpart E of the ~~revised~~ regulatory capital rule that have exited the parallel run process and that have received notification from its primary Federal supervisor under section 121(d) of the advanced approaches rule are required to complete the “Advanced RWA” sub-schedule.

MDRM codes have been included in the sub-schedule (column C) and correspond to the definitions for the FFIEC 101 line items where applicable.

BHCs and IHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC or IHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital requirements during the forecast period, then the BHC or IHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to the final market risk capital rule released by the U.S. banking agencies (77 Federal Register 53060, August 30, 2012) for details of the requirements of the rule.

**Advanced Approaches Credit Risk (Including CCR and non-trading credit risk), with 1.06 scaling factor and Operational Risk**

**Line items 1 through 57: Advanced Approaches Credit Risk (Including CCR and non-trading credit risk), with 1.06 scaling factor and Operational Risk**

**Line item 1 Advanced Approaches Credit RWA**

This item is a shaded cell and is derived from sum of items 2, 13, 20, 47, 49, 55 32 or 33, and 40 if greater than 0 or 50 if greater than zero.

**Line items 2 through 57 Various**

Definition of the BHC's or IHC's projections should correlate to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the current advanced approaches capital rules (72 Federal Register 69288, December 7, 2007).

**Market Risk**

If a BHC or IHC does not have a particular portfolio or no trading book at all, risk-weighted assets should be reported as 0.

**For items 58 through 73, refer to instructions for items 12 through 30, respectively, for market risk under the "General RWA" sub-schedule.**

**Line item 74 Other RWA**

If the BHC or IHC is unable to assign RWA to one of the above categories, even on a best-efforts basis, they should be reported in this line.

**Line item 75 Excess eligible credit reserves not included in tier 2 capital**

Include excess eligible credit reserves not included in tier 2 capital, consistent with the current advanced approaches capital rules (72 Federal Register 69288, December 7, 2007).

**Line item 76 Total RWA**

This item is a shaded cell and is derived from sum of items 1, 56, 73, 74 minus item 75.

**A.1.d—Capital**

The Capital – CCAR and Capital – DFAST sub-schedules collect projections of the main drivers of equity capital and the key components of the regulatory capital schedule. MDRM codes are provided in the 'Notes' column for many of the line items.

A BHC or IHC should consult the CCAR Instructions and the capital plan rule (12 CFR 225.8) for information regarding the capital action assumptions to use in completing the Capital – CCAR sub-schedule. A BHC or IHC should consult the CCAR instructions and the covered company company-run stress test rule (12 CFR 252.56(b)) for information regarding the capital action assumptions to use in completing the Capital – DFAST sub-schedule. In the mid-cycle stress tests, a BHC or IHC should leave the Capital – CCAR sub-schedule blank.

All data collected in the Capital sub-schedules should be reported on a quarterly basis and not on a

year-to-date, cumulative basis. Note that line item 115, Common shares outstanding, should be reported in millions of shares.

All **advanced approaches** BHCs and IHCs are required to provide projections of common equity tier 1 capital, tier 1 capital, and total capital based on the **revised** regulatory capital rule for all quarters. **For reporting quarters starting January 1, 2018, a non-advanced approaches firm must continue to apply, indefinitely, the risk weight and the deduction treatment applicable during 2017 – in accordance with relevant transition provisions for 2017 in section 300 of the capital rules – for MSAs, deferred tax assets arising from temporary differences that could not be realized through net operating loss carrybacks, significant investments in the capital of unconsolidated financial institutions in the form of common stock, non-significant investments in the capital of unconsolidated financial institutions, and significant investments in the capital of unconsolidated financial institutions that are not in the form of common stock.**

Under the Board's capital plan and stress test rules, a BHC's or IHC's calculations of pro forma regulatory capital ratios over the planning horizon shall not include estimates using the advanced approaches (See 12 CFR 225.8.(b)(3)(i), 12 CFR 252.43(d)(1), and 12 CFR 252.53(d)(1)). Accordingly, for actual and projected line items on the FR Y-14A Summary Schedule Capital – CCAR and Capital – DFAST sub-schedules, BHCs and IHCs should not use the advanced approaches. For example, in line item 34, "All other deductions from (additions to) common equity tier 1 capital before threshold-based deductions," an advanced approaches BHC should not include expected credit losses that exceed the eligible credit reserves.

The projections should clearly show any proposed capital distributions or other scenario-dependent actions that would affect the BHC's or IHC's regulatory capital, including any assumptions required under the Board's regulations.

#### **SCHEDULE HI-A—CHANGES IN BANK OR INTERMEDIATE HOLDING COMPANY EQUITY CAPITAL**

Line items 1 through 17: ITEMS RELATED TO SCHEDULE HI-A—CHANGES IN BANK OR INTERMEDIATE HOLDING COMPANY EQUITY CAPITAL

##### **Line item 1 Total bank or intermediate holding company equity capital most recently reported for the end of previous QUARTER**

Report total bank or intermediate holding company equity capital most recently reported for the end of previous quarter, as defined in FR Y-9C, Schedule HI-A, line item 1 (except FR Y-9C, Schedule HI-A, line item 1, is reported for the end of the previous calendar year).

##### **Line item 2 Effect of changes in accounting principles and corrections of material accounting errors**

Report the effect of changes in accounting principles and corrections of material accounting errors, as defined in FR Y-9C, Schedule HI-A, line item 2.

##### **Line item 3 Balance end of previous QUARTER as restated**

This item is derived as the sum of line items 1 and 2, as defined in FR Y-9C, schedule HI-A, line item 3.

##### **Line item 4 Net Income (loss) attributable to bank or intermediate holding company**

Report net income (loss) attributable to bank or intermediate holding company, as defined in FR Y-9C, Schedule HI-A, line item 4.

**Line item 5 Sale of perpetual preferred stock, gross**

Report the sale of perpetual preferred stock, gross, as defined in FR Y-9C, Schedule HI-A, line item 5.a.

**Line item 6 Conversion or retirement of perpetual preferred stock**

Report the conversion or retirement of perpetual preferred stock, as defined in FR Y-9C, Schedule HI-A, line item 5.b.

**Line item 7 Sale of common stock, gross**

Report the sale of common stock, gross, as defined in FR Y-9C, Schedule HI-A, line item 6.a.

**Line item 8 Conversion or retirement of common stock**

Report the conversion or retirement of common stock, as defined in FR Y-9C, Schedule HI-A, line item 6.b. Note: increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, or common stock as a result of the actual issuance of common stock for the employee stock compensation should be captured in this line item.

**Line item 9 Sale of treasury stock**

Report the sale of treasury stock, as defined in FR Y-9C, Schedule HI-A, line item 7.

**Line item 10 Purchase of treasury stock**

Report the purchase of treasury stock, as defined in FR Y-9C, Schedule HI-A, line item 8.

**Line item 11 Changes incident to business combinations, net**

Report the changes incident to business combinations, net, as defined in FR Y-9C, Schedule HI-A, line item 9.

**Line item 12 Cash dividends declared on preferred stock**

Report cash dividends declared on preferred stock, as defined in FR Y-9C, Schedule HI-A, line item 10.

**Line item 13 Cash dividends declared on common stock**

Report cash dividends declared on common stock, as defined in FR Y-9C, Schedule HI-A, line item 11.

**Line item 14 Other comprehensive income**

Report other comprehensive income, as defined in FR Y-9C, Schedule HI-A, line item 12.

**Line item 15 Change in the offsetting debit to the liability for Employee Stock Ownership Plan (ESOP) debt guaranteed by the bank or intermediate holding company**

Report the change in the offsetting debit to the liability for Employee Stock Ownership Plan (ESOP) debt guaranteed by the bank or intermediate holding company, as defined in FR Y-9C, Schedule HI-A, line item 13.

**Line item 16 Other adjustments to equity capital (not included above)**

Report other adjustments to equity capital, not included above, as defined in FR Y-9C, Schedule HI-A, line item 14. Report amounts separately and provide a text explanation of each type of adjustment to equity capital included in this line item in item Memoranda 1 (line item 125) at the end of this sub-schedule. Note: increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation should not be captured in this line item, instead the impact should be captured in line items 7, 8, 9, and/or 10 as appropriate.

**Line item 17 Total bank or intermediate holding company equity capital end of current period**

This line item is a shaded cell and is derived from the sum of line items 3, 4, 5, 6, 7, 8, 9, 11, 14, 15 and 16, less line items 10, 12 and 13. Note that this line item should correspond to the definition in FR Y-9C, Schedule HC, line item 27a.

**Regulatory Capital per Revised Regulatory Capital Rule (July 2013)**

All advanced approaches BHCs and IHCs and opt-in BHCs and IHCs must complete the following section. Where applicable, please reflect the **appropriate** transition provisions for the appropriate line item, **per the 2013 revised regulatory capital rule.**<sup>9</sup>

**Line item 18 AOCI opt-out election**

A holding company that is not an advanced approaches holding company may make a one-time election to opt-out of the requirement to include most components of AOCI in common equity tier 1 capital (with the exception of accumulated net gains and losses on cash flow hedges related to items that are not recognized at fair value on the balance sheet). A holding company that makes an AOCI opt-out election must enter “1” for “Yes” in line item 18. There are no transition provisions applicable to reporting line item 21, if a holding company makes an AOCI opt-out election.

A holding company (except an advanced approaches holding company) must make its AOCI opt-out election on the holding company’s March 31, 2015 FR Y-9C report. For a holding company that comes into existence after March 31, 2015, the holding company must make its AOCI opt-out election on the holding company’s first FR Y-9C report. After a holding company initially makes its AOCI opt-out election, the holding company must report its election in each Y-14A report thereafter. With prior notice to the Federal Reserve, a holding company resulting from a merger, acquisition, or purchase transaction may make a new AOCI opt-out election, as described in section 22(b)(2) of the **revised** regulatory capital rules.

<sup>9</sup> [insert transitions freeze final Federal Register notice citation]

## **Common Equity Tier 1**

### **Line item 19 Common stock and related surplus, net of treasury stock and unearned employee stock ownership plan (ESOP) shares**

Report the amount of common stock and related surplus as defined in FR Y-9C, Schedule HC-R, part I, line item 1.

### **Line item 20 Retained earnings**

Report the amount of the holding company's retained earnings as defined in FR Y-9C, Schedule HC-R, part I, line item 2.

### **Line item 21 Accumulated other comprehensive income (AOCI)**

Report the amount of AOCI as defined in FR Y-9C, Schedule HC-R, part I, line item 3.

### **Line item 22 Common equity tier 1 minority interest includable in common equity tier 1 capital.**

Report the amount of the holding company's common equity tier 1 minority interest includable in common equity tier 1 capital as defined in FR Y-9C, Schedule HC-R, part I, line item 4.

### **Line item 23 Common equity tier 1 capital before adjustments and deductions**

This line item is a shaded cell and is derived from the sum of line items 19 through 22. This item should align with the definition in FR Y-9C, Schedule HC-R, part I, line item 5.

### **Common equity tier 1 capital: adjustments and deductions (where applicable, report all line items reflective of transition provisions)**

### **Line item 24 Goodwill net of associated deferred tax liabilities (DTLs)**

Report the amount of goodwill as defined in FR Y-9C, Schedule HC-R, part I, line item 6.

### **Line item 25 Intangible assets (other than goodwill and mortgage servicing assets (MSAs)), net of associated DTLs**

Report the amount of intangible assets as defined in FR Y-9C, Schedule HC-R, part I, line item 7.

### **Line item 26 Deferred Tax Assets (DTAs) that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs**

Report the amount of DTAs as defined in FR Y-9C, Schedule HC-R, part I, line item 8.

### **AOCI-related adjustments**

**If Item 18 is "1" for "Yes", complete items 27 through 31 only for AOCI related adjustments.**

### **Line item 27: AOCI related adjustments: Net unrealized gains (losses) on available-for-sale securities**

Report the amount of net unrealized holding gains (losses) on available-for-sale securities, net of applicable taxes, as defined in FR Y-9C, Schedule HC-R, part I, line item 9a. If the amount is a net gain, report it as a positive value in this line item. If the amount is a net loss, report it as a negative value in this line item.

**Line item 28: AOCI related adjustments: Net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures**

Report as a positive value net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures as defined in FR Y-9C, Schedule HC-R, part I, line item 9b.

**Line item 29: AOCI related adjustments: Accumulated net gains (losses) on cash flow hedges**

Report the amount of accumulated net gains (losses) on cash flow hedges as defined in FR Y-9C, Schedule HC-R, part I, line item 9c. If the amount is a net gain, report it as a positive value in this line item. If the amount is a net loss, report it as a negative value in this line item.

**Line item 30: AOCI related adjustments: Amounts recorded in AOCI attributed to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans**

Report the amounts recorded in AOCI as defined in FR Y-9C, Schedule HC-R, part I, line item 9d, resulting from the initial and subsequent application of ASC Subtopic 715-20 (formerly FASB Statement No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans") to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans. A holding company may exclude this portion related to pension assets deducted in the line item above. If the amount is a net gain, report it as a positive value in this line item. If the amount is a net loss, report it as a negative value in this line item.

**Line item 31: AOCI related adjustments: Net unrealized gains (losses) on held-to-maturity securities that are included in AOCI**

Report the amount of net unrealized gains (losses) that are not credit-related on held-to-maturity securities and are included in AOCI as defined in FR Y-9C, Schedule HC-R, part I, item 9e. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

**If Item 18 is "0" for "No", complete item 32 only for AOCI related adjustments.**

**Line item 32 Accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects that relate to the hedging of items that are not recognized at fair value on the balance sheet**

Report the amount of accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects that relate to the hedging of items not recognized at fair value on the balance sheet, as defined in FR Y-9C, Schedule HC-R, part I, line item 9f. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

**Line item 33 Other deductions from (additions to) common equity tier 1 capital before threshold-based deductions: Unrealized net gain (loss) related to changes in the fair value of liabilities that are due to changes in own credit risk**

Report the amount of unrealized net gain (loss) as defined in FR Y-9C, Schedule HC-R, part I, line

item 10a. If the amount is a net gain, report it as a positive value in this line item. If the amount is a net loss, report it as a negative value in this line item.

**Line item 34 Other deductions from (additions to) common equity tier 1 capital before threshold-based deductions: All other deductions from (additions to) common equity tier 1 capital before threshold-based deductions**

Report the amount of other deductions from (additions to) common equity tier 1 capital as defined in FR Y-9C, Schedule HC-R, part I, line item 10b, that are not included in line items above.

Under the Board's capital plan and stress test rules, a BHC's calculations of pro forma regulatory capital ratios over the planning horizon shall not include estimates using the advanced approaches (See 12 CFR 225.8.(b)(3)(i), 12 CFR 252.43(d)(1), and 12 CFR 252.53(d)(1)). Accordingly, for this line item, an advanced approaches BHC that has exited parallel run should not include expected credit losses that exceed the eligible credit reserves.

**Line item 35 Non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that exceed the 10 percent threshold for non-significant investments**

This line item should be reported reflective of any applicable transition provisions, and should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 11.

**Line item 36 Subtotal (item 23 minus items 24 through 35)**

This item is a shaded cell and is derived from line item 23 minus line items 24 through 35. This should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 12.

**Line item 37 Significant investments in the capital of unconsolidated financial institutions in the form of common stock, net of associated DTLs, that exceed 10 percent common equity tier 1 capital deduction threshold**

This line item should be derived from line item 71, reflective of any applicable transition provisions, and should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 13.

**Line item 38 MSAs, net of associated DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold**

This line item should be derived from line item 76, reflective of any applicable transition provisions, and should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 14.

**Line item 39 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold**

This line item should be derived from line item 79, reflective of any applicable transition provisions, and should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 15.

**Line item 40 Amount of significant investments in the capital of unconsolidated financial institutions in the form of common stock; MSAs, net of associated DTLs; and DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs; that exceeds the 15 percent common equity tier 1 capital deduction threshold**

This line item should be derived from line item 84, reflective of any applicable transition provisions,

and should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 16.

**Line item 41 Deductions applied to common equity tier 1 capital due to insufficient amount of additional tier 1 capital and tier 2 capital to cover deductions**

Report the total amount of deductions as defined in FR Y-9C, Schedule HC-R, part I, line item 17, if the holding company does not have a sufficient amount of additional tier 1 capital and tier 2 capital to cover these corresponding additional tier 1 and tier 2 deductions in line items 47 and 57.

**Line item 42 Total adjustments and deductions for common equity tier 1 capital**

This line item is a shaded cell that is derived from the sum of line items 37 through 41. This item should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 18.

**Line item 43 Common equity tier 1 capital**

This line item is a shaded cell that is derived from line item 36 minus line item 42. This line item is the numerator of the holding company's common equity tier 1 risk-based capital ratio, which should align with the definition in FR Y-9C, Schedule HC-R, part I, line item 19.

**Additional tier 1 capital**

**Line item 44 Additional tier 1 capital instruments plus related surplus**

Report this line item as defined in FR Y-9C, Schedule HC-R, part I, line item 20.

**Line item 45 Non-qualifying capital instruments subject to phase out from additional tier 1 capital**

Report this line item as defined in FR Y-9C, Schedule HC-R, part I, line item 21, subject to the applicable phase-out schedule as described within the Y-9C.

**Line item 46 Tier 1 minority interest not included in common equity tier 1 capital**

Report this line item as defined in FR Y-9C, Schedule HC-R, part I, line item 22.

**Line item 47 Additional tier 1 capital before deductions**

This is a shaded cell that is derived as the total of line items 44 through 46. This item should align with the definition in FR Y-9C, Schedule HC-R, part I, line item 23.

**Line item 48 Additional tier 1 capital deductions**

Report this line item as consistent with FR Y-9C, Schedule HC-R, part I, line item 24, including all applicable transition provisions.

**Line item 49 Additional tier 1 capital**

Report this line item as defined in FR Y-9C, Schedule HC-R, Part I, line item 25.

**Tier 1 capital**

**Line item 50 Tier 1 capital (sum of items 43 and 49)**

This line item is a shaded cell and is derived from the sum of line items 43 and 49. This line item is the numerator of the holding company's tier 1 risk-based capital ratio and tier 1 leverage ratio and

should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 26.

**Tier 2 capital**

**Line item 51 Tier 2 capital instruments plus related surplus**

Report the amount as defined in FR Y-9C, Schedule HC-R, part I, line item 27.

**Line item 52 Non-qualifying capital instruments subject to phase out from tier 2 capital**

Report the total amount of non-qualifying capital instruments that were included in tier 2 capital as defined in FR Y-9C, Schedule HC-R, part I, line item 28.

**Line item 53 Total Capital minority interest that is not included in tier 1 capital**

Report the amount of total capital minority interest as defined in FR Y-9C, Schedule HC-R, part I, line item 29.

**Line item 54 Allowance for loan and lease losses includable in tier 2 capital**

Report the portion of the holding company's allowance for loan and lease losses that are includable in tier 2 capital, as defined in FR Y-9C, Schedule HC-R, part I, line item 30a.

**Line item 55 (Advanced approaches holding companies that exit parallel run only): eligible credit reserves includable in tier 2 capital**

BHCs and IHCs do not have to report this line item.

**Line item 56 Unrealized gains on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures includable in tier 2 capital**

BHCs and IHCs should report this line item consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 31.

**Line item 57 Tier 2 capital before deductions**

This line item is a shaded cell that is derived from the sum of line items 51, 52, 53, 54, and 56. This line item should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 32.a.

**Line item 58 (Advanced approaches holding companies that exit parallel run only): Tier 2 capital before deductions, reflective of transition procedures**

BHCs and IHCs do not have to report this line item.

**Line item 59 Tier 2 capital deductions**

Report total tier 2 capital deductions as defined in the FR Y-9C, Schedule HC-R, part I, line item 33.

**Line item 60 Tier 2 capital**

This line item is a shaded cell that is derived from line item 57 minus line item 59. This line item should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 34.a.

**Line item 61 (Advanced approaches holding companies that exit parallel run): Tier 2 capital, reflective of transition provisions**

BHCs and IHCs are not required to complete this line item.

## **Total Capital**

### **Line item 62 Total capital**

This line item is a shaded cell that is derived from the sum of line items 50 and 60. This line item is the numerator of the holding company's total risk-based capital ratio and should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 35.a.

### **Line item 63 (Advanced approaches holding companies that exit parallel run only): Total capital, reflective of transition provisions (sum of items 50 and 61)**

BHCs and IHCs are not required to complete this line item.

## **Threshold Deductions Calculations**

### ***Non-significant investments in the capital of unconsolidated financial institutions in the form of common stock, net of associated DTLs***

**Line item 64 Aggregate non-significant investments in the capital of unconsolidated financial institutions, including in the form of common stock, additional tier 1, and tier 2 capital**  
Aggregate holdings of capital instruments relevant to non-significant investments in the capital of unconsolidated financial entities. This should correspond to the definition of non-significant investments in FR Y-9C, Schedule HC-R, part I, line item 11.

### **Line item 65 10 percent common equity tier 1 deduction threshold for non-significant investments in the capital of unconsolidated financial institutions in the form of common stock**

This line item is a shaded cell and is derived as ten percent of (line item 23 less line items 24 through 34).

### **Line item 66 Amount of non-significant investments that exceed the 10 percent deduction threshold for non-significant investments**

This line item is a shaded cell and is derived as line item 64 less line item 65. If line item 65 is greater than line item 64 this is set to zero. This line item should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 11.

### ***Significant investments in the capital of unconsolidated financial institutions in the form of common stock, net of associated DTLs***

### **Line item 67 Gross significant investments in the capital of unconsolidated financial institutions in the form of common stock**

Aggregate holdings of capital instruments relevant to significant investments in the capital of unconsolidated financial entities, including direct, indirect and synthetic holdings in both the banking book and trading book.

### **Line item 68 Permitted offsetting short positions in relation to the specific gross holdings**

**included above**

Offsetting positions in the same underlying exposure where the maturity of the short position either matches the maturity of the long position or has a residual maturity of at least one year.

**Line item 69 Significant investments in the capital of unconsolidated financial institutions in the form of common stock net of short positions**

This line item is a shaded cell and is the greater of line item 67 minus line item 68 or zero. This line item should correspond to the definition of significant investments in FR Y-9C, Schedule HC-R, part I, line item 13.

**Line item 70 10 percent common equity tier 1 deduction threshold**

This line item is a shaded cell and is derived from 10 percent of line item 36.

**Line item 71 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold**

This line item is a shaded cell and is the greater of line item 69 minus line item 70. If line item 70 is greater than line item 69 this is set to zero. This line item should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 13.

***MSAs, net of associated DTLs*****Line item 72 Total mortgage servicing assets classified as intangible**

Report the amount of MSAs included in Schedule HC-M, line item 12(a), prior to any netting of associated DTLs.

**Line item 73 Associated deferred tax liabilities which would be extinguished if the intangible becomes impaired or derecognized under the relevant accounting standards**

The amount of mortgage servicing assets to be deducted from common equity tier 1 is to be offset by any associated deferred tax liabilities. If the bank chooses to net its deferred tax liabilities associated with mortgage servicing assets against deferred tax assets, those deferred tax liabilities should not be deducted again here.

**Line item 74 Mortgage servicing assets net of related deferred tax liabilities**

This line item is a shaded cell and is derived as line item 72 minus line item 73. This line item should correspond to the definition of MSAs in FR Y-9C, Schedule HC-R, part I, line item 14.

**Line item 75 10 percent common equity tier 1 deduction threshold**

This line item is a shaded cell and is derived as 10 percent of line item 36.

**Line item 76 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold**

This line item is a shaded cell and is derived from line item 74 minus line item 75. If line item 75 is greater than line item 74 this is set to zero. This line item should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 14.

***DTAs arising from temporary differences that could not be realized through net operating loss***

***carrybacks, net of related valuation allowances and net of DTLs***

**Line item 77 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs**

Report this line item consistent with the definition of DTAs in FR Y-9C, Schedule HC-R, part I, line item 15.

**Line item 78 10 percent common equity tier 1 deduction threshold**

This line item is a shaded cell and is derived as 10 percent of line item 36.

**Line item 79 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold**

This line item is a shaded cell and is derived from line items 77 minus 78. If line item 78 is greater than line item 77 this is set to zero. This line item should be consistent with the definition in FR Y-9C, Schedule HC-R, part I, line item 15.

***Aggregate of items subject to the 15% limit (significant investments, mortgage servicing assets and deferred tax assets arising from temporary differences)***

**Line item 80 Sum of items 69, 74, and 77**

This line item is a shaded cell and is derived as the sum of line items 69, 74, and 77.

**Line item 81 15 percent common equity tier 1 deduction threshold**

This line item is a shaded cell and is derived as 15 percent of line item 36. **For advanced-approaches firms, \$**Starting January 1, 2018, this line item is derived as 17.65 percent of (line item 36 minus line item 80).

**Line item 82 Sum of items 71, 76, and 79**

This line item is a shaded cell and is derived as the sum of line items 71, 76, and 79.

**Line item 83 Item 80 minus item 82**

This line item is a shaded cell and is derived from line items 80 minus line item 82.

**Line item 84 Amount to be deducted from common equity tier 1 due to 15 percent deduction threshold, prior to transition provision (greater of item 83 minus item 81 or zero)**

This line item is a shaded cell and is derived as line items 81 minus line item 83. If line item 83 is greater than line item 81 this is set to zero. This should correspond to the definition in FR Y-9C, Schedule HC-R, part I, line item 16.

**Total Assets for the Leverage Ratio (12 CFR 217)**

**Line item 85 Average total consolidated assets**

Report the amount of average total consolidated assets as defined in FR Y-9C, Schedule HC-R, part I line item 36.

**Line item 86 Deductions from common equity tier 1 capital and additional tier 1 capital**

Report the amount of deductions from common equity tier 1 capital and additional tier 1 capital as defined in the FR Y-9C, Schedule HC-R, part I line item 37.

**Line item 87 Other deductions from (additions to) assets for leverage ratio purposes**

Report the amount of other deductions from assets as defined in FR Y-9C, Schedule HC-R, part I line item 38. If the amount is a net deduction, report it as a positive value in this line item. If the amount is a net addition, report it as a negative value in this line item.

**Line item 88 Total assets for the leverage ratio (line item 85 minus line items 86 and 87)**

This line item is a shaded cell and is derived as line item 85 minus line items 86 and 87. This should correspond to the definition in FR Y-9C, Schedule HC-R, part I line item 39.

**REGULATORY CAPITAL AND RATIOS****Line item 89 Common Equity Tier 1**

This line item is a shaded cell and is derived from line item 43.

**Line item 90 Tier 1 Capital**

This line item is a shaded cell and is derived from line item 50.

**Line item 91 Total Capital**

This line item is a shaded cell and is derived from line item 62.

**Line item 92 Total Capital (advanced approaches institutions that exit parallel run only)**

Respondents are not required to complete this line item.

**Line item 93 Total risk-weighted assets using standardized approach**

This should correspond to the definition of total risk-weighted assets in FR Y-9C, Schedule HC-R, part I, line item 40.a. For Capital – CCAR, please report the total amount of Standardized RWA, as reported on line item 44 of FR Y-14 A.1.c.2, Schedule A – Summary Standardized RWA sub-schedule. For Capital – DFAST, report total risk-weighted assets as calculated consistent with the DFAST capital action assumptions.

**Line item 94 (Advanced approaches holding companies that exit parallel run only): total risk-weighted assets using advanced approaches rules**

BHCs and IHCs are not required to fill out this line item.

**Line item 95 Total Assets for the Leverage Ratio per ~~revised~~ regulatory capital rule**

This is derived from line item 88 and should correspond to definition in FR Y-9C, Schedule HC-R, part I, line item 39.

**Line item 96 Supplementary Leverage Ratio Exposure**

Starting January 1, 2018, BHCs subject to the supplementary leverage ratio should report their total supplementary leverage ratio exposure consistent with the definition in 12 CFR 217.

**Line item 97 Common Equity Tier 1 Ratio (%)**

This line item is derived from line item 89 divided by line item 93. This line item should correspond to definition in FR Y-9C, Schedule HC-R, part I, line item 41.A.

**Line item 98 Common Equity Tier 1 Ratio (%) (advanced approaches institutions that exit parallel run only)**

BHCs and IHCs are not required to fill out this line item.

**Line item 99 Tier 1 Capital Ratio (%)**

This line item is derived from line item 90 divided by line item 93. This line item should correspond to definition in FR Y-9C, Schedule HC-R, part I, line item 42.A.

**Line item 100 Tier 1 Capital Ratio (%) (advanced approaches institutions that exit parallel run only)**

BHCs and IHCs are not required to fill out this line item.

**Line item 101 Total risk-based capital ratio (%)**

This line item is derived from line item 91 divided by line item 93. This line item should correspond to definition in FR Y-9C, Schedule HC-R, part I, line item 43.A.

**Line item 102 Total risk-based capital ratio (%) (advanced approaches institutions that exit parallel run only)**

BHCs and IHCs are not required to fill out this line item.

**Line item 103 Tier 1 Leverage Ratio (%)**

This line item is derived from line item 90 divided by line item 95. This line item should correspond to definition in FR Y-9C, Schedule HC-R, part I, line item 44.

**Line item 104 Supplementary Leverage Ratio (%)**

This line item is derived from line item 90 divided by line item 96. This item is reported starting January 1, 2018.

**Schedule HC-F—Other Assets****Line item 105 Net deferred tax assets**

Report net deferred tax assets, as defined in FR Y-9C, Schedule HC-F, line item 2.

**Schedule HC-G—Other Liabilities****Line item 106 Net deferred tax liabilities**

Report net deferred tax liabilities, as defined in FR Y-9C, Schedule HC-G, line item 2.

**Issuances associated with the U.S. Department of Treasury Capital Purchase Program****Line item 107 Senior perpetual preferred stock or similar items**

Report issuances of senior perpetual preferred stock or similar items associated with the U.S. Department of Treasury capital purchase program, as defined in FR Y-9C, Schedule HC-M, line item 24.a.

**Line item 108 Warrants to purchase common stock or similar items**

Report issuances of warrants to purchase common stock or similar items associated with the U.S. Department of Treasury capital purchase program, as defined in FR Y-9C, Schedule HC-M, line item 24.b.

**Deferred Tax Asset Information**

**Line item 109 Potential net operating loss carrybacks**

Report the amount of taxes previously paid that the bank or intermediate holding company could recover through net operating loss carrybacks. Report the full amount recoverable without consideration of the bank holding company's DTA/DTL position at the reporting date. For purposes of this line item, the firm should not include taxes paid in jurisdictions that do not allow a firm to recover taxes in prior fiscal years. Report disaggregated data for taxes paid in memorandum line items 125, 126, and 127.

**Line item 110 Deferred tax assets that arise from net operating loss and tax credit carryforwards, net of DTLs, but gross of related valuation allowances**

Report the aggregate amount of DTAs that arise from net operating loss and tax credit carryforwards, net of associated DTLs, but gross of associated valuation allowances. This line item should correspond to the definition of DTAs in FR Y-9C, Schedule HC-R, part I, line item 8, before the application of any transition provisions plus any related valuation allowances.

**Line item 111 Valuation allowances related to deferred tax assets that arise from net operating loss and tax credit carryforwards**

Report any valuation allowances related to DTAs that arise from net operating loss and tax credit carryforwards, net of associated DTLs.

**Line item 112 Deferred tax assets arising from temporary differences, net of DTLs**

Report the aggregate amount of DTAs arising from temporary differences net of DTLs. If DTLs exceed DTAs from temporary differences, this item should be reported as a negative number. This line item should correspond to the gross amount of DTAs arising from temporary differences, net of DTLs as defined in FR Y-9C, Schedule HC-R, part I, line item 15, before any netting associated with potential net operating loss carrybacks or related valuation allowances.

**Line item 113 Valuation allowances related to DTAs arising from temporary differences**

Report any valuation allowances related to DTAs arising from temporary differences.

**Supplemental Capital Action Information**

**Line item 114 Cash dividends declared on common stock**

**Line item 115 Common shares outstanding (Millions)**

Report the number (in millions) of common shares outstanding at the time dividends on common

stock are declared such that line item 116 reflects the firm's intended quarterly distribution of common dividends per share.

**Line item 116 Common dividends per share (\$)**

Report the firm's intended quarterly distribution in common dividends per share.

**Line item 117 Issuance of common stock for employee compensation**

Report the amount (in \$millions) of the issuance of common stock for employee compensation. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation.

**Line item 118 Other issuance of common stock**

Report the amount (in \$millions) of other issuance of common stock (other than for employee compensation).

**Line item 119 Total issuance of common stock**

**Line item 120 Share repurchases to offset issuance for employee compensation**

Report the amount (in \$millions) of share repurchases to offset the issuance of stock for employee compensation.

**Line item 121 Other share repurchases**

Report the amount (in \$millions) of all other share repurchases.

**Line item 122 Total share repurchases**

**Supplemental Information on Trust Preferred Securities Subject to Phase-Out from Tier 1 Capital**

**Line item 123 Outstanding trust preferred securities**

Report the outstanding notional balance of trust preferred securities as defined in FR Y-9C, Schedule HC, line item 19b.

**Line item 124 Trust preferred securities included in item 49**

Report trust preferred securities qualifying for tier 1 capital and included in line item 49 above.

**MEMORANDA:**

**Memoranda Line item 125 Itemized other adjustments to equity capital**

Report amounts separately of other adjustments to equity capital included in line item 16, and provide a text explanation of each type of adjustment.

**Itemized historical data related to taxes paid:**

**Memoranda Line item 126 Taxes paid during fiscal year ended two years ago**

Report the amount of taxes paid during fiscal year ended two years ago that are included in line item 109, assuming that fiscal years align with calendar years.

**Memoranda Line item 127 Taxes paid during fiscal year ended one year ago**

Report the amount of taxes paid during fiscal year ended one year ago that are included in line item 109, assuming that fiscal years align with calendar years.

**Memoranda Line item 128 Taxes paid through the as-of date of the current fiscal year**

Report the amount of taxes paid during the current fiscal year through the as-of date that are included in line item 109, assuming that fiscal years align with calendar years.

**Memoranda Line item 129 Reconcile the Supplemental Capital Action and HI-A projections**

In this line item, reconcile the supplemental capital actions reported with HI-A projections reported in line items 1 through 15; that is, allocate the capital actions among the HI-A buckets.

**Supporting Documentation**

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

**A.2 Retail**

Loans on the retail schedules should be reported based on the loan's classification on the FR Y-9C, Schedule HC-C (i.e. based on the loans collateral, counterparty, or purpose). Refer to the FR Y-9C instructions for Schedule HC-C for guidance on loan classification. All loans should be reported net of charge-offs.

Throughout the retail-related sub-schedules, Domestic refers to portfolios held in domestic US offices (as defined in the FR Y-9C glossary), and International refers to portfolios outside of the domestic US offices.

**A.2.a—Retail Balance and Loss Projections**

The Retail Balance and Loss Projections sub-schedule collects projections of business-line level balances and losses on BHCs' and IHCs' held for investment loans accounted for at amortized cost (accrual loans). Loans held for sale and loans held for investment under the fair value option should not be included.

**Retail Loan Categories****A. First Lien Mortgages (in Domestic Offices)**

The loan population includes all domestic first lien mortgage loans directly held on the BHC's or IHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.2.(a).

**B. First Lien HELOANs (in Domestic Offices)**

The Loan population includes all domestic first lien home equity loans directly held on the BHC's or IHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a).

**C. Closed-End Junior Liens (in Domestic Offices)**

The loan population includes all domestic loans directly held on the BHC's or IHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b).

**D. HELOCs (in Domestic Offices)**

The loan population includes all first and junior lien domestic lines directly held on the BHC's or IHC's portfolio. Portfolio lines are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1).

**E. First Lien Mortgages and HELOANs (International)**

The loan population includes all non-domestic loans directly held on the BHC's or IHC's portfolio. Portfolio loans are all loans as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a).

**F. Closed-End Junior Liens and Home Equity Lines Of Credit (International)**

The loan population includes all non-domestic loans/lines directly held on the BHC's or IHC's portfolio. Portfolio loans are all loans/lines as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), and item 1.c.(1).

**G. Corporate Card (Domestic)**

Employer-sponsored domestic credit cards for use by a company's employees. This includes US corporate credit card loans as defined in the FR Y-9C, Schedule HC-C, item 4.a, and US corporate card loans reported in other FR Y-9C lines.

Only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

Loans for which a commercially-graded corporation is ultimately responsible for repayment of credit losses incurred should not be reported in this Sub-schedule.

**H. Business Card (Domestic)**

Small business domestic credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as an applicant. Report at the control account level or the individual pay level (not at the sub-account level). This includes SME credit card loans as defined in the FR Y-9C, Schedule HC-C, item 4.a, and US corporate card loans reported in other FR Y-9C lines.

Only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

Loans for which a commercially-graded corporation is ultimately responsible for repayment of credit losses incurred should not be reported in this Sub-schedule.

**I. Charge Card (Domestic)**

Domestic credit cards for which the balance is repaid in full each billing cycle as defined in the FR Y-9C, Schedule HC-C item 6.a or 9.b.

Exclude charge cards to corporations and small businesses (report in Corporate Card or Business Card, as appropriate).

**J. Bank Card (Domestic)**

Regular general purpose domestic credit cards as defined in the FR Y-9C, Schedule HC-C, item 6.a or 9.b.

Bank cards include products that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity and co-brand cards in this category, and student cards, if applicable. This product type also includes private label or proprietary credit cards, which are tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil and gas cards in this loan type.

Exclude bank cards to corporations and small businesses (report in Corporate Card or Business Card, as appropriate).

**K. Business and Corporate Card (International)**

Report employer-sponsored non-domestic credit cards for use by a company's employees and small business non-domestic credit card accounts where the loan is underwritten with the sole proprietor or primary business owner as an applicant. Such loans as defined in the FR Y-9C, Schedule HC-C, item 4.b, and International corporate and business card loans reported in other FR Y-9C lines.

For corporate cards, only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

For bank cards, only include cards where there is any individual liability associated with the sub-lines such that individual borrower characteristics are taken into account during the underwriting decision, and/or performance on the credit is reported to the credit bureaus.

Loans for which a commercially-graded corporation is ultimately responsible for repayment of credit losses incurred should not be reported in this Sub-schedule.

**L. Bank and Charge Card (International)**

Include both non-domestic credit cards for which the balance is repaid in full each billing cycle and regular general purpose non-domestic credit cards as defined in the in FR Y-9C, Schedule HC-C item 6.a or 9.b.

Bank cards include products that can be used at a wide variety of merchants, including any who accept MasterCard, Visa, American Express or Discover credit cards. Include affinity and co-brand cards in this category, and student cards, if applicable. This product type also includes private label or proprietary credit cards, which are tied to the retailer issuing the card and can only be used in that retailer's stores. Include oil and gas cards in this loan type.

Exclude bank cards to corporations and small businesses (report in Corporate Card or Business Card, as appropriate).

**M. Auto Loans (Domestic)**

Include all domestic as defined in the FR Y-9C, Schedule HC-C, item 6.c and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

**N. Auto Loans (International)**

Include all non-domestic as defined in the FR Y-9C, Schedule HC-C, item 6.c and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

**O. Auto Leases (Domestic)**

Include domestic auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

**P. Auto Leases (International)**

Include non-domestic auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a and repossessed automobiles as defined in the FR Y-9C, Schedule HC-F, item 6.

**Q. Student Loan**

Include student loans as defined in the FR Y-9C, Schedule HC-C, items 6.b and 6.d.

**R. Small Business Loan - Scored (Domestic)**

The loan population of domestic small business loans is dependent on two factors: 1) the classification of the loan as defined in the FR Y-9C, Schedule HC-C (i.e. based on the collateral, counterparty, or purpose of the loan); and (2) whether the method to measure credit risk for the loan is different than that used for ordinary corporate loans.

- a. Reportable loans may include those small business loans that are included in the FR Y-9C, Schedule HC-C, items 2.a, 2.b, 3, 4.a and 4.b (excluding SME credit card loans included on Item 4.a) 7, 9.b.(1), 9.b.(2) and 10.b.
- b. To be classified as a small business loan, the method to measure credit risk must be different than the method used for other corporate loans. Commercial internal risk ratings or grades tend to not be used to assess credit risk for ordinary corporate loans. Meanwhile, small business loans tend to be scored or delinquency managed. Additionally, loans that are nevertheless internally risk weighted but that use a scale different from that used for ordinary corporate loans may also be considered small business loans.

**S. Small Business Loan - Scored (International)**

The population of international small business loans includes all non-domestic loans that fit the definition of small business loans (see above).

**T. Other Consumer Loans and Leases (Domestic)**

- a. Include all domestic loans as defined in the FR Y-9C, Schedule HC-C, items 6.b and 6.d excluding student loans and non-purpose based securities loans. Non-purpose based securities loans are loans secured by a portfolio of securities that are used for the purpose of something other than purchasing securities.
- b. Include domestic non-auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a.

**U. Other Consumer Loans and Leases (International)**

- a. Include all non-domestic loans as defined in the FR Y-9C, Schedule HC-C, items 6.b and 6.d excluding student loans and non-purpose securities based loans. Non-purpose securities based loans are loans secured by a portfolio of securities that are used for the purpose of something other than purchasing securities.

b. Include non-domestic non-auto leases as defined in the FR Y-9C, Schedule HC-C, item 10.a.

**For Sections A through U: Report line items 1 through 8 for the current quarter and nine subsequent projected quarters (PQ1 through PQ9).** Reporting of projections for credit cards should be based on all open accounts (active and inactive), but not charged-off accounts

**Line item 1 Balances**

Report according to FR Y-9C definitions (end of quarter levels). Report end of quarter levels for each Section. Where requested, please segment the total balances reported by age. For those lines, balances should be classified according to the origination date of the account with which the balance is associated.

**Line item 2 New Originations**

Report the total dollar amount of new originations net of sales to Agencies. Report only originations for those loans and leases that the bank or intermediate holding company has the intent and ability to hold for the foreseeable future or until maturity or payoff.

**Line item 3 Paydowns**

Report the total dollar of repayments received in the given quarter.

**Line item 4 Asset Purchases**

Report the total dollar of assets purchased in the given quarter. Include mortgages repurchased from GNMA, GSEs, and private securitizations that are put back into the accrual book.

**Line item 5 Asset Sales**

Report the total dollar of assets sold in the given quarter, net of sales to Agencies.

**Line item 6 Loan Losses**

Report the total dollar of net charge-offs recognized in the given quarter.

**Line item 7 Cumulative Interim Loan Losses - Non-PCI**

Report the total unpaid principal balance that has been charged-off on loans in the segment through quarter-end of the reporting period on non-Purchased Credit-Impaired (PCI) loans. Interim charge-offs include all cumulative partial charge-offs/write-downs for loan that have not been fully charged-off or otherwise liquidated.

**Line item 8 Cumulative Interim Loan Losses - PCI**

Report the total interim losses through quarter-end of the reporting period that have been or are expected to be covered by the non-accretable mark or the reserve set up post-mark (ALLL) to cover additional shortfalls in expected cash flows on Purchased Credit-Impaired (PCI) loans. This measure should not include liquidated loans.

For more information on purchased credit-impaired loans, refer to the FR Y-9C, Schedule HC-N, Memorandum item 9.

### **A.2.b—Retail Repurchase Projections**

Large and noncomplex firms are not required to complete this subschedule.

The Retail Repurchase sub-schedule collects projected data on loans sold by the BHC or IHC that may be subject to repurchase risk due to breaches of representations and warranties made during the sale of the loans, as defined in the FR Y-9C, Schedule HC-P, item 6. It also collects data on loans insured by the US Government for which the insurance coverage could be denied or indemnification required if loan defects are identified. Projected losses in these tables should correspond to the sold loan populations reported in Schedule G – Retail Repurchase Exposures.

This sub-schedule collects the projected future lifetime losses that would be charged-off through the repurchase reserve under each scenario.

#### **Table Information:**

Information reported in this schedule will be collected in Tables A through G. Please report information aggregated by Vintage for each table and corresponding data fields below. The Vintage of each column refers to the calendar year that the loan was sold (i.e., 2004 through the current year).

In cases where the data may not be available by Vintage, report the data in the Unallocated column. *Projected Future Losses to BHC or IHC Charged to Repurchase Reserve* associated with Vintages prior to 2004 should be included in the Unallocated column.

**Tables A through F:** For Tables A through F, data will be represented in three sections.

#### **Section 1: BHC OR IHC ABLE TO REPORT OUTSTANDING UPB AND DELINQUENCY INFORMATION REQUESTED**

The row variables for Section 1 identified in Tables A through F should be completed using the following categories:

##### **Estimated Lifetime Net Credit Losses (Excluding Exempt Population):**

Report the firm's estimate of lifetime net credit losses by investors in the loans (inclusive of net credit losses realized-to-date) under the scenario in question, excluding from the estimate losses on the exempt population as defined in Schedule G – Retail Repurchase Exposures.

##### **Projected Future Losses to BHC or IHC Charged to Repurchase Reserve (Excluding Exempt Population):**

Report lifetime future losses related to sold or government-insured loans under the scenario in question that the BHC or IHC expects to charge through its repurchase reserve. Refer to the FR Y-9C, Schedule HC-P, item 7 for a further definition of "repurchase reserve". Any amount of projected future losses associated with Vintages prior to 2004 should be highlighted in the supporting documentation and included in the Unallocated column. Planned future originations with the intent to sell where there are expected losses/reserves associated with new vintages should not be included on the Retail Repurchase sub-schedule.

## **Section 2: BHC OR IHC UNABLE TO REPORT OUTSTANDING UPB OR DELINQUENCY INFORMATION REQUESTED**

The row variable for Section 2 identified in Tables A through F should be completed using the following category:

### **Projected Future Losses to BHC and IHC Charged to Repurchase Reserve (Excluding Exempt Population):**

Report lifetime future losses related to sold or government-insured loans under the scenario in question that the BHC or IHC expects to charge through its repurchase reserve.

Data collected in Sections 1 and 2 should be mutually exclusive.

## **Section 3: LOSS PROJECTIONS**

The row variable for Section 3 identified in Tables A through F should be completed using the following category:

### **Projected Future Losses to BHC or IHC Charged to Repurchase Reserve:**

Lifetime future losses related to sold or government-insured loans under the scenario in question that the BHC or IHC expects to charge through its repurchase reserve.

As part of Section 3 for Tables A through F, please distribute the projected future lifetime losses that would be charged-off through the repurchase reserve under each scenario, as defined in Table Instructions below, over the quarters displayed defined in each column header (i.e., PQ1 through PQ9, and PQ10 or later).

For Tables A through F, the sum of the projected future losses in Sections A.3 – F.3 expected to be charged off to the repurchase reserve should equal the sum of the projected future losses expected to be charged off through the repurchase reserve in Sections A.1 – F.1 and A.2 – F.2.

The Projection Validity Check cells will read “TRUE” when these projected losses are filled out correctly.

Further, the sum of the projected future losses reported in Sections A.3 - F.3 is calculated in Section G.3. The sum of losses expected to be charged to the repurchase reserve is linked to the net charge-off lines in the Repurchase Reserve on the Income Statement to ensure consistency across the sheets of the FR Y-14A summary workbook.

### **Table Instructions**

The tables below should correspond to the sold loan populations reported in Schedule G – Retail Repurchase Exposures.

#### **Tables A—Loans Sold to Fannie Mae (FNMA)**

#### **Tables B—Loans Sold to Freddie Mac (FHLMC)**

**Tables C—Loans Insured by the US Government**

Loans insured by the US Government include loans insured by the Federal Housing Administration (FHA) or the Farmers Home Administration (FmHA) or guaranteed by the Veterans Administration (VA) that back Government National Mortgage Association (GNMA) securities, i.e., “GNMA loans.” Include all loans insured by the US Government including those on balance sheet (including any GNMA buyouts or on-balance sheet FHA exposures) or sold into a GNMA security.

**Tables D—Loans Securitized with Monoline Insurance**

Include loans packaged into a securitization and wrapped with monoline insurance. If it cannot be identified whether a given loan is monoline insured, include the loan in this category.

**Tables E—Loans Securitized without Monoline Insurance**

Include loans packaged into a securitization but not wrapped with monoline insurance;

**Tables F—Whole Loans Sold**

Include loans sold as whole loans to parties other than Fannie Mae or Freddie Mac, even if the whole loans were subsequently sold to Fannie Mae or Freddie Mac.

**Table G—Total Loss Projections**

This item is a shaded cell and is derived from the sum of Tables A3, B3, C3, D3, E3, and F3.

## A.3 AFS/HTM Securities

### General Instructions

High-Level OTTI Methodology and Assumptions for AFS and HTM Securities by Portfolio, Projected OTTI for AFS and HTM Securities by Portfolio, Projected OCI and Fair Value for AFS and Impaired HTM Securities, and Actual AFS and HTM Fair Market Value Sources by Portfolio collect data on the following types of securities:

- 1) *government agency mortgage-backed securities (MBS)*: MBS issued or guaranteed by U.S. Government agencies;
- 2) *auction rate securities*: auction-rate securities are variable rate securities with long-term maturities whose interest rates are periodically reset through auctions occurring at predetermined short-term intervals (generally 7, 14, 28, or 35 days);
- 3) *collateralized debt obligations (CDOs)*: CDOs are asset-backed securities collateralized by a discrete portfolio of fixed income assets and that make payments based on the performance of those assets;
- 4) *collateralized loan obligations (CLOs)*: CLOs are securitizations of portfolios of loans through a bankruptcy-remote special-purpose vehicle (SPV) that issues asset-backed securities in one or more classes (or tranches). In general, CLOs are backed by a variety of assets, including whole commercial loans, revolving credit facilities, letters of credit, and bankers' acceptances;
- 5) *commercial mortgage-backed securities (CMBS)*: Exclude securities that have been issued or guaranteed by the Federal National Mortgage Association (FNMA) or the Federal Home Loan Mortgage Corporation (FHLMC) or guaranteed by the Government National Mortgage Association (GNMA). Report these securities as "Agency MBS" (above);
- 6) *common stock (equity)*;
- 7) *auto asset-backed securities (ABS)*: ABS collateralized by auto loans;
- 8) *credit card ABS*: ABS collateralized by credit card loans;
- 9) *student loan ABS*: ABS collateralized by student loans;
- 10) *other ABS (excluding home equity loan ABS)*: all other ABS that cannot properly be reported as auto ABS, credit card ABS, student loan ABS or home equity loan ABS;
- 11) *corporate bonds*: corporate bonds are debt obligations issued by corporations and may be secured or unsecured;
- 12) *covered bonds*: securities generally classified as "covered bonds" that feature recourse to cash flows of a pool of mortgages or public-sector loans on the balance sheet of an issuing financial institution;

- 13) *domestic non-government agency residential mortgage-backed securities (RMBS, includes home equity loan ABS)*: RMBS, including securities backed by home equity loans that are issued by domestic non-government agency entities. Such as Alt-A (option ARM), Alt-A FRM, Alt-A ARM, closed-end second, HELOC, Scratch & Dent, Subprime, Prime Fixed, and Prime ARM securities;
- 14) *foreign RMBS*: RMBS of foreign issuers;
- 15) *municipal bonds*: bonds issued by U.S. states, cities, counties, and other governmental entities at or below the state level. Include bonds issued by Canadian provinces or other local government entities and bonds issued by other non-US local government entities;
- 16) *mutual funds*: investments in mutual funds, including money market mutual funds and mutual funds that invest solely in U.S. government securities;
- 17) *preferred stock (equity)*: refer to the FR Y-9C Glossary entry for "Preferred Stock";
- 18) *sovereign bonds*: bonds issued by the central governments of foreign countries. Also, include in this category obligations of foreign country central banks, foreign central government units or agencies, fully government-guaranteed obligations of municipal or state-owned enterprises; and obligations of supranational organizations such as the International Bank for Reconstruction and Development (World Bank), Inter-American Development Bank, and Asian Development Bank;
- 19) *U.S. Treasuries & other government agency non-mortgage-backed securities*: U.S. government agency obligations issued by U.S. government agencies and U.S. government-sponsored agencies, including but not limited to, Small Business Administration "Guaranteed Loan Pool Certificates," U.S. Maritime Administration obligations, and Export-Import Bank participation certificates. Include obligations (other than mortgage-backed securities) issued by the Farm Credit System, the Federal Home Loan Bank System, the Federal Home Loan Mortgage Corporation, the Federal National Mortgage Association, the Financing Corporation, Resolution Funding Corporation, the Student Loan Marketing Association, and FDIC Structured Sale Guaranteed Notes and NCUA Guaranteed Notes; and
- 20) *other securities* (for "other" AFS and HTM securities, please provide the security type in row 22, currently labeled "Other", adding extra rows below as necessary): all securities that cannot properly be reported in the categories above.

In circumstances whereby the BHC or IHC holds securities in both AFS and HTM categories within a given asset class, separate each security into separate rows. If using additional rows, BHCs or IHCs should ensure that the totals sum appropriately) as defined in the FR Y-14Q, Schedule B, Securities. All BHCs or IHCs should estimate results using the conditions specified in the macroeconomic scenario. Securities should correspond with where the reporter has classified the asset on the balance sheet of the FR Y-9C.

### **A.3.a—Projected OTTI for AFS Securities and HTM by Security**

Large and noncomplex firms are not required to complete this subschedule.

For each individual security that incurred a loss in P&L, state the identifier value (CUSIP or ISIN) and the amount of loss projected (over the entire forecast horizon). Generally, securities should always be reported with a public identifier, if available, such as a valid CUSIP, ISIN, or SEDOL. If a valid CUSIP, ISIN or SEDOL identifier exists for the security, please report the value of the chosen identifier (the CUSIP, ISIN, or SEDOL code) and indicate the identifier type as "CUSIP", "ISIN", or "SEDOL". If a CUSIP, ISIN, or SEDOL identifier is not available for a given security, please report an alternative public identifier value, if available, and report the identifier type. If only a private or internal identifier is available, please indicate "INTERNAL." Create a separate line item for each position. Total projected losses should reconcile to the total sum of projected losses (across all quarters) provided in the Projected OTTI for AFS and HTM Securities by Portfolio Schedule (A.3.c).

In circumstances whereby the BHC or IHC holds securities in both AFS and HTM categories within a given asset class, separate each security into separate line items.

### **A.3.b—High-Level OTTI Methodology and Assumptions for AFS and HTM Securities by Portfolio**

Large and noncomplex firms are not required to complete this subschedule.

Complete the unshaded cells in the table provided. In the "Threshold for Determining OTTI" column, report either the price-based threshold, the ratings-based threshold, the cash flow model-based threshold, or other threshold. Report the aggregate cumulative lifetime loss on underlying collateral (% original balance) as the total undiscounted loss amount (including both historical and projected losses) for the underlying collateral as a percentage of original principal balance of the securities aggregated by portfolio. In the "discount rate methodology" column, state whether a market-based or accounting-based (e.g., book /purchase price) discount is used. In the final three columns: provide the name(s) of any vendor(s) and any vendor models that are used, indicate whether all securities were reviewed for potential OTTI for stress testing and provide the macro-economic and financial variables used in loss estimation.

### **A.3.c—Projected OTTI for AFS and HTM Securities by Portfolio**

Provide the credit loss portion and non-credit loss portion of projected OTTI (for relevant portfolios) for the quarters detailed in the tables provided. Values should be quarterly, not cumulative.

OTTI related to the security's credit loss is recognized in earnings, whereas the OTTI related to other factors (defined as the non-credit loss portion) is included as part of a separate component of other comprehensive income (OCI). For only those securities determined to be other-than-temporarily impaired, BHCs and IHCs should provide both projected losses that would be recognized in earnings and any projected losses that would be captured in OCI. Amortized Cost should represent all Securities held, regardless of if they are impaired or not. Only securities projected to experience an other-than-temporary impairment loss in the P&L should be reported in the "Credit Loss Portion" and "Non-Credit Loss Portion" columns. OTTI values should be stated as positive values.

#### **A.3.d—Projected OCI and Fair Value for AFS and Impaired HTM**

This Schedule must be completed for all BHCs and IHCs regardless of subjectivity to the advanced approaches rule.

The “Total Actual Fair Market Value” column is the end-of-quarter fair value of the portfolio assets for the reporting quarter.

The “Beginning Fair Market Value” in each column for the projected quarters represents the beginning-of-quarter fair value of the AFS and impaired HTM portfolio assets evaluated during the projected quarter. For avoidance of doubt, Securities purchased in the middle of the quarter should be accounted for in the Beginning Fair Market Value of the subsequent quarter.

The “Fair Value Rate of Change” is the weighted average percent change in fair value over the quarter for assets projected to be held at the beginning and end of the relevant quarter. (The “Fair Value Rate of Change” is **not** a ratio of projected OCI to Beginning Fair Market Value). The Fair Value Rate of Change should represent the change in price of the assets whereby the change in fair value does not include amortizations or paydowns. Reinvested assets should be included if the securities were held at the beginning and end of the relevant quarter.

The “Projected OCI” in each column represents the pre-tax incremental change in Accumulated Other Comprehensive Income during the period due to changes in the fair value of the securities in the portfolio and may also reflect changes in amortized cost, including changes due to amortization and accretion, or any other anticipated factors affecting the amortized cost amounts of AFS and impaired HTM holdings. Future OCI may include fair value gains and losses on new instruments if re-investments are anticipated. These columns, including the “Total Projected OCI in all Quarters”, may be affected by changes in a securities’ amortized cost due to a projected experience of OTTI and estimate of OTTI write-down for a given quarter.

#### **A.3.e—Actual AFS and HTM Fair Market Value Sources by Portfolio**

Large and noncomplex firms are not required to complete this subschedule.

Provide information on the sources of actual fair market values as of the reporting date. In the “Principal Market Value Source” column, state whether a vendor or proprietary model is used. If using a third party vendor, provide the name of the vendor. BHCs and IHCs should also indicate how often securities are normally marked to market (e.g., daily, weekly, quarterly, etc.).

#### **Supporting documentation:**

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

## A.4 Trading

**Only the BHCs and IHCs subject to the market shock scenario are required to complete this sub-schedule.**

Large and noncomplex firms are not required to complete this subschedule.

The Trading sub-schedule collects firm-wide trading profit and loss (P/L) results decomposed into the various categories listed (e.g., Equities, FX, Rates) as of a date specified by the Federal Reserve or another recent reporting date prior to the supplied as-of date as appropriate (see When to Report section of the General Instructions for additional detail). These categories are not meant to denote lines of business or desks, but rather firm-wide totals by risk. The decomposition of losses into risk areas should sum to equal the total trading mark-to-market (MTM) loss reported on the income statement. Report total P/L for the entire scenario horizon. When reporting P/L numbers, report profits as positive numbers and losses as negative numbers.

### Column Instructions

#### **Column A Firmwide Trading Total**

Report firm-wide total trading profit and loss for the entire scenario horizon. Do not include P/L related to CVA hedges in this column.

#### **Column B Contributions from Higher-Order Risks**

Report contributions to P/L included in Column A from higher-order risks. Higher order risks are those inter-asset risks attributable to terms not represented in the FR Y-14Q. The highest order term represented in the FR Y-14Q will vary based on the specific asset class. For example, the commodity spot vol grids do not capture risks attributable to the co-movement of multiple underlying commodities.

#### **Column C Firmwide CVA Hedges Total**

Report firm-wide total P/L related to the Credit Value Adjustment (CVA) hedges.

### Line item Instructions

The categories are not meant to denote lines of business or desks, but rather firmwide totals by risk. Categorization matches that on the FR Y-14Q. See FR Y-14Q Trading Schedule instructions for additional detail.

#### **Line item 1 Equity**

Report the contribution to P/L from exposures associated with firmwide Equity risk.

#### **Line item 2 FX**

Report the contribution to P/L from exposures associated with firmwide FX risk.

#### **Line item 3 Rates**

Report the contribution to P/L from exposures associated with firmwide Rates risk.

#### **Line item 4 Commodities**

Report the contribution to P/L from exposures associated with firmwide Commodities risk.

**Line item 5 Securitized Products**

Report the contribution to P/L from exposures detailed on the Securitized Products and Agencies sub-schedules of the FR Y-14Q Trading Schedule. For Agency products, the P/L related to interest rates risk should be reported in the Rates section (Line 3), while the P/L associated with OAS/credit risk elements should be reported in this line item.

**Line item 6 Other Credit**

Report the contribution to P/L from all credit products other than those specified on the Securitized Products or Agencies sub-schedules of the FR Y-14Q Trading Schedule. For Muni products, the P/L related to interest rates risk should be reported in the Rates section (Line 3), while the P/L associated with credit risk elements should be reported in this line item.

**Line item 7 Private Equity**

Report the contribution to P/L from exposures detailed on the Private Equity Sub-schedule of the FR Y-14Q Trading Schedule.

**Line item 8 Other Fair Value Assets**

Report the contribution to P/L from exposures detailed on the Other Fair Value Assets Sub-schedule of the FR Y-14Q Trading Schedule.

**Line item 9 Cross-Asset Terms**

Report the contribution to P/L from intra-asset risks attributable to the co-movement of multiple asset classes. For example, an equity option paying off in a foreign currency would have both Equity and FX risk. The P/L due to this co-dependence would be entered into line 9 and should not be divided among the individual categories listed in Lines 1-8.

**Line item 10 Total**

Report the total of lines 1 through 9. This total must equal line 58, Trading mark-to-market (MTM) loss, reported on the Income Statement sub-schedule of this Schedule.

**Supporting Documentation**

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

## **A.5 Counterparty Credit Risk (CCR)**

Large and noncomplex firms are not required to complete this subschedule.

The CCR sub-schedule collects projected counterparty credit losses as of a date specified by the Federal Reserve. Losses should be reported as positive values and gains should be reported as negative values..

### **Line item 1 Issuer Default Losses (Trading book)**

Report losses arising from potential default of the issuers of securities held in the trading book.

### **Line item 1a Issuer Default losses from securitized products (Trading book)**

Report losses arising from potential default of the issuers of securitized products, including RMBS, CMBS, and other securitized products as specified on the Securitized Products Sub-schedule of the FR Y-14Q Trading Schedule.

### **Line item 1b Issuer Default losses from other credit sensitive instruments (Trading book)**

Report losses arising from potential default of the issuers of all other credit sensitive instruments (i.e., all products considered in Trading IDR losses other than securitized products), such as sovereigns, advanced economy corporate credits, and emerging market corporate credits.

### **Line item 2 Counterparty Credit MTM Losses (CVA Losses)**

Report Counterparty Credit MTM Losses. Report total losses as equivalent to the BHC's or IHC's calculation of aggregate stressed CVA less unstressed CVA for each scenario. This figure, the sum of items 2a and 2b should correspond to the difference between aggregate stressed CVA and aggregate unstressed CVA, as reported in FR Y-14Q Schedule L – Counterparty, Sub-schedule 1.e, for all scenarios.

#### **Line item 2a Counterparty CVA losses**

Report Counterparty CVA losses.

#### **Line item 2b Offline Reserve CVA Losses**

Report CVA losses that result from offline/additional CVA reserve.

#### **Line item 3 Counterparty Default Losses**

Report losses arising from potential default of one or more counterparties.

#### **Line item 3a Impact of Counterparty Default Hedges**

Report the reduction to Counterparty Default losses reported in item 3 due to the gains from single name CDS hedges (as defined in Schedule L of the FR Y-14Q) of defaulting counterparties.

#### **Line item 4 Other Counterparty losses**

Report other counterparty losses not reported in items 1, 2 or 3 above, as required by CCAR instructions.

#### **Supporting Documentation**

Please refer to Appendix A: Supporting Documentation for guidance on providing supporting documentation.

## A.6 BHC or IHC Operational Risk Scenario Inputs and Projections

Operational risk losses are defined in the Revised Capital Framework as losses arising from inadequate or failed internal processes, people and systems, or from external events. Operational risk losses include legal losses but exclude boundary events. Boundary events are operational losses that could also be classified as credit event losses. An operational loss is defined as a financial loss (excluding insurance or tax effects) that results from an operational loss event and includes all expenses associated with an operational loss event except for opportunity costs, forgone revenue, and costs related to risk management and control enhancements implemented to prevent future operational losses. An operational loss event is defined as a financial loss that results from a risk exposure to the firm. Some examples of operational loss events that BHCs and IHCs may consider are losses related to improper business practices (including class action lawsuits), execution errors, cyber security breaches, natural disasters, and fraud. Operational risk loss projections should be included in the PPNR Projections sub-schedule in line 29, Operational Risk Expense.

See Schedule E – Operational Risk for additional operational risk reporting requirements.

### Definitions

Refer to the following definitions when completing the five Operational Risk Scenario Inputs and Projections sub-schedule

- 1. Risk Segment:** The BHC's or IHC's internal classification of operational risk into granular risk categories used for risk management and operational risk loss projection purposes.
- 2. Loss Projection:** Loss estimates for each of the five Scenarios generated by different methodologies such as statistical models, scenario analysis, historical averages, etc.
- 3. Dollar Contribution to Operational Loss Projection (FR Y14 A Schedule 1.6):** For each risk segment, report the projected operational loss amount. The total of all risk segments for each CCAR Scenario should agree to the projected "Operational risk expense" amount included in Line 29 in the Scenario's PPNR Projections sub-schedule.

### Sub-schedule Instructions

The BHC and IHC Operational Risk Scenario Inputs and Projections sub-schedule collects information about the composition of the operational risk loss projections. Each reporting institution should identify the operational risks to which it is exposed, develop and define the risk segments that represent the firm's risks, and project operational losses using relevant data. Data can include external data, internal data, scenario analysis, risk assessment, etc. As appropriate, quantitative methodologies may be used to convert relevant data into loss projections. The overall Operational Risk loss projections should include input for each risk segment. Reporting institutions are expected to provide the type of data, a brief description of the loss event, how it was categorized (risk segment), and the total loss projection by risk segment.

### **Loss Projections based on Legal Reserves and Settlements**

As part of the overall Operational Risk loss projections, BHCs and IHCs should report the potential impact of losses resulting from a firm's actions to prevent or mitigate an operational loss settlement with clients, or to prevent future legal action. Each of the Operational Risk loss projections in each of the required CCAR Scenarios should include all projected settlements, make-whole payments, payouts that satisfy adverse legal rulings, and other legal losses if they are not covered on the PPNR Projections Sub-schedule under items 14N and 30 (Provisions to Repurchase Reserve / Liability for Residential Mortgage Representations and Warranties). If specifically linked to operational risk, BHCs and IHCs should include all legal consultation fees, retainer fees, and provisions to the legal reserve within the Operational Risk loss projections.

### **Unrelated Professional Services**

The cost of outside consulting, routine "business as usual" legal expenses, external audit, and other professional services that are unrelated to operational risk should be included in item 31 (Professional and Outside Services Expenses) on the PPNR Projections Sub-schedule.

### **Supporting documentation:**

Please refer to Appendix A: Supporting Documentation.

## A.7 Pre-Provision Net Revenue (PPNR)

### **A. General Technical Details**

This section provides general guidance and data definitions for the three PPNR sub-schedules included in the Summary Schedule: PPNR Projections sub-schedule, PPNR Net Interest Income (NII) sub-schedule, and PPNR Metrics sub-schedule. The three sub-schedules are described in detail below.

Certain commonly used terms and abbreviations, including PPNR, are defined at the end of this section. Other definitions are embedded in the Schedule. Undefined terms should be assumed to follow FR Y-9C definitions. In cases where FR Y-9C guidance is unavailable, BHCs and IHCs should use internal definitions and include information about the definitions used in the Supporting Documentation Instructions for FR Y-14A projections.

All line item definitions and identification numbers are consistent between the FR Y-14A and FR Y-14Q and data should be reported accordingly. Where specific FR Y-14 PPNR and/or FR Y-9C guidance exists for business line and/or other items, provide both historical and projections data consistently throughout time in accordance with the instructions. If a BHC or IHC has not done so in prior filings, restate and resubmit. If a BHC or IHC is unable to consistently adhere to definitions, it can request an exemption.

All quarterly figures should be reported on a quarterly basis (not on a year-to-date basis).

Provide data for all non-shaded cells, except where the data requested is optional. The BHC or IHC is not required to populate cells shaded gray.

If there are no data for certain numerical fields, then populate the fields with a zero (0). If the fields are optional and a BHC or IHC chooses not to report data, leave the fields blank. For numerical fields requesting information in percent (e.g. average rates earned), use standard format where .01 = 1%. Do not use non numerical characters in numerical fields.

If there is no information for certain descriptive fields, then populate the fields with "N/A." Do not leave descriptive fields blank.

The BHCs or IHCs need to ensure that (a) revenues and expenses reported always reconcile on a net basis to FR Y-9C, Schedule HI, item 3 plus item 5.m minus 7.e plus item 7.c.(1) minus item 40 of PPNR Projections sub-schedule (note that this does not include losses resulting from the trading shock exercise), (b) Net Interest Income is equal between the PPNR Projections and PPNR Net Interest Income sub-schedules, and that (c) Average balances reported for the purposes of the PPNR Net Interest Income sub-schedule equal FR Y-9C, Schedule HC-K, item 5 for average assets and an average of FR Y-9C, Schedule HC, item 21 for average liabilities. BHCs and IHCs should follow the same guidance when restating data to correct any errors either internally identified or identified by the Federal Reserve.

### **Materiality Thresholds**

BHCs and IHCs for which deposits comprise less than 25 percent of total liabilities for any period reported in any of the four most recent FR Y-14Q should complete the PPNR Projections sub-

schedule as well as the Metrics by Business Segment/Line and “Firm-Wide Metrics: PPNR Projections Sub-schedule” sections of the PPNR Metrics sub-schedule. The Net Interest Income sub-schedule is optional for these BHCs and IHCs. All other BHCs and IHCs should complete all three sub-schedules, including the Net Interest Income sub-schedule and the Net Interest Income sub-schedule section of the PPNR Metrics sub-schedule.

Report data for all quarters for a given business segment in the PPNR Projections and PPNR Metrics sub-schedules if the total revenue of that business segment (calculated as the sum of net interest income and noninterest income for that segment), relative to total revenue of the BHC or IHC exceeded 5 percent in any of the most recent four actual quarters as provided by the BHC or IHC in the FR Y-14Q.

If international revenue exceeded 5 percent of total revenue in any of the most recent four actual quarters as provided by the BHC in the FR Y-14Q, provide regional breakouts (PPNR Metrics sub-schedule, items 42A-42 D) for all quarters in the PPNR Metrics sub-schedule.

If International Retail and Small Business revenues exceeded 5 percent of Total Retail and Small Business Segment revenue and Total Retail and Small Business Segment revenues were material based on an applicable 5 percent threshold in any of the most recent four actual quarters as provided by the BHC or IHC in the FR Y-14Q, provide related metrics data for all quarters (PPNR Metrics sub-schedule, item 10).

#### **Net Interest Income: Primary and Supplementary Designation**

BHCs and IHCs are expected to report all line items for all sub-schedules subject to applicable thresholds as detailed in the instructions. In addition, for all BHCs and IHCs that are required to complete the *PPNR Net Interest Income* sub-schedule, the PPNR Net Interest Income sub-schedule should be designated as “Primary Net Interest Income.” The PPNR Projections Sub-schedule for such BHCs and IHCs will be “Supplementary Net Interest Income” by default. For BHCs and IHCs that are not required to complete the PPNR Net Interest Income sub-schedule the PPNR Projections Sub-schedule should be designated as “Primary Net Interest Income.” PPNR Net Interest Income Sub-schedule will be “Supplementary Net Interest Income” for such BHCs and IHCs by default, but is optional. Note that this designation would refer only to the net interest income portion of the sub-schedules.

#### **B. Commonly Used Terms and Abbreviations**

**Credit cards:** Unless specified otherwise, use the same definitions as provided in the FR Y-14M Credit Card schedule

**Domestic Revenues:** Revenues from the US and Puerto Rico only. Note that this differs from the definition of domestic on the FR Y-9C.

**International Revenues:** International Revenues should be those generated from transactions with clients that are domiciled outside the U.S. and Puerto Rico.

**Pre-provision Net Revenue (PPNR):** Sum of net interest income and noninterest income net of noninterest expense, with components expected to reconcile with those reported in the FR Y-9C

when adjusted for certain items. As presented on the PPNR schedules, the adjustments include exclusions of Valuation Adjustment for BHC's and IHC's debt under fair value option (FVO), goodwill impairment, loss resulting from trading shock exercise (if applicable), as well as adjustments related to operational risk expense required for PPNR purposes. For the related items, reference the PPNR Projections sub-schedule and related instructions for the items 29, 40-42. Gains and losses on AFS and HTM securities, including other than temporary impairments (OTTI) estimates, are not a component of PPNR. All revenue and expenses related to mortgage servicing rights (MSRs) are components of PPNR to be reported in the associated noninterest income and noninterest expense line items on the PPNR schedules. Total Loans Held for Sale and Loans Accounted for under the Fair Value Option (item 57 of the Income Statement sub-schedule) are excluded only if they are a result of a market shock exercise. Other Losses (item 66) are excluded as applicable and are expected to be infrequent.

**Revenues:** Sum of net interest income and noninterest income adjusted for selected exclusions, as reported on line item 27 of the PPNR Projections sub-schedule.

**Run-Off or Liquidating Businesses:** operations that do not meet an accounting definition of "discontinued operations" but which the BHC or IHC intends to exit. In order to facilitate the calculation of the proper net interest income on the *Net Interest Income sub-schedule*, report total balances related to discontinued operations as a negative number in "Other" in items 15 and 38 and the corresponding average rates earned in items 31 and 46. BHCs and IHCs should provide a detailed listing of the type (by corresponding line item on the *Net Interest Income sub-schedule*) of such balances reported as negative items in "Other" and the corresponding rates in the submission documentation.

### **A.7.a—PPNR Projections Sub-schedule**

The PPNR Projections sub-schedule is based on standardized reporting of each component of PPNR, using business segment/line views as discussed below. If there is a difference between the FR Y-14 standardized reporting requirements and the BHCs' or IHCs' internal view used for internal capital planning purposes, the BHCs or IHCs should report data in the PPNR sub-schedules only per the standardized FR Y-14 requirements. The BHCs and IHCs are encouraged to provide data consistent with their own internal view in supporting documentation, accompanying the FR Y-14A Projections and discuss data differences. If the BHCs or IHCs are unable to comply with the requirements, they can request a temporary exemption. This guidance applies to PPNR Submission/Projections and PPNR Net Interest Income sub-schedules. Please see guidance for PPNR Metrics in the PPNR Metrics section of the instructions.

#### **Revenue Components**

Revenue items are divided into net interest income and noninterest income, with totals expected to reconcile with what would be reported in the FR Y-9C when adjusted for Valuation Adjustment for firm's own debt under fair value option (FVO), loss resulting from trading shock exercise (if applicable), and operational risk expense adjustments required for PPNR purposes. For related items, reference PPNR Projections sub-schedule and related instructions for line items 29, 40, and 42. In the documentation supporting the FR Y-14A PPNR submission, BHCs and IHCs are encouraged to discuss operational risk losses reported as contra-revenues for FR Y-9C purposes and their reallocation to Operational Risk expense in accordance with the PPNR instructions. Do not report gains and losses on AFS and HTM securities, including other than temporary impairments (OTTI) estimates, as a component of PPNR.

Report all items either in the segments that generated them and/or segments that they were allocated to through funds transfer pricing (FTP). Net interest income allocation to the defined segments should be based on the cost of funds applicable to those segments as determined by the BHC or IHC. Supporting Documentation instructions regarding methodology used should be provided in the memo required with the FR Y-14A Projections. Business segments and related sub-components do not have to correspond to but may include certain line items on the FR Y-9C schedule. The Business segment structure of the sub-schedule is defined by product/service (e.g., credit cards, investment banking) and client type (e.g., retail, medium size businesses); it is not defined by client relationship.

BHCs and IHCs are encouraged to note which line items contain Debit Valuation Adjustments (DVA) and/or Credit Valuation Adjustments (CVA) (note: these are different from fair value adjustment on the BHC's or IHC's own debt under the Fair Value Option (FVO) which is excluded from PPNR by definition), including amounts if available, and whether these are generated with the purpose to generate profit.

All revenue and expenses related to mortgage servicing rights (MSRs) and the associated noninterest income and noninterest expense line items should be evolved over the nine quarter projection horizons, and reported in the pre-provision net revenue (PPNR) schedules.

Gains or losses on loans held for sale and loans accounted for under the fair value option (HFS/FVO loans) should be reported in the relevant items on the PPNR Projections Sub-schedule in accordance with the BHC's or IHC's normal accounting procedures. Starting in January 2014,

all BHCs and IHCs should project gains or losses on HFS/FVO loans for all nine quarters using only the macroeconomic scenario without reference to the global market shock.

### **Business Segment Definitions**

Subject to applicable thresholds, reporting of net interest income and noninterest income items is requested based on a business segment/line view, with business segments/lines defined as follows:

- As general guidance, small business clients are those with annual sales of less than \$10 million. Business, government, not-for-profit, and other institutional entities of medium size are those with annual sales between \$10 million and \$2 billion. Large business and institutional entities are those with annual sales of more than \$2 billion. If a BHC's or IHC's internal reporting for these client segments deviates from this general guidance, continue to report according to internal definitions and describe how the BHC or IHC defined these or similar client segments and the scope of related business segments/lines (internal and those defined in the FR Y-14 PPNR sub-schedules) in the memo supporting the FR Y-14A submission.
- A BHC may include public funds in the segment reporting based on the type of the relationship that exists between the public funds and the BHC. For example, if the BHC or IHC acts in a custodial or administrative capacity, the BHC or IHC may report public funds in Investor Services. If a BHC or IHC is involved in the management of funds, the BHC or IHC may report the public funds in Investment Management.

**Net Interest Income by Business Segment** (unless specified otherwise, all numbers are global).

#### **Line item 1 Retail and Small Business**

This item is a shaded cell and is derived, per column, from the sum of items 1A and 1G. For items 1A through 1F, domestic includes U.S. and Puerto Rico only.

Report in the appropriate sub-item all net interest income related to retail and small business banking and lending, including both ongoing as well as run-off and liquidating businesses<sup>10</sup>. Exclude any revenues related to Wealth Management/Private Banking (WM/PB) clients even if they are internally classified as retail. BHCs or IHCs may include such revenues in WM/PB line items instead. In case of WM/PB mortgage repurchase contra-revenues, if any, report them as outlined in the PPNR Projection sub-schedule.

#### **Line item 1A Domestic**

This item is a shaded cell and is derived, per column, from the sum of items 1B through 1F.

#### **Line item 1B Credit and Charge Cards**

Report net interest income from domestic BHC or IHC issued credit and charge cards to retail customers including those that result from partnership agreements. May include revenue that is generated on domestic accounts due to foreign exchange transactions. Exclude the following:

- other unsecured borrowing and debit cards;
- small business cards (report in Other Retail and Small Business Lending, item 1F);

---

<sup>10</sup> See "Commonly Used Terms and Abbreviations" for the definition.

- wholesale and commercial cards (report in Treasury Services, item 8).
- Cards to Wealth Management/Private Banking clients (report in Wealth Management/Private Banking, line 19B)

**Line item 1C Mortgages**

Report net interest income from domestic residential mortgage loans offered to retail customers.

**Line item 1D Home Equity**

Report net interest income from domestic home equity loans and lines of credit (HELOANs/HELOCs) provided to retail customers.

**Line item 1E Retail and Small Business Deposits**

Report net interest income from domestic branch banking and deposit-related products and services provided to retail and small business customers. Include debit card revenues in this line. May include revenue that is generated on domestic accounts due to foreign exchange transactions. This item does not include any lending revenues.

**Line item 1F Other Retail and Small Business Lending**

Report net interest income from other domestic retail and small business lending products and services. These include, but are not limited to, small business cards, loans, auto loans, student loans, or personal unsecured credit. All domestic lending revenues not captured in Credit Cards, Mortgages, and Home Equity should be reported here.

**Line item 1G International Retail and Small Business**

Report net interest income from retail and small business generated outside of the U.S. and Puerto Rico. Includes, but is not limited to, all international revenues from credit/charge/debit cards, mortgages, home equity, branch and deposit services, auto, student, and small business loans.

**Line item 2 Commercial Lending**

Report net interest income from lending products and services provided to business, government, not-for-profit, and other institutional entities of medium size, as well as to commercial real estate investors and owners. Exclude treasury, deposit, and investment banking services.

**Line item 3 Investment Banking**

Report in the appropriate sub-item all net interest income generated from investment banking services provided to business and institutional entities of both medium and large size. Include revenues from new issue securitizations for third parties. Business lines are defined as follows:

- **Advisory:** Corporate strategy and financial advisory, such as services provided for mergers and acquisitions (M&A), restructuring, financial risk management, among others.
- **Equity Capital Markets:** Equity investment banking services (e.g., IPOs or secondary offerings).
- **Debt Capital Markets:** Generally non-loan debt investment banking services.
- **Syndicated/Corporate Lending:** Lending commitments to larger corporate clients, including event or transaction-driven lending (e.g., to finance M&A, leveraged buyouts, bridge loans). Generally, all syndicated lending origination activity should be included here (not in Commercial Lending).

**Line item 4 Merchant Banking/ Private Equity**

Report net interest income from private equity (PE), real estate, infrastructure, and principal investments in hedge funds. May include principal investment related to merchant banking activities.

**Line item 5 Sales and Trading**

This item is a shaded cell and is derived, per column, from the sum of items 5A and 5B. Report in the appropriate sub-item all net interest income generated from sales and trading activities. Any interest income from carry should be included in Sales & Trading net interest income. May include short-term trading made for positioning or profit generation related to the Sales & Trading activities in this line item.

**Line item 5A Prime Brokerage**

Report net interest income generated from securities financing, securities lending, custody, clearing, settlement, and other services for hedge funds and other prime brokerage clients. Include all prime brokerage revenues in this line and not in any other business segments/lines.

**Line item 5B Other**

Report net interest income from all other Sales & Trading activities. These include, but are not limited to:

- Equities: Commissions, fees, dividends, and trading gains and losses on equity products. Exclude prime brokerage services.
- Fixed Income: Commissions, fees, and trading gains and losses on rates, credit, and other fixed income products. Exclude prime brokerage services.
  - Rates: Generally U.S. Treasury, investment grade sovereign, U.S. agency bonds, and interest rate swaps. Rates revenues related to trading activities outside of the Sales & Trading division need not be included into the Rates trading in this section, but describe where they are allocated in the BHC's or IHC's documentation supporting the FR Y-14A submission.
  - Credit: Generally corporate bonds, loans, ABS, muni, emerging markets, CDS. If a BHC or IHC classifies some of the credit related trading (such as distressed debt) in segments other than "Sales & Trading," it can continue to report it as in its internal financial reports but indicate where they are reported in the documentation supporting FR Y-14A submission.
  - Other: e.g., FX/Currencies if not included above.
- Commodities: Commissions, fees, and trading gains and losses on commodity products. Exclude prime brokerage services.

**Line item 6 Investment Management**

Report all net interest income generated from investment management activities. Business lines are defined as follows:

- Asset Management: Professional management of mutual funds and institutional accounts. Institutional clients may include endowments, not-for-profit entities, governments, and others.
- Wealth Management/Private Banking (WM/PB): Professional portfolio management and advisory services for individuals. Individual clients may be defined as mass market, affluent, and high net worth. Activities may also include tax planning, savings, inheritance, and wealth planning, among others. May include deposit and lending services to WM/PB clients here and retail brokerage services for both WM/PB and non WM/PB clients.

### **Line item 7 Investment Services**

Report all net interest income generated from investment servicing. Exclude prime brokerage revenues. Business lines are defined as follows:

- Asset Servicing: Custody, fund services, securities lending, liquidity services, collateral management; and other asset servicing. Include record keeping services for 401K and employee benefit plans, but exclude funding or guarantee products offered to such clients.
- Issuer Services: Corporate trust, shareowner services, depository receipts, and other issuer services.
- Other Investment Services: Clearing and other investment services.

### **Line item 8 Treasury Services**

Report all net interest income from cash management, global payments, working capital solutions, deposit services, and trade finance from business and institutional entities of both medium and large size. Include wholesale/corporate and commercial cards.

### **Line item 9 Insurance Services**

Report all net interest income from insurance activities including, but not limited to, individual (e.g., life, health), auto and home (property and casualty), title insurance and surety insurance, and employee benefits insurance.

### **Line item 10 Retirement/Corporate Benefit Products**

Report premiums, fees, and other net interest income generated from retirement and corporate benefit funding products, such as annuities, guaranteed interest products, and separate account contracts. The fees/revenues that may be recorded here are generally generated as a result of the BHC or IHC accepting risks related to actuarial assumptions or the estimation of market returns where guarantees of future income streams have been made to clients.

### **Line item 11 Corporate/Other**

Report net interest income associated with:

- Capital and asset-liability management (ALM) activities. Among other items, may include investment securities portfolios (but not gains and losses on AFS and HTM securities, including OTTI, as these are excluded from PPNR by definition). Also may include principal investment supporting the corporate treasury function to manage firm-wide capital, liquidity, or structural risks.
- Run-off or liquidating businesses<sup>11</sup> (but exclude retail and small business run-off/liquidating businesses, per Retail and Small Business segment definition)
- Non-financial businesses (e.g., publishing, travel services)
- Corporate support functions (e.g., Human Resources, IT)
- Other non-core revenues not included in other segments (e.g., intersegment eliminations).

### **Line item 12 Optional Immaterial Business Segments**

BHCs and IHCs have the option to report less material business segment revenue in Optional Immature Business Segments. The reported total optional immaterial business segment revenue relative to total revenue cannot exceed 10 percent. If the total immaterial business segment revenue relative to total revenue would be greater than 10 percent in any of the most recent four

---

<sup>11</sup> See "Commonly Used Terms and Abbreviations" for the definition.

actual quarters as provided by the BHC or IHC in the FR Y-14Q, report data for the largest business segment among the immaterial business segments for all quarters in the PPNR Projections and PPNR Metrics sub-schedules such that the amount reported in the Optional Immaterial Business segments line items does not exceed 10 percent. BHCs and IHCs should provide comprehensive information in the Supporting Documentation Instructions on which business segments are included in the Optional Immaterial Business segments line items in both FR Y-14Q and FR Y-14A schedules, their relative contribution to the totals reported in both schedules and the manner in which the revenues were projected for FR Y-14A purposes. List segments included in this line item in Footnote 7.

#### **Line item 13 Total Net Interest Income**

This item is a shaded cell and is derived, per column, from the sum of items 1, 2 through 5, and 6 through 12. Line item 13, per column, should equal item 49 on PPNR NII Sub-schedule, if completed.

**Noninterest Income by Business Segment** (unless specified otherwise, all numbers are global).

#### **Line item 14 Retail and Small Business**

This item is a shaded cell and is derived, per column, from the sum of items 14A and 14T.

#### **Line item 14A Domestic**

This item is a shaded cell and is derived, per column, from the sum of items 14B, 14E, 14O, and 14S.

Report in the appropriate sub-item all domestic revenues related to retail and small business banking and lending, including both ongoing as well as run-off and liquidating businesses<sup>12</sup>. Exclude any revenues related to Wealth Management/Private Banking (WM/PB) clients even if they are internally classified as retail. BHCs and IHCs may include such revenues in WM/PB line items instead. In case of WM/PB mortgage repurchase contra-revenues, if any, report them as outlined in the PPNR Projection sub-schedule.

#### **Line item 14B Credit and Charge Cards**

This item is a shaded cell and is derived, per column, from the sum of items 14C and 14D.

Report in the appropriate sub-item all noninterest income generated from domestic BHC or IHC issued credit and charge cards to retail customers including those that result from a partnership agreements. May include revenue that is generated on domestic accounts due to foreign exchange transactions and corporate cards. Exclude the following:

- other unsecured borrowing and debit cards;
- small business cards (report in Other Retail and Small Business Lending, item 14S);
- wholesale and commercial cards (report in Treasury Services, item 21);
- Cards to Wealth Management/Private Banking clients (report in Wealth Management/Private Banking, line 19B)

#### **Line item 14C Credit and Charge Card Interchange Revenues - Gross**

Report interchange revenues from all domestic BHC or IHC issued credit and charge cards including those that result from a partnership agreement. Report before any contra-revenues

---

<sup>12</sup> See "Commonly Used Terms and Abbreviations" for the definition.

(e.g., rewards, etc.).

**Line item 14D Other**

Report all other fee income and revenue earned from credit and charge cards not captured in item 14C.

**Line item 14E Mortgage and Home Equity**

This item is a shaded cell and is derived, per column, from the sum of items 14F, 14I and 14N. Report in the appropriate sub-item noninterest income generated from domestic residential mortgage loans offered to retail customers and domestic home equity loans and lines of credit (HELOANs/HELOCs) provided to retail customers.

**Line item 14F Production**

This item is a shaded cell and is derived, per column, from the sum of items 14G and 14H.

**Line item 14G Gains/Losses on Sale**

Report gains/(losses) from the sale of domestic mortgages and home equity originated through all production channels (retail, broker, correspondent, etc.) with the intent to sell. Such gains/losses should include deferred fees and costs that are reported as adjustments to the carrying balance of the sold loan, fair value changes on loan commitments with rate locks that are accounted for as derivatives, fair value changes on mortgage loans held-for-sale designated for fair value treatment, lower-of-cost or market adjustments on mortgage loans held-for-sale not designated for fair value treatment, fair value changes on derivative instruments used to hedge loan commitments and held-of-sale mortgages, and value associated with the initial capitalization of the MSR upon sale of the loan.

**Line item 14H Other**

Report all other fee income and revenue earned from mortgage production not captured in item 14G.

**Line item 14I Servicing**

This item is a shaded cell and is derived, per column, from the sum of items 14J, 14K, 14L, and 14M.

**Line item 14J Servicing & Ancillary Fees**

Report fees received from activities relating to the servicing of mortgage loans, including (but not limited to) the collection principal, interest, and escrow payments from borrowers; payment of taxes and insurance from escrowed funds; monitoring of delinquencies; execution of foreclosures; temporary investment of funds pending distribution; remittance of fees to guarantors, trustees, and others providing services; and accounting for and remittance of principal and interest payments to the holders of beneficial interests in the financial assets.

**Line item 14K MSR Amortization**

Include economic amortization or scheduled and unscheduled payments, net of defaults under both FV and LOCOM accounting methods.

**Line item 14L MSR Value Changes due to Changes in Assumptions/Model Inputs/Other Net of Hedge Performance**

Report changes in the MSR value here and not in any other items. Report changes in the MSR hedges here and not in any other items. Include MSR changes under both FV and LOCOM accounting methods.

**Line item 14M Other**

Report all other revenue earned from servicing activities not captured in lines 14J through 14L.

**Line item 14N Provisions to Repurchase Reserve/Liability for Residential Mortgage Representations and Warranties (contra-revenue)**

Report provisions to build any non-litigation reserves/accrued liabilities that have been established for losses related to sold or government-insured residential mortgage loans (first or second lien). Do not report such provisions in any other items; report them only in line items 14N or 30, as applicable. Exclude all provisions to litigation reserves/liability for claims related to sold residential mortgages (report in item 29).

**Line item 14O Retail and Small Business Deposits**

This item is a shaded cell and is derived, per column, from the sum of items 14P, 14Q and 14R. Report in the appropriate sub-item noninterest income from domestic branch banking and deposit-related products and services provided to retail and small business customers. Include debit card revenues in this line. May include revenue that is generated on domestic accounts due to foreign exchange transactions.

**Line item 14P Non-Sufficient Funds/Overdraft Fees – Gross**

Report noninterest income from fees earned from insufficient fund deposit balances and overdrawn client deposit accounts. Report before any contra-revenues (e.g., waivers, etc.).

**Line item 14Q Debit Interchange – Gross**

Report noninterest income from interchange fees earned on debit cards. Report before any contra-revenues (e.g., rewards, etc.).

**Line item 14R Other**

Among items included here are debit card contra-revenues and overdraft waivers, as applicable.

**Line item 14S Other Retail and Small Business Lending**

Report noninterest income from other domestic retail and small business lending products and services. These include, but are not limited to, small business cards, other small business loans, auto loans, student loans, or personal unsecured credit.

**Line item 14T International Retail and Small Business**

Report noninterest income from retail and small business generated outside of the US and Puerto Rico. Includes, but is not limited to, all revenues from credit/charge/debit cards, mortgages, home equity, branch and deposit services, auto, student, and small business loans.

**Line item 15 Commercial Lending**

Report noninterest income from lending products and services provided to business, government, not-for-profit, and other institutional entities of medium size, as well as to commercial real estate investors and owners. Exclude treasury, deposit, and investment banking services provided to

commercial lending clients.

**Line item 16 Investment Banking**

This item is a shaded cell and is derived, per column, from the sum of items 16A through 16D. Report in the appropriate sub-item noninterest income generated from investment banking services provided to business and institutional entities of both medium and large size. Include revenues from new issue securitizations for third parties.

**Line item 16A Advisory**

Corporate strategy and financial advisory, such as services provided for mergers and acquisitions (M&A), restructuring, financial risk management, among others.

**Line item 16B Equity Capital Markets**

Equity investment banking services (e.g., IPOs or secondary offerings).

**Line item 16C Debt Capital Markets**

Generally non-loan debt investment banking services.

**Line item 16D Syndicated/Corporate Lending**

Lending commitments to larger corporate clients, including event or transaction-driven lending (e.g., to finance M&A, leveraged buyouts, bridge loans). Generally, all syndicated lending origination activity should be included here (not in Commercial Lending).

**Line item 17 Merchant Banking/ Private Equity**

This item is a shaded cell and is derived, per column, from the sum of items 17A through 17C.

Report in the appropriate sub-item revenues from the sponsorship of, management of, or from investing in, distinct long-term investment vehicles, such as real estate funds, private equity funds, hedge funds or similar vehicles. Also include direct long-term investments in securities and assets made primarily for capital appreciation, or investments where the BHC or IHC is likely to participate directly in corporate governance. Do not include revenues from sales & trading operations, corporate lending outside of a fund structure, investing in a HTM or AFS securities portfolio, brokerage or mutual fund operations.

**Line item 17A Net Investment Mark-to-Market**

Report the net gain or loss from sale or from the periodic marking to market of Merchant Banking/Private Equity investments.

**Line item 17B Management Fees**

Report fees and commissions paid by third parties to the BHC or IHC in connection with sale, placement or the management of above described investment activities.

**Line item 17C Other**

Report any noninterest income items not included in items 17A and 17B. Also include the BHC's or IHC's proportionate share of the income or other adjustments from its investments in equity method investees.

**Line item 18 Sales and Trading**

This item is a shaded cell and is derived, per column, from the sum of items 18A, 18D, 18H, and 18K. Report in the appropriate sub-item noninterest income generated from sales and trading activities. Any interest income from carry should be included in Sales & Trading under net interest income. May include short-term trading made for positioning or profit generation related to the Sales & Trading activities in this line item.

**Line item 18A Equities**

This item is a shaded cell and is derived, per column, from the sum of items 18B and 18C.

**Line item 18B Commission and Fees**

Report commissions, fees, and dividends on equity products. Exclude prime brokerage services.

**Line item 18C Other**

Report all noninterest income for equities sales and trading, excluding prime brokerage (to be reported as a separate line item) and excluding commissions and fees. This includes trading profits and other noninterest non-commission income.

**Line item 18D Fixed Income**

This item is a shaded cell and is derived, per column, from the sum of items 18E, 18F, and 18G. Report in the appropriate sub-item commissions, fees, and trading gains and losses on rates, credit, and other fixed income products. Exclude prime brokerage services.

**Line item 18E Rates**

Generally U.S. Treasury, investment grade sovereign, U.S. agency bonds, and interest rate swaps. Rates revenues related to trading activities outside of the Sales & Trading division need not be included into the Rates trading in this section, but describe where they are allocated in the BHC's or IHC's documentation supporting the FR Y-14A submission.

**Line item 18F Credit**

Generally corporate bonds, loans, ABS, muni, emerging markets, CDS. If a BHC or IHC classifies some of the credit related trading (such as distressed debt) in segments other than "Sales & Trading," it can continue to report it as in its internal financial reports but indicate where they are reported in the documentation supporting FR Y-14A submission.

**Line item 18G Other**

Report other fixed income products if not included above (e.g., FX/Currencies).

**Line item 18H Commodities**

This item is a shaded cell and is derived, per column, from the sum of items 18I and 18J.

**Line item 18I Commission and Fees**

Report commissions, fees, and trading gains and losses on commodity products. Exclude prime brokerage services.

**Line item 18J Other**

Report other noninterest income generated from commodity products, excluding prime brokerage services.

**Line item 18K Prime Brokerage**

This item is a shaded cell and is derived, per column, from the sum of items 18L and 18M. Report in the appropriate sub-item noninterest income from securities financing, securities lending, custody, clearing, settlement, and other services for hedge funds and other prime brokerage clients. Include all prime brokerage revenues in this line and not in any other business segments/lines.

**Line item 18L Commission and Fees**

Report commissions and fees on prime brokerage services.

**Line item 18M Other**

Report other noninterest income generated from prime brokerage services.

**Line item 19 Investment Management**

This item is a shaded cell and is derived, per column, from the sum of items 19A and 19B. Report in the appropriate sub-item all noninterest income generated from investment management activities.

**Line item 19A Asset Management**

Professional management of mutual funds and institutional accounts. Institutional clients may include endowments, not-for-profit entities, governments, and others.

**Line item 19B Wealth Management/Private Banking (WM/PB)**

Professional portfolio management and advisory services for individuals. Individual clients may be defined as mass market, affluent, and high net worth. Activities may also include tax planning, savings, inheritance, and wealth planning, among others. May include deposit and lending services to WM/PB clients here and retail brokerage services for both WM/PB and non WM/PB clients.

**Line item 20 Investment Services**

This item is a shaded cell and is derived, per column, from the sum of items 20A, 20D, and 20E. Report in the appropriate sub-item all noninterest income generated from investment servicing. Exclude prime brokerage revenues.

**Line item 20A Asset Servicing**

This item is a shaded cell and is derived, per column, from the sum of items 20B and 20C. Report in the appropriate sub-item all noninterest income from custody, fund services, securities lending, liquidity services, collateral management, and other asset servicing. Include record keeping services for 401K and employee benefit plans, but exclude funding or guarantee products offered to such clients.

**Line item 20B Securities Lending**

Report noninterest income generated from securities lending.

**Line item 20C Other**

Report all other noninterest income asset servicing, excluding securities lending.

**Line item 20D Issuer Services**

Corporate trust, shareowner services, depository receipts, and other issuer services.

**Line item 20E Other**

Report noninterest income from clearing and other investment services not included above.

**Line item 21 Treasury Services**

Report cash management, global payments, working capital solutions, deposit services, and trade finance from business and institutional entities of both medium and large size. Include wholesale and commercial cards.

**Line item 22 Insurance Services**

Report all noninterest income from insurance activities including, but not limited to, individual (e.g., life, health), auto and home (property and casualty), title insurance and surety insurance, and employee benefits insurance.

**Line item 23 Retirement/Corporate Benefit Products**

Report premiums, fees, and other noninterest income generated from retirement and corporate benefit funding products, such as annuities, guaranteed interest products, and separate account contracts. The fees/revenues that may be recorded here are generally generated as a result of the BHC or IHC accepting risks related to actuarial assumptions or the estimation of market returns where guarantees of future income streams have been made to clients.

**Line item 24 Corporate/Other**

Report noninterest income associated with:

- Capital and asset-liability management (ALM) activities. Among other items, may include investment securities portfolios (but not gains and losses on AFS and HTM securities, including OTTI, as these are excluded from PPNR by definition). Also may include principal investment supporting the corporate treasury function to manage firm-wide capital, liquidity, or structural risks.
- Run-off or liquidating businesses<sup>12</sup> (but exclude retail and small business run-off/liquidating businesses, per Retail and Small Business segment definition)
- Non-financial businesses (e.g., publishing, travel services)
- Corporate support functions (e.g., Human Resources, IT)
- Other non-core revenues not included in other segments (e.g., intersegment eliminations).

**Line item 25 Optional Immaterial Business Segment**

BHCs and IHCs have the option to report less material business segment revenue in separate line items “Optional Immature Business Segments”. The reported total optional immaterial business segment revenue relative to total revenue cannot exceed 10 percent. If the total immaterial business segment revenue relative to total revenue would be greater than 10 percent in any of the most recent four actual quarters as provided by the BHC or IHC in the FR Y-14Q, report data for the largest business segment among the immaterial business segments for all quarters in the PPNR Projections and PPNR Metrics sub-schedules such that the amount reported in the Optional Immature Business segments line items does not exceed 10 percent. BHCs and IHCs should

provide comprehensive information in the Supporting Documentation on which business segments are included in the Optional Immaterial Business segments line items in both FR Y-14Q and FR Y-14A schedules, their relative contribution to the totals reported in both schedules and the manner in which the revenues were projected for FR Y-14A purposes. List segments included in this line item in Footnote 7.

**Line item 26 Total Noninterest Income**

This item is a shaded cell and is derived, per column, from the sum of items 14, 15, 16, 17, 18, 19, 20, and 21 through 25. Excludes Valuation Adjustment for firm's own debt under fair value option (FVO) reported in item 40 and the result of trading shock exercise (where applicable), as it is reported in item 42.

**Line item 27 Total Revenues**

This item is a shaded cell and is derived, per column, from the sum of items 13 and 26.

**Noninterest Expense Components**

Noninterest Expense figures are to be broken out as detailed on the sub-schedule. The total is expected to reconcile with what would be reported in the FR Y-9C when adjusted for certain items. As presented on the PPNR sub-schedules, the adjustments include exclusions of goodwill impairment and adjustments related to operational risk expense required for PPNR purposes. For the related items, reference PPNR Projections sub-schedule and related instructions for the line items 29 and 41.

Expense data on the PPNR Submission sub-schedule are only intended to be reported as firm-wide BHC or IHC expenses, with exception of line item 34A, i.e. Marketing Expense for Domestic Credit Cards. This line item is for Domestic Credit Cards business line only. See the description of the Domestic Credit Card business line in the Business Segment Definitions section of the document.

If the Worker's Compensation expense is an expected item, or is regularly budgeted and paid out similar to an insurance premium or accrual of agreed-upon expenses, then a BHC or IHC would report it as Compensation expense or line item 28. If the Worker's Compensation results from a legal settlement, or is part of a large payout to prevent litigation, solve a complaint, or satisfy a penalty or fine, then a BHC or IHC would report it in line item 29 with Operational Risk Expenses.

**Line item 28 Compensation Expense**

This item is a shaded cell and is derived, per column, from the sum of items 28A through 28E.

**Line item 28A Salary**

Exclude stock based and cash variable pay compensation and report in items 28D and 28E, respectively.

**Line item 28B Benefits**

Exclude stock based and cash variable pay compensation and report in items 28D and 28E, respectively.

**Line item 28C Commissions.**

Report commissions only in "Commissions" line item 28C; do not report commissions in any other compensation line items.

**Line item 28D Stock Based Compensation**

Report all expenses related to stock based compensation as defined by ASC Topic 718, Compensation-Stock Compensation (formerly FASB Statement No. 123(R), *Shared-Based Payment*).

**Line item 28E Cash Variable Pay**

Report expenses related to all discretionary variable compensation paid (or to be paid) in the form of cash. Include deferred variable compensation plans not associated with BHC or IHC stock.

**Line item 29 Operational Risk Expense**

This item is a shaded cell and is derived, per column, from the item on the OpRisk Projected Losses Sub-schedule. All operational loss items, including operational losses that are contra revenue amounts or cannot be separately identified, should be reported in the operational risk expense. Any legal consultation or retainer fees specifically linked to an operational risk event should be included in the Operational Risk Expense. Include all provisions to litigation reserves/liability for claims related to sold residential mortgages and all litigation settlements and penalties in this line item and not in any other line item. The reporting of the operational risk expense item will not necessarily be consistent with FR Y-9C reporting.

**Line item 30 Provisions to Repurchase Reserve/Liability for Residential Mortgage Representations and Warranties**

Provisions to build any non-litigation reserves/accrued liabilities that have been established for losses related to sold or government-insured residential mortgage loans (first or second lien). Do not report such provisions in any other items; report them only in line items 14N or 30, as applicable. Exclude all provisions to litigation reserves/liability for claims related to sold residential mortgages (report in item 29).

**Line item 31 Professional and Outside Services Expenses**

Among items included are routine legal expenses (i.e., legal expenses not related to operational losses), audit and consulting fees, and other fees for professional services.

**Line item 32 Expenses of Premises and Fixed Assets**

Report expenses of premises and fixed assets, as defined in the FR Y-9C, Schedule HI, item 7.b.

**Line item 33 Amortization Expense and Impairment Losses for Other Intangible Assets**

Report amortization expense and impairment losses for other intangible assets, as defined in the FR Y-9C, Schedule HI, item 7.c.(2).

**Line item 34 Marketing Expense**

This item is a shaded cell and is derived, per column, from the sum of items 34A and 34B.

**Line item 34A Domestic Credit and Charge Card Marketing Expense**

Include domestic BHC or IHC issued credit and charge cards, as defined in item 1B, including those that result from a partnership agreement. Include both direct and allocated expenses. Report any

expenses that are made to expand the company's card member and/or merchant base, facilitate greater segment penetration, enhance the perception of the company's credit card brand, and/or increase the utilization of the existing card member base across the spectrum of marketing and advertising mediums.

**Line item 34B Other**

Report all marketing expenses not related to domestic credit and charge cards captured in line 34A.

**Line item 35 Other Real Estate Owned Expense**

All expenses associated with other real estate owned that would normally be reported in the FR Y-9C, Schedule HI, item 7.d., "Other noninterest expense".

**Line item 36 Provision for Unfunded Off-Balance Sheet Credit Exposures (to build/decrease item 141 (BHCKB557) in Balance Sheet)**

Report the provision for credit losses on off-balance sheet credit exposures normally reported as one of the items in FR Y-9C, Schedule HI, item 7.d.

**Line item 37 Other Noninterest Expense**

Provide a further break out of significant items included in Other Noninterest Expense in footnote 4, such that no more than 5% of Noninterest Expense are reported without further breakout.

Report the line item breakout for the combined 9 quarters of projected "Other noninterest expense" (line item 37). A quarterly breakout of these data should be included in the Supporting Documentation.

**Line item 38 Total Noninterest Expense**

This item is a shaded cell and is derived, per column, from the sum of items 28, 29 through 34, and 35 through 37. Excludes Goodwill Impairment included in item 41.

**Line item 39 Projected PPNR**

This item is a shaded cell and is derived, per column, from item 27 less 38. By definition, PPNR will calculate as net interest income plus noninterest income less noninterest expense, excluding items broken out in items 40 and 41.

**Line item 40 Valuation Adjustment for Firm's Own Debt Under Fair Value Option (FVO)**

List segments from which item was excluded in Footnote 9. In footnote 27, list FR Y-9C, Schedule HI items in which this amount is normally reported and has been excluded from in this reporting view.

**Line item 41 Goodwill Impairment**

Report impairment losses for goodwill, as defined in the FR Y-9C, Schedule HI, item 7.c.(1). Under GAAP (ASC 350-20-35-30), "Goodwill of a reporting unit shall be tested for impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount." However, it is acceptable for purposes of this exercise to provide annual estimates as long as the resulting quarterly capital projections would not differ materially from those generated using quarterly impairment projections.

**Line item 42 Loss Resulting from Trading Shock Exercise (if applicable)**

This item is a shaded cell and is derived, per column, from the sum of items 58 through 62 on the Sub-schedule 1.a, Income Statement. BHCs and IHCs should not report changes in value of the MSR asset or hedges within the trading book. List segments from which item was excluded in Footnote 25.

### **A.7.b—PPNR Net Interest Income (NII) Sub-schedule**

BHCs and IHCs for which deposits comprise 25 percent or more of total liabilities for any period reported in any of the four most recent FR Y-14Q are required to submit the Net Interest Income sub-schedule. BHCs and IHCs should complete non-shaded cells only; all shaded cells with embedded formulas will self-populate.

This sub-schedule requires BHCs and IHCs to provide average asset and liability balances and average yields to calculate net interest income. The total net interest income calculated should equal the total net interest income reported using a business segment/line view in the PPNR Projections sub-schedule.

The average balances and rates are meant to reflect the average over each quarter as best as possible. The Federal Reserve understands that because of changes in balances over the period, the simple multiplication of average loan rates and balances may not yield the actual interest income. In these cases, the BHCs or IHCs may report the average loan rate so that it equals a weighted average rate over the period and the interest income total for each quarter reflects historical results or the BHC's or IHC's projection, as applicable. If the average rates are materially impacted by large shifts in balances over the period, highlight this in documentation supporting the FR Y-14A submission.

Rates on this sub-schedule are intended to provide a product level view exclusive of transfer pricing activity and should be reported on a gross basis. The reporting of net interest income on the PPNR Projections and PPNR Submission Sub-schedules provide a business line view and should be reported net of transfer pricing adjustments.

#### **Average Assets**

BHCs and IHCs should reference FR Y-9C and other definitions provided in the PPNR Net Interest Income sub-schedule when completing this section. Align the asset categories definitions, where no FR Y9C code is provided, with those on the Balance Sheet sub-schedule of the FR Y-14A Summary Schedule. The FR Y-9C code references are intended only to provide guidance for the types of items to be included or excluded; but NOT the type of balance to be provided. All requested balance items are averages.

In the case of loans, align definitions with the “total loans” section of the Balance Sheet sub-schedule. Include purchased credit impaired loans PCI loan balances and the interest income recognized on these loans. However, report the aggregate of all nonaccrual loans as line item 9, rather than including them in each loan type. Although nonaccrual loans are reported in aggregate for reporting purposes, BHCs and IHCs are encouraged to provide details on the nonaccrual loans by Balance Sheet sub-schedule definition, if available, in the documentation supporting their FR Y-14A submission.

Balance sheet forecasts are intended to be reported in a manner consistent with how the BHC or IHC reports such balances on the FR-Y9C based on the BHCK references in the notes column of the balance sheet sub-schedule, or otherwise in accordance with FR Y-14A reporting instructions where no references are provided. Such balances should then be reported consistently on the PPNR Net II Sub-schedule (in both FR Y-14A and FR Y-14Q schedules). If this reporting results in

recording certain non-earning assets in the average trading assets line on the PPNR Net II sub-schedule (or any other line item with an associated rate), a BHC or IHC should simply reduce the weighted average rate applied to that balance to ensure that income forecasts are calculated appropriately.

Average balances on the PPNR Net Interest Income sub-schedules (both on FR Y-14Q and FR Y-14A) are intended to be reported in a manner consistent with items on the Balance Sheet sub-schedule of FR Y-14A schedule. As such, average asset balances on PPNR Net Interest Income sub-schedule are to reconcile to average of asset balances based on FR Y-9C BHCK2170 (which reflects fair value of AFS securities).

**Line item 1 First Lien Residential Mortgages (in domestic offices)**

Report the average balance of first lien residential mortgages in domestic offices (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a), column B).

**Line item 2 Second/Junior Lien Residential Mortgages (in domestic offices)**

This item is a shaded cell and is derived, per column, from the sum of items 2A and 2B.

**Line item 2A Closed-End Junior Liens**

Report the average balance of second/junior lien residential mortgages in domestic offices (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), column B).

**Line item 2B Home Equity Lines of Credit (HELOCs)**

Report the average balance of home equity lines of credit in domestic offices (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1), column B).

**Line item 3 C&I Loans**

Report the average balance of C&I Graded, Small Business (Scored/Delinquency Managed), Corporate Card, and Business Card loans.

**Line item 4 CRE Loans (in domestic offices)**

Report the average balance of CRE loans in domestic offices as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1), and 1.e.(2), column B.

**Line item 5 Credit Cards**

Report the average balance of credit cards (as defined in the FR Y-9C, Schedule HC-C, item 6.a, column A).

**Line item 6 Other Consumer**

This item is a shaded cell and is derived, per column, from the sum of items 6A through 6C.

**Line item 6A Auto Loans**

Report the average balance of auto loans as defined in the FR Y-9C, Schedule HC-C, item 6.c, column A.

**Line item 6B Student Loans**

Report the average balance of student loans.

**Line item 6C Other (including loans backed by securities (non-purpose lending))**  
Report the average balance of other loans.

**Line item 7 Real Estate Loans (not in domestic offices)**

This item is a shaded cell and is derived, per column, from sum of items 7A and 7B. (Also, defined as FR Y-9C, Schedule HC-C, item 1, column A, less above items 1, 2, 5, and FR Y-9C, Schedule HC-C, item 1.b, column B.)

**Line item 7A Residential Mortgages (first and second lien)**

Report the average balance of first and second lien residential mortgages not in domestic offices.

**Line item 7B Other**

Report the average balance of other real estate loans not in domestic offices.

**Line item 8 Other Loans and Leases**

Report the average balance of other loans and leases. Include loans secured by farmland as defined in FR Y-9C, Schedule HC-C, item 1.b, column B, and other loans not accounted for in the above categories. If total net interest income does not reconcile to FR Y-9C total per PPNR definition using fair value average balances for AFS securities, use "Other" balances (line items 15 and 38) and corresponding rates (line items 31 and 46) to offset the difference.

**Line item 9 Nonaccrual Loans**

Report the average balance of nonaccrual loans, as defined in the FR Y-9C, Schedule HC-N, item item 10 (Column C) less Schedule HC-N, item9 (Column C). Institutions are to provide additional details within the supporting documentation; the composition of the non-accrual loans by key loan type over the reported time periods for each of the scenarios.

**Line item 10 Securities (AFS and HTM) – Treasuries and Agency Debentures**

Report the average balance of AFS/HTM balances in Treasury and Agency debentures, as defined in the FR Y-9C, Schedule HC-B, items 1, 2.a and 2.b, columns A and D.

**Line item 11 Securities (AFS and HTM) – Agency RMBS (both CMOs and pass-throughs)**

Report the average balance of AFS/HTM balances in Agency RMBS, as defined in the FR Y-9C, Schedule HC-B, items 4.a.(1), 4.a.(2), 4.b.(1) and 4.b.(2), columns A and D.

**Line item 12 Securities (AFS and HTM) - Other**

Report the average balance of all AFS/HTM investments not reported in items 10 and 11, defined in the FR Y-9C, Schedule HC, items 2.a and 2.b less Net II Sub-schedule items 10 & 11.

**Line item 13 Trading Assets.**

Report the average balance of trading assets as defined in the FR Y-9C, Schedule HC-K, item 4.a.

**Line item 14 Deposits with Banks and Other**

Report the average balance of deposits with banks.

**Line item 15 Other Interest/Dividend-Bearing Assets**

Report the average balance of other interest/dividend-bearing asset not accounted for in the above

categories (e.g. Fed Funds Sold, Repos, etc.). In Footnote 2, breakout and explain nature of significant items included in other average interest-bearing asset balances such that no more than 5% of total average interest-bearing asset balances are reported without a further breakout.

**Line item 16 Other Assets**

Report the average balance of all non-interest bearing assets. Line 16 of the Net Interest Income Sub-schedule is intended for a BHC and IHC to report noninterest bearing assets, and accordingly is excluded from the calculation of interest income.

**Line item 17 Total Average Asset Balances**

This item is a shaded cell and is derived, per column, from sum of items 1, 2, 3 through 6, 7, and 8 through 16, as defined in the FR Y-9C, Schedule HC, item 12.

**Average Rates Earned**

All rates are annualized.

**Line item 18 First Lien Residential Mortgages (in domestic offices)**

Report the earned average rate of first lien residential mortgages in domestic offices as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a), column B.

**Line item 19 Second/Junior Lien Residential Mortgages (in domestic offices)**

This item is a shaded cell and is derived, per column, from sum of items 19A and 19B.

**Line item 19A Closed-End Junior Liens**

Report the earned average rate of second/junior lien residential mortgages in domestic offices as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), column B.

**Line item 19B Home Equity Lines of Credit (HELOCs)**

Report the earned average rate of home equity lines of credit in domestic offices as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1), column B.

**Line item 20 C&I Loans (excluding small business (scored/delinquency managed)**

Report earned average rate of large commercial credits and small business (graded) loans. Note that the definitions for Large Commercial Credits and Small Business (Graded) are aligned with Balance Sheet definitions (e.g., in the current reports, consistent with CCAR 2012 Balance Sheet sub-schedule).

**Line item 21 CRE Loans (in domestic offices)**

Report the earned average rate of CRE loans in domestic offices as defined in the FR Y-9C, Schedule HC-C, items 1.a.(1), 1.a.(2), 1.d, 1.e.(1), and 1.e.(2), column B.

**Line item 22 Credit Cards**

Report earned average rate of credit cards as defined in the FR Y-9C, Schedule HC-C, item 6.a, column A.

**Line item 23 Other Consumer**

This item is a shaded cell and is derived, per column, from the sum of items 23A through 23C.

**Line item 23A Auto Loans**

Report earned average rate of auto loans as defined in the FR Y-9C, Schedule HC-C, item 6.c, column A.

**Line item 23B Student Loans**

Report earned average rate of student loans.

**Line item 23C Other, incl. loans backed by securities (non-purpose lending)**

Report earned average rate of other loans.

**Line item 24 Real Estate Loans (not in domestic offices)**

Item 24 is a shaded cell and is derived, per column, from sum of items 24A and 24B. (Also, defined as FR Y-9C, Schedule HC-C, item 1, column A, less above items 18, 19, 21, and FR Y-9C, Schedule HC-C, item 1.b, column B.)

**Line item 24A Residential Mortgages (first and second lien)**

Report the earned average rate of first and second lien residential mortgages not in domestic offices.

**Line item 24B Other**

Report the earned average rate of other real estate loans not in domestic offices.

**Line item 25 Other Loans and Leases**

Report the earned average rate of other loans and leases. Include loans secured by farmland as defined in Schedule HC-C, FR Y-9C, Schedule HC-C, item 1.b, column B, and other loans not accounted for in the above categories. If total net interest income does not reconcile to FR Y-9C total per PPNR definition using fair value average balances for AFS securities, use "Other" balances (line items 15 and 38) and corresponding rates (line items 27 and 43) to offset the difference.

**Line item 26 Nonaccrual Loans**

Report the earned average rate of nonaccrual loans. Interest income earned on nonaccrual balances is generally expected to be small.

**Line item 27 Securities (AFS and HTM) – Treasuries and Agency Debentures**

Report the earned average rate earned on AFS/HTM balances in Treasury and Agency debentures.

**Line item 28 Securities (AFS and HTM) – Agency RMBS (both CMOs and pass-throughs)**

Report the earned average rate earned on AFS/HTM balances in Agency RMBS.

**Line item 29 Securities (AFS and HTM) - Other**

Report the earned average rate earned on all other AFS/HTM balances.

**Line item 30 Trading Assets**

Report the earned average rate of trading assets as defined in the FR Y-9C, Schedule HC-K, item 4.a.

**Line item 31 Deposits with Banks and Other**

Report the earned average rate of deposits with banks.

**Line item 32 Other Interest/Dividend-Bearing Assets**

Report the earned average rate of other interest/dividend-bearing asset not accounted for in the above categories.

**Line item 33 Total Interest Income**

This item is a shaded cell and is derived, per column, from sum of the products of items 1 and 18, 2 and 19, 2A and 19A, 2B and 19B, 3 and 20, 4 and 21, 5 and 22, 6A and 23A, 6B and 23B, 6C and 23C, 7A and 24A, 7B and 24B, 8 and 25, 9 and 26, 10 and 27, 11 and 28, 12 and 29, 13 and 30, 14 and 31, & 15 and 32 annualized.

**Average Liability Balances**

For the classification of domestic and foreign deposit liabilities, BHCs and IHCs should report based on internal definitions (those deemed to best represent the behavior characteristics of deposits). For all other liabilities, BHCs and IHCs should reference FR Y-9C and other definitions provided in the PPNR Net interest Income sub-schedule when completing this section.

**Line item 34 Deposits-Domestic**

This item is a shaded cell and is derived, per column, from sum of items 34A through 34E.

A sum of average domestic and foreign deposits should be equal to a sum of average FR Y-9C, Schedule HC, items 13.a.(1), 13.a.(2), 13.b.(1), and 13.b.(2).

**Line item 34A Noninterest-bearing Demand**

Report balances using internal definitions.

**Line item 34B Money Market Accounts**

Report balances using internal definitions.

**Line item 34C Savings**

Report balances using internal definitions.

**Line item 34D Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other Transaction Accounts**

Report balances using internal definitions.

**Line item 34E Time Deposits**

Report balances using internal definitions.

**Line item 35 Deposits-Foreign**

This item is a shaded cell and is derived, per column, from the sum of items 35A and 35B.

A sum of average domestic and foreign deposits should be equal to a sum of average FR Y-9C,

Schedule HC, items 13.a.(1), 13.a.(2), 13.b.(1), and 13.b.(2).

**Line item 35A Foreign Deposits**

Report balances using internal definitions.

**Line item 35B Foreign Deposits-Time**

Report balances using internal definitions.

**Line item 36 Fed Funds, Repos, & Other Short Term Borrowing**

This item is a shaded cell and is derived, per column, from the sum of items 36A through 36C.

**Line item 36A Fed Funds**

Report the average balance of Fed Funds purchased in domestic offices as defined in the FR Y-9C, Schedule HC, item 14.a.

**Line item 36B Repos**

Report the average balance of Securities sold under agreement to repurchase as defined in the FR Y-9C, Schedule HC, item 14.b.

**Line item 36C Other Short Term Borrowing**

Report the average balance of liabilities reported as other borrowed money and subordinated notes and debentures (as defined in the FR Y-9C, Schedule HC, items 16 and items 19.a. which the firm would define as short term borrowings).

A sum of line items 36C ("other short term borrowing") and 39 ("other interest bearing liabilities") equals a sum of average BHCK3190, average BHCK4062, and average interest-bearing liabilities reported in BHCK2750; line item 40 ("other liabilities") captures average non-interest bearing liabilities in BHCK2750.

**Line item 37 Trading Liabilities**

Report the average balance of Trading Liabilities as defined in the FR Y-9C, Schedule HC, item 15.

**Line item 38 Subordinated Notes Payable to Unconsolidated Trusts Issuing Trust Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities**

Report the average balance of Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities as defined in the FR Y-9C, Schedule HC, item 19b.

**Line item 39 Other Interest-Bearing Liabilities**

Report the average balance of liabilities reported as Other Borrowed Money and Subordinated Notes and Debentures as defined in the FR Y-9C, Schedule HC, items 16 and items 19a which are not already reported in line item 35c Other Short Term Borrowing. This includes all long-term debt not included in line item 38 above. A sum of line items 36C ("other short term borrowing") and 39 ("other interest bearing liabilities") equals a sum of average BHCK3190, average BHCK4062, and average interest-bearing liabilities reported in BHCK2750; line item 40 ("other liabilities") captures average non-interest bearing liabilities in BHCK2750.

**Line item 40 Other Liabilities**

Report the average balance of liabilities reported as Other Liabilities as defined in the FR Y-9C,

Schedule HC, item 20. A sum of line items 36C ("other short term borrowing") and 39 ("other interest bearing liabilities") equals a sum of average BHCK3190, average BHCK4062, and average interest-bearing liabilities reported in BHCK2750; line item 40 ("other liabilities") captures average non-interest bearing liabilities in BHCK2750.

**Line item 41 Total Average Liability Balances**

This item is a shaded cell and is derived, per column, from sum of items 34, 35, 36, and 37 to 40.

**Average Liability Rates**

All rates are annualized.

**Line item 42 Deposits—Domestic**

This item is a shaded cell and is derived, per column, from sum of items 42A through 42E.

**Line item 42A Noninterest-bearing Demand**

This item is a shaded cell; rates are equal to zero by definition.

**Line item 42B Money Market Accounts**

Report the earned average rate of Money Market Accounts reported in item 34B.

**Line item 42C Savings**

Report the earned average rate of Savings Accounts reported in item 34C.

**Line item 42D Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other Transaction Accounts**

Report the earned average rate of Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other Transaction Accounts reported in item 34D.

**Line item 42E Time Deposits**

Report the earned average rate of Time Deposits reported in item 34E.

**Line item 43 Deposits-Foreign**

This item is a shaded cell and is derived, per column, from the sum of items 43A and 43B.

**Line item 43A Foreign Deposits**

Report the earned average rate of Foreign Deposits reported in item 35A.

**Line item 43B Foreign Deposits-Time**

Report the earned average rate of Foreign Deposits—Time reported in item 35B.

**Line item 44 Fed Funds, Repos, & Other Short Term Borrowing**

This item is a shaded cell and is derived, per column, from the sum of items 44A through 44C.

**Line item 44A Fed Funds**

Report the average rate paid for Fed Funds purchased in domestic offices as defined in the FR Y-9C, Schedule HC, item 14a.

**Line item 44B Repos**

Report the average rate paid for Securities Sold under agreements to repurchase as defined in the FR Y-9C, Schedule HC, item 14b.

**Line item 44C Other Short Term Borrowing**

Report the average rate paid on liabilities reported as other borrowed money and subordinated notes and debentures as defined in the FR Y-9C, Schedule HC, items 16 and items 19a which the firm defined as short term borrowings.

**Line item 45 Trading Liabilities**

Report the average rate of Trading Liabilities as defined in the FR Y-9C, Schedule HC, item 15.

**Line item 46 Subordinated Notes Payable to Unconsolidated Trusts Issuing Trust****Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities**

Report the average rate of Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities as defined in the FR Y-9C, Schedule HC, item 19b.

**Line item 47 Other Interest-Bearing Liabilities**

Report the average rate paid on the liabilities reported as other borrowed money and subordinated notes and debentures as defined in the FR Y-9C, Schedule HC, items 16 and 19a which the firm defined as Other Interest Bearing Liabilities.

**Line item 48 Total Interest Expense**

This item is a shaded cell and is derived, per column, from sum of the products of items 34A and 42A, 34B and 42B, 34C and 42C, 34D and 42D, 34E and 42E, 35A and 43A, 35B and 43B, 36A and 44A, 36B and 44B, 36C and 44C, 37 and 45, 38 and 46, and 39 and 47, annualized.

**Line item 49 Total Net Interest Income**

This item is a shaded cell and is derived, per column, from item 33 minus item 48. Amount should equal Sub-schedule 7.a, PPNR Submission Sub-schedule, item 13.

### **A.7.c—PPNR Metrics**

The PPNR Metrics sub-schedule requests information on certain metrics relevant for the assessment of various components of PPNR. Elements in Section C of the PPNR Metrics sub-schedule (line items 53 through 87 and either 88A or 88B&C) are required only for BHCs and IHCs that must complete the Net Interest Income sub-schedule. All other metrics are required of all BHCs and IHCs, subject to applicable thresholds.

Metrics in Section A, "Metrics by Business Segment/Line," correspond to Business Segments/Lines on PPNR Submission sub-schedule. In contrast, Sections B and C are both for firm-wide metrics.

In providing industry market size information, BHCs and IHCs can use third party data and are not required to independently derive these metrics. Any supporting information should be described in detail, including the data source, and corresponding data should be provided in the sub-schedule. A BHC or IHC, if relying upon third party data for building projections, should still be cognizant of how their estimates would be appropriate across the range of assumed macro-economic conditions in various scenarios or if some adjustment may be appropriate. BHCs and IHCs should use internal definitions of proprietary trading and clearly describe the covered activities and transactions in methodology narratives.

If a BHC or IHC is unable to provide a metric on the PPNR Metrics sub-schedule, it should offer a data series for alternative metrics that are considered by the BHC or IHC in projecting the relevant component(s) of PPNR and include in the Supporting Documentation required with the FR-14A Projections a discussion of why the standard metric could not be provided.

**Section A. Metrics by Business Segment/Line** (unless specified otherwise, all numbers are global).

"Metrics by Business Segment/Line" correspond to Business Segments/Lines on the PPNR Submission Sub-schedule. This means that each metric is reflective of revenues reported on the PPNR Submission sub-schedule for a given business segment/line, unless explicitly stated otherwise.

#### **Retail and Small Business Segment**

##### **Domestic**

For line items 1 through 9, domestic includes U.S. and Puerto Rico only.

##### **Credit and Charge Cards**

###### **Line item 1 Total Open Accounts – End of Period**

Report number of total open accounts at the end of period for credit and charge cards.

###### **Line item 2 Credit and Charge Card Purchase Volume**

Report credit and charge card purchase volume, net of returns. Exclude cash and balance transfer volumes.

**Line item 3 Credit and Charge Card Rewards/Partner Sharing Expense**  
Report credit card rewards/partner sharing expense for credit and charge cards.

In Footnote 23, list which line item(s) on PPNR Submission Sub-schedule contain(s) the Cards Rewards/Partner Sharing contra-revenues and/or expenses.

Note if this item includes any contra-revenues other than Rewards/Partner Sharing (e.g. Marketing Expense Amortization) in footnote 34.

## **Mortgages and Home Equity**

**Line item 4 Average Third-Party Residential Mortgages Serviced**

Report the average outstanding principal balance for residential mortgage loans the BHC or IHC services for others.

**Line item 5 Residential Mortgage Originations Industry Market Size - Volume**

Report total volume of domestic mortgages that originated during the quarter. A BHC or IHC would provide US industry-wide origination volume (\$millions) for closed-end loans secured by first liens on 1 to 4 family residential properties during a given quarter. This would not include any home equity loans or lines of credit.

**Line item 6 Mortgages and Home Equity Sold During the Quarter**

Report first and junior lien mortgages and home equity loans sold during the quarter as defined in FR Y-9C, Schedule HC-P, items 3.a, 3.b, 3.c.(1), 3.c.(2). FR Y-9C name is "Residential Mortgages Sold During the Quarter"; this metric need not be limited to Mortgages and Home Equity business line.

**Line item 7 Servicing Expenses**

Report expenses for servicing first and junior lien mortgages and home equity loans. Include both direct and allocated expenses.

## **Retail and Small Business Deposits**

**Line item 8 Total Open Checking and Money Market Accounts - End of Period**

Report only the number of checking and money market accounts that are deposit accounts under FR Y-9C guidance and are consistent with the definitions provided for "Retail and small business banking and lending services" segment and "Retail and small business deposits" business line within this segment in the PPNR instructions.

**Line item 9 Debit Card Purchase Transactions**

Report number of transactions (not dollar value).

## **International Retail and Small Business**

International retail and small business located in regions outside the U.S. and Puerto Rico.

**Line item 10 Credit and Charge Card Revenues**

Provide metrics data for all quarters, but only if international retail and small business segment revenues exceeded 5% of total retail and small business segment and total retail and small business revenue exceeded 5% of total revenues in any of the last four actual quarters requested in the PPNR schedule.

**Investment Banking Segment**

**Only firms that report greater than \$100 million any projected quarter in item 16, Investment Banking, of Schedule A.7.a (PPNR Projections) should report the investment banking metrics below (Lines 11 to 26).**

**Line item 11 Number of Employees**

Report the number of full-time equivalent employees at end of current period as defined in the FR Y-9C, Schedule HI, Memorandum item 5, for investment banking segment.

**Line item 12 Compensation - Total**

Include both direct and allocated expenses for investment banking segment.

**Line item 13 Stock Based Compensation and Cash Variable Pay**

Include both direct and allocated expenses for investment banking segment.

**Advisory****Line item 14 Deal Volume**

Report the global dollar volume of all completed deals for the reporting BHC or IHC.

**Line item 15 Industry Market Size - Fees**

Report global fees earned by all relevant industry participants in this area.

**Line item 16 Industry Market Size - Completed Deal Volume**

Report the global dollar volume of completed deals for all relevant industry participants.

**Line item 17 Backlog**

A global backlog should be based on probability weighted fees. The data should be consistent with historical internal reporting, not by market measurement. The last quarter should be the BHC's or IHC's latest backlog estimate. Backlog reporting is not required on a projections basis.

**Equity Capital Markets****Line item 18 Deal Volume**

Report the global dollar volume of all deals for the reporting BHC or IHC.

**Line item 19 Industry Market Size - Fees**

Report global fees earned by all relevant industry participants in this area.

**Line item 20 Industry Market Size - Volume**

Report global dollar volume of completed deals for all relevant industry participants.

**Debt Capital Markets****Line item 21 Deal Volume**

Report the global dollar volume of all deals for the reporting BHC or IHC.

**Line item 22 Industry Market Size - Fees**

Report global fees earned by all relevant industry participants in this area.

**Line item 23 Industry Market Size - Volume**

Report the global dollar volume of completed deals for all relevant industry participants.

**Syndicated Lending****Line item 24 Deal Volume**

Report the global dollar volume of all deals for the reporting BHC or IHC.

**Line item 25 Industry Market Size - Fees**

Report global fees earned by all relevant industry participants in this area.

**Line item 26 Industry Market Size - Volume**

Report the global dollar volume of completed deals for all relevant industry participants.

**Sales and Trading Segment****Line item 27 Number of Employees**

Report the number of full-time equivalent employees at end of current period as defined in the FR Y-9C, Schedule HI, Memorandum item 5, for sales and trading segment.

**Line item 28 Compensation - Total**

Include both direct and allocated expenses for sales and trading segment.

**Line item 29 Stock Based Compensation and Cash Variable Pay**

Include both direct and allocated expenses for sales and trading segment.

**Equities****Line item 30 Average Asset Balance**

Report average asset balance for the quarter of all mark-to-market assets associated directly with the equity sales and trading businesses.

## **Fixed Income**

### **Line item 31 Average Asset Balance**

Report average asset balance for the quarter of all mark-to-market assets associated directly with the fixed income sales and trading businesses.

## **Commodities**

### **Line item 32 Average Asset Balance**

Report average asset balance for the quarter of all mark-to-market assets associated directly with the commodities sales and trading businesses.

## **Prime Brokerage**

### **Line item 33 Average Client Balances**

Report gross client balances (adding credits, debits, and shorts) that are consistent with and drivers of prime brokerage revenues being reported on the PPNR schedule.

### **Line item 34 Transaction Volume**

Report total dollar volume of all transactions during the quarter.

## **Investment Management Segment**

### **Asset Management**

#### **Line item 35 AUM – Total**

This item is a shaded cell and is derived, per column, from the sum of items 35A through 35C.

#### **Line item 35A AUM – Equities**

Report total assets under management for which the investment mandate/strategy is primarily equities.

#### **Line item 35B AUM – Fixed Income**

Report total assets under management for which the investment mandate/strategy is primarily fixed income.

#### **Line item 35C AUM – Other**

Report total assets under management for which the investment mandate/strategy cannot be classified as either Equities or fixed income. For example, include alternative investments, currency products, etc.

**Line item 36 Net Inflows/Outflow**

Report impact of net inflows/outflows on assets under management.

**Wealth Management/Private Banking****Line item 37 Fee Earning Client Assets - Total**

This item is a shaded cell and is derived, per column, from the sum of items 37A through 37C.

**Line item 37A Fee Earning Client Assets - Equities**

Report total Fee Earning Client Assets invested directly or indirectly primarily in equities.

**Line item 37B Fee Earning Client Assets - Fixed Income**

Report total Fee Earning Client Assets invested directly or indirectly primarily in fixed income.

**Line item 37C Fee Earning Client Assets - Other**

Report total Fee Earning Client Assets for which the investment cannot be classified as either Equities or fixed income. For example, include some types of alternative investments, currency products, etc.

**Line item 38 Net Inflows/Outflow**

Report impact of net inflows/outflows on Fee Earning Client Assets.

**Line item 39 Number of Financial Advisors**

Provide a relevant headcount number (e.g. financial advisors, portfolio managers) to facilitate the assessment of revenue productivity in the Wealth Management/Private Banking business line.

**Investment Services Segment****Asset Servicing****Line item 40 Assets under Custody and Administration**

Report total assets under custody and administration as of the end of the quarter.

**Section B. Firm Wide Metrics: PPNR Projections Sub-schedule****Line item 41 Number of Employees**

Report the number of full-time equivalent employees at end of current period as defined in the FR Y-9C, Schedule HI, Memorandum item 5.

**Line item 42 Revenues - International**

This item is a shaded cell and is derived, per column, from the sum of items 42A through 42D. These items are based on holding company consolidated reporting and not on legal-entity basis.

**Line item 42A Revenues - APAC**

Provide Asia and Pacific (includes South Asia, Australia, and New Zealand) region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule. For specific country assignments, use internal definitions.

**Line item 42B Revenues - EMEA**

Provide Europe, Middle East, and Africa region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule. For specific country assignments, use internal definitions.

**Line item 42C Revenues - LatAm**

Provide Latin America, including Mexico region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule. For specific country assignments, use internal definitions.

**Line item 42D Revenues - Canada**

Provide Canada region breakouts for all quarters, but only if international revenue exceeded 5% of the total revenue in any of the last four actual quarters requested in the PPNR schedule.

**Line item 43 Revenues - Domestic**

This item is a shaded cell and is derived, per column, from PPNR Submission Sub-schedule item 27 less item 42. The item will capture all revenues so long as international revenues do not exceed 5% of total revenue in any of the last four actual quarters requested in the PPNR schedule.

**Line item 44 Severance Costs**

In Footnote 14, list items on PPNR Submission sub-schedule that include this item if any.

**Line item 45 Collateral Underlying Operating Leases for Which the Bank is the Lessor**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 126.

Refers to the balance sheet carrying amount of any equipment or other asset rented to others under operating leases, net of accumulated depreciation. This item should correspond to the amount provided in the FR Y-9C, Schedule HC-F item 6 (see item 13 in the instructions). The amount included should only reflect collateral rented under operating leases and not include collateral subject to capital/ financing type leases.

**Line item 45A Auto**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 127.

**Line item 45B Other**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 128.

**Line item 46 OREO Balance**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 122, as

defined in the FR Y-9C, Schedule HC, item 7. Reporting of OREO items on FR Y-14Q PPNR Metrics is expected to be consistent with reporting of OREO items on FR Y-14A PPNR Metrics sub-schedule which sources the data directly from FR Y-14A Balance Sheet sub-schedule. Thus, reporting of OREO items on FR Y-14Q PPNR Metrics sub-schedule is consistent with reporting of OREO items on FR Y-14A Balance Sheet sub-schedule.

**Line item 46A Commercial**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 123.

**Line item 46B Residential**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 124.

**Line item 46C Farmland**

This item is a shaded cell and is derived, per column, from Balance Sheet Sub-schedule item 125.

**Line item 47 Non-Recurring PPNR Items**

Report the total income statement impact of all material non-recurring and infrequent items.

Examples of such items include gains or losses on sales of business lines, gains or losses on extinguishment of debt, gains or losses on mergers / joint ventures, etc. Break out and explain these excluded items in footnote 32.

**Line item 48 Trading Revenue**

Report trading revenue as defined in the FR Y-9C, Schedule HI, item 5.c.

**Line item 49 Net Gains/(Losses) on Sales of Other Real Estate Owned**

Report trading revenue as defined in the FR Y-9C, Schedule HI, item 5.j.

In Footnote 19, list business segments reported on PPNR Submission Sub-schedule that include this item, if any.

**Section C. Firm Wide Metrics: Net Interest Income Sub-schedule** (Required only for BHCs or IHCs that were required to complete the Net Interest Income Sub-schedule)

**Line item 50 Carrying Value of Purchased Credit Impaired (PCI) Loans**

Report carrying value of purchased credit-impaired loans held for investment as defined in the FR Y-9C, Schedule HC-C, memorandum item M.5.b.

**Line item 51 Net Accretion of discount on PCI Loans included in interest Revenues**

Report the net accretion of discount on PCI loans included in net interest income as included on the PPNR Submission Sub-schedule and Net Interest Income Sub-schedule.

**Line item 52 Loans Held for Sale - First Lien Residential Liens in Domestic Offices (Average Balances)**

Report average balance of first lien residential loans held for sale as included in the Net Interest Income Sub-schedule.

**Line item 53 Average Rate on Loans Held for Sale – First Lien Residential Liens in Domestic Offices**

Report average rate paid on first lien residential loans held for sale as included in the Net Interest Income Sub-schedule.

**Quarter End Weighted Average Life of Assets**

The Weighted Average Life (WAL) should reflect the current position, the impact of new business activity, as well as the impact of behavioral assumptions such as prepayments or defaults, based on the expected remaining lives, inclusive of behavioral assumptions. It should reflect the weighted average of time to principal actual repayment (as modeled) for all positions in that portfolio, rounded to the nearest monthly term. For revolving products, the WAL should reflect the underlying repayment behavior assumptions assumed by the institution, which would include contractual repayments, any assumed excess payments or prepayments, and defaults. The WAL for the FR Y-14Q disclosures should reflect the spot balance sheet position for each time period. The WAL should be reflective of the timing assumed by the institutions for those assets/liabilities trading portfolios to be held on the balance sheet and not at the individual position level. For the FR Y-14A, given that it covers forecasted time periods, the WAL should be forward-looking which incorporates the changes to the projected WAL, including new business activity. Reference the PPNR Net Interest Income sub-schedule for product definitions.

**Line item 54 First Lien Residential Mortgages (in Domestic Offices)**

Report the quarter end weighted average life of domestic first lien residential mortgages (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(a), column B).

**Line item 55 Closed-End Junior Residential Liens (in Domestic Offices)**

Report the quarter end weighted average life of domestic closed-end junior residential liens (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(2)(b), column B).

**Line item 56 Home Equity Lines Of Credit (HELOCs)**

Report the quarter end weighted average life of domestic home equity lines of credit (as defined in the FR Y-9C, Schedule HC-C, item 1.c.(1), column B).

**Line item 57 C&I Loans**

Report the quarter end weighted average life of C&I Graded, Small Business (Scored/Delinquency Managed), Corporate Card, and Business Card loans.

**Line item 58 CRE Loans (in Domestic Offices)**

Report the quarter end weighted average life of domestic CRE loans (as defined in the FR Y-9C, Schedule HC-C, the sum of items 1.a.(1), 1.a.(2), 1.d., 1.e.(1) 1.e.(2)), Column B.

**Line item 59 Credit Cards**

Report the quarter end weighted average life of credit cards (as defined in the FR Y-9C, Schedule HC-C, item 6.a., column A).

**Line item 60 Auto Loans**

Report the quarter end weighted average life of auto loans (as defined in the FR Y-9C, Schedule HC-C, item 6.c., column A).

**Line item 61 Student Loans**

Report the quarter end weighted average life of student loans.

**Line item 62 Other, incl. loans backed by securities (non-purpose lending)**

Report the quarter end weighted average life of Other Consumer Loans, incl. loans backed by securities (non-purpose lending).

**Line item 63 Residential Mortgages (First and Second Lien, Not in Domestic Offices)**

Report the quarter end weighted average life of all residential mortgages (first and second lien) not in domestic offices.

**Line item 64 Other Real Estate Loans (Not in Domestic Offices)**

Report the quarter end weighted average life of other real estate loans not in domestic offices.

**Line item 65 Other Loans & Leases**

Report the quarter end weighted average life of other loans and leases. Include loans secured by farmland (as defined in the FR Y-9C, Schedule HC-C, item 1.b, column B), and other loans not accounted for in the above categories.

**Line item 66 Securities (AFS and HTM) - Treasuries and Agency Debentures**

Report the quarter end weighted average life of AFS/HTM balances in Treasury and Agency Debentures (as defined in the FR Y-9C, Schedule HC-B, items 1, 2.a and 2.b, columns A and D). The WAL reporting items (items 69-71) on PPNR Metrics within the Summary Schedule is intended to reflect the weight average remaining life for the reported period. The number is to reflect both the weighted average life of the current positions as well as the impact of assumed new business.

**Line item 67 Securities (AFS and HTM) - Agency RMBS (both CMOs and pass-throughs)**

Report the quarter end weighted average life of AFS/HTM balances in Agency RMBS (as defined in the FR Y-9C, Schedule HC-B, items 4.a.(1), 4.a.(2), 4.b.(1) and 4.b.(2), columns A and D). The WAL reporting items (items 66 - 68) on PPNR Metrics within the Summary Schedule is intended to reflect the weight average remaining life for the reported period. The number is to reflect both the weighted average life of the current positions as well as the impact of assumed new business.

**Line item 68 Securities (AFS and HTM) - Other**

Report the quarter end weighted average life of all other AFS/HTM (defined in the FR Y-9C, Schedule HC, as items 2.a and 2.b less PPNR Metrics Sub-schedule line items 66 & 67). The WAL reporting items (items 66-68) on PPNR Metrics within the Summary Schedule is intended to reflect the weight average remaining life for the reported period. The number is to reflect both the weighted average life of the current positions as well as the impact of assumed new business.

**Line item 69 Trading Assets**

Report the quarter end weighted average life of trading assets (as defined in the FR Y-9C, Schedule HC-K, item 4.a.). For trading assets, WAL should be reflective of the timing assumed by the institutions for those assets to be held on the balance sheet and not necessarily the duration of the underlying positions.

**Line item 70 All Other Earning Assets**

Report the quarter end weighted average life of all other interest-bearing assets not accounted for in the above categories.

**Quarter End Weighted Average Life of Liabilities**

The Weighted Average Life (WAL) should reflect the current position, the impact of new business activity, as well as the impact of behavioral assumptions such as prepayments or defaults, based on the expected remaining lives, inclusive of behavioral assumptions. It should reflect the weighted average of time to principal actual repayment (as modeled) for all positions in that portfolio, rounded to the nearest monthly term. For revolving products, the WAL should reflect the underlying repayment behavior assumptions assumed by the institution, which would include contractual repayments, any assumed excess payments or prepayments, and defaults. The WAL for the FR Y-14Q disclosures should reflect the spot balance sheet position for each time period. For the FR Y-14A, given that it covers forecasted time periods, the WAL should be forward-looking which incorporates the changes to the projected WAL, including new business activity. Reference PPNR Net Interest Income sub-schedule for product definitions.

**Line item 71 Domestic Deposits – Time**

Report the quarter end weighted average life for Domestic Time Deposits (using internal definitions).

**Line item 72 Foreign Deposits – Time**

Report the quarter end weighted average life of Foreign Time Deposits (using internal definitions).

**Line item 73 Fed Funds**

Report the quarter end weighted average life of Fed Funds purchased in domestic offices (as defined in the FR Y-9C, Schedule HC, item 14.a.).

**Line item 74 Repos**

Report the quarter end weighted average life of Securities sold under agreement to repurchase (as defined in the FR Y-9C, Schedule HC, item 14.b.).

**Line item 75 Other Short Term Borrowing**

Report the quarter end weighted average life of liabilities reported as other borrowed money and subordinated notes and debentures (as defined in the FR Y-9C, Schedule HC, items 16. and 19.a., of which the firm would define as short term borrowings).

**Line item 76 Trading Liabilities**

Report the weighted average life of Trading Liabilities (as defined in the FR Y-9C, Schedule HC, item 15). For trading liabilities, WAL should be reflective of the timing assumed by the institutions for those assets to be held on the balance sheet and not necessarily the duration of the underlying positions.

**Line item 77 Subordinated Notes Payable to Unconsolidated Trusts Issuing TruPS and TruPS Issued by Consolidated Special Purpose Entities**

Report the quarter end weighted average life of Preferred Securities (TruPS) and TruPS Issued by Consolidated Special Purpose Entities (as defined in the FR Y-9C, Schedule HC, item 19.b.).

#### **Line item 78 All Other Interest Bearing Liabilities**

Report the quarter end weighted average life of all long-term debt not included in line item 80 above.

#### **Average Domestic Deposit Repricing Beta**

Domestic deposit repricing is rate movement in an environment where the repricing assumption assumed by each of the major deposit products is not restricted by a cap, floor, or zero. Beta should be reported as a balance-weighted average of the actual utilized betas of the line items that contribute to the roll up point requested. The as of date of the balance weights must be equal to the reporting date for all applicable scenarios.

For the balance-weighted average beta, each deposit category should be reported using a blend of brokered and retail deposits. Beta refers to the average repricing response rate the firm projects for each of the deposit products relative to movements in interest rates and might be different based on the scenario.

The betas for line items 79 through 82 should be reported in basis points (bp) and reflect movement in the yield curve, either up or down in relationship to an assumed 100 bps movement and specific to each scenario, if applicable. For beta-related line items 79 to 84 on the PPNR Metrics template, a negative number can be reported in the downward rate movements. However, a negative would be indicating that the firm is projecting an “increase” in the beta when rates movements are down.

#### **Line item 79 Money Market Accounts**

Report (in decimal form basis points) the balance-weighted average beta of domestic money market accounts (using internal definitions for this product).

#### **Line item 80 Savings**

Report (in basis points) the balance-weighted average beta of domestic savings accounts (using internal definitions for this product).

#### **Line item 81 NOW, ATS, and other Transaction Accounts**

Report (in basis points) the balance-weighted average beta of Negotiable Order of Withdrawal (NOW), Automatic Transfer Service (ATS), and other transaction accounts (using internal definitions for these products).

#### **Line item 82 Time Deposits**

Report (in basis points) the balance-weighted average beta of time deposits (using internal definitions for this product).

#### **Average Foreign Deposit Repricing Beta**

Foreign deposit repricing is rate movement in an environment where the repricing assumption assumed by each of the major deposit products is not restricted by a cap, floor, or zero. Beta should be reported as a balance-weighted average of the actual utilized betas of the line items that

contribute to the roll up point requested. The as of date of the balance weights must be equal to the reporting date for all applicable scenarios.

For the balance-weighted average beta, each deposit category should be reported using a blend of brokered and retail deposits. Beta refers to the average repricing response rate the firm projects for each of the deposit products relative to movements in interest rates and might be different based on the scenario.

The beta ratios for line items 83 through 85C should be reported in basis points (bp) movement in the yield curve, either up or down in relationship to an assumed 100 bps movement and specific to each scenario, if applicable.

**Line item 83 Foreign Deposits**

Report (in basis points) the balance-weighted average beta of foreign deposits (using internal definitions for this product).

**Line item 84 Foreign Deposits-Time**

Report (in basis points) the balance-weighted average beta of foreign time deposits (using internal definitions for this product). It is appropriate to report this item as a "balance-weighted average beta of foreign time deposits.

**Line item 85 New Domestic Business Pricing for Time Deposits**

New business pricing for time deposits refers to the anticipated average rate on newly issued time deposits, including renewals. Given that time deposits have a stated maturity, all time deposits issued for that time period are considered new business. The sub-schedule is requesting re-pricing beta under normal rate scenarios for both an upward and downward rate movement.

**Line item 85A Curve (if multiple terms assumed)**

Report the primary reference curve used by the firm for pricing time deposits.

If more than one curve for the pricing of time deposits is used, the curve used to price the majority of the time deposits should be noted on the schedule and additional pricing information should be provided in the supplementary information. If the institution only assumes a single maturity term for new issuance, then the institution should provide the relative index (line item 85B) and spread used to estimate new business pricing in lieu of the curve (line item 85C).

The term "curve" refers to the reference rate used to price time deposits. Given that the pricing of time deposits is dependent on the term, the institution should provide the overall curve used to price time deposits.

**Line item 85B Index Rate (if single term assumed)**

Report the index (e.g., 30 day LIBOR) used to price time deposits when a single maturity term for new issuances is assumed. The index should be the one to which the beta in line item 82 is applied.

**Line item 85C Spread (Relative to the Index Rate)**

Report the weighted average spread used to price time deposits above the index rate when a single maturity term for new issuances is assumed.

## **Schedule B—Scenario**

These instructions provide guidance for reporting the variables used in the firm-defined macroeconomic scenarios underlying the projections of losses, revenue, and capital. These scenarios include the supervisory baseline scenario, supervisory adverse scenario, supervisory severely adverse, BHC baseline scenario, and BHC stress scenario, as well as, any additional scenarios generated by the firm or supplied by the Federal Reserve. (Additional Scenario #1; Additional Scenario #2; etc.)

The template consists of three sub-schedules that each BHC or IHC must complete. Additional sub-schedules are provided if the BHC or IHC generated additional variables for the supervisory scenarios or reported additional scenarios beyond the BHC baseline and BHC stress scenarios. The sub-schedules in the template are:

**Scenario Variable Definitions:** This sub-schedule should be used to list and define the variables included in the BHC or IHC baseline and BHC or IHC stress scenarios, as well as, any additional BHC or IHC scenarios reported.

- The sub-schedule provides space for the supervisory baseline scenario, supervisory adverse scenario, supervisory severely adverse scenario, BHC baseline scenario, and BHC stress scenario, as well as, space for an additional scenario. The sections for the BHC baseline and BHC stress scenarios must be completed. If no additional scenarios are provided, then this section of the sub-schedule may be left blank. If one or more additional scenarios are provided, then a section should be created for each additional scenario and labeled accordingly (Additional Scenario #1; Additional Scenario #2; etc.)
- For each scenario, list the variables included in the scenario in the column titled "Variable Name."
- Variable definitions should be provided in the column titled "Variable Definition." Variable definitions should include a description of the variable and the denomination and/or frequency of the variable (e.g., "Billions of 2005 dollars" or "in percent, average of monthly values").
- The forecasts and historical data for all the scenario variables are constructed on the same basis. Thus, if a variable is, over history, constructed as an average, its forecast should be interpreted as an average as well. For reference, below are the definitions (i.e. period-average or period-end) of the financial market variables in the scenario:
  - U.S. 3-month Treasury yield: Quarterly average of 3-month Treasury bill secondary market rate discount basis.
  - U.S. 10-year Treasury yield: Quarterly average of the yield on 10-year U.S. Treasury bonds.
  - U.S. BBB corporate yield: Quarterly average of the yield on 10-year BBB-rated corporate bonds.
  - U.S. mortgage rate: Quarterly average of weekly series of Freddie Mac data.
  - U.S. Dow Jones Total Stock Market Index: End of quarter value, Dow Jones.
  - U.S. Market Volatility Index (VIX): Chicago Board Options Exchange converted to quarterly by using the maximum value in any quarter.
- For convenience, the sub-schedule provides space for 10 variables per scenario, but any number of variables may be reported, depending on the variables actually used in the scenario. Extra

lines may be created as needed. The same variables do not necessarily have to be included in each scenario.

- Firms should include all economic and financial market variables that were important in projecting results, including those that affect only a subset of portfolios or positions. For example, if asset prices had a meaningful impact, the assumed level of the equity market and interest rates should be included, or if bankruptcy filings affect credit card loss estimates, then the assumed levels of these should be reported.
- For additional variables generated for the supervisory adverse scenario or supervisory severely adverse scenario, BHCs and IHCs should set the paths to be as consistent as possible with the paths of the variables already specified in the scenario.
- Firms should also include any variables capturing regional or local economic or asset value conditions, such as regional unemployment rates or housing prices, if these were used in the projections.
- Firms should include historical data, as well as projections, for any macroeconomic, regional, local, or financial market variables that are not generally available. Historical data for these variables can be included in a separate sub-schedule.

#### **B.1—Supervisory Baseline Scenario**

This sub-schedule should be used to report the values of any additional variables generated for the supervisory baseline scenario.

#### **B.2—Supervisory Adverse Scenario**

This sub-schedule should be used to report the values of any additional variables generated for the supervisory adverse scenario.

#### **B.3—Supervisory Severely Adverse Scenario**

This sub-schedule should be used to report the values of any additional variables generated for the supervisory severely adverse scenario.

#### **B.4—BHC Baseline Scenario**

This sub-schedule should be used to report the values of the variables included in the BHC baseline scenario.

#### **B.5—BHC Adverse Scenario**

This sub-schedule should be used to report the values of the variables included in the BHC stress scenario.

#### **B.6+ —Additional Scenario #1/#2/etc.**

These sub-schedules should be used to report the values of the variables included in any additional scenarios.

Please create a separate sub-schedule (tab) for each additional scenario. Name the sub-schedules “Additional Scenario #1;” “Additional Scenario #2;” etc.

**All Scenarios:** The following applies to all of the Scenario tabs:

- The variables should be the same (and have the same names) as the variables listed

in the corresponding sections of the *Scenario Variable Definitions* Sub-schedule.

- List quarterly values for the variables starting with the last realized value through the end of the forecast horizon.
- If a BHC or IHC needs to infer a monthly (instead of quarterly) progression of variables, it should smooth or prorate the variables, rather than holding the quarterly value constant over the quarter months.
- Please enter all variables as levels rather than as changes or growth rates (for instance, the dollar value of real GDP rather than the GDP growth rate).

## **Schedule C—Regulatory Capital Instruments**

### **General guidance**

The Regulatory Capital Instruments annual (FR Y-14A) schedule collects actual (historical) data and projections over the nine quarter horizon of BHCs' or IHCs' balances of the funded instruments that are included in regulatory capital. The schedule collects data on the historical balances and projected balances of funded regulatory capital instruments by instrument type, in addition to projections for issuances and redemptions that contribute to changes in balances under the BHC baseline scenario.

A BHC must indicate whether the submission of the FR Y-14A Regulatory Capital Instruments schedule relates to the original submission of the BHC's planned capital actions ("Original" submission), the optional adjustment to planned capital actions prior to the finalization of the CCAR results ("Adjusted" submission), or a request to make additional capital distributions above those included in the BHC's capital plan between CCAR exercises ("Incremental" submission). The original submission is due April 5 of each calendar year. The adjusted submission would be submitted if the firm chooses to adjust its planned capital actions based on the preliminary results of CCAR. The Board will notify companies of the date on which it expects companies to submit planned capital actions at least 14 calendar days prior to the expected deadline for submitted planned capital actions. Incremental capital actions would be submitted at the time the firm wishes to seek approval for additional capital distributions (see 12 CFR 225.8(g)) or notify the Federal Reserve of its intention to make additional capital distributions under the de minimis exception of the capital plan rule (see 12 CFR 225.8(g)(2)).

This schedule collects the total balances of capital instruments and planned redemptions and issuances at an aggregate instrument-type level (e.g., common stock, non-cumulative perpetual preferred, subordinated debt, etc.).

The instructions for the sub-schedule should be read in conjunction with the regulatory capital guidelines issued by the Federal Reserve, the FR Y-9C report and instructions and the **revised** regulatory capital rule (see generally 12 CFR 217).

BHCs and IHCs must report information on both a notional basis and on the basis of the dollar amount included in regulatory capital. For "Notional Amount" report the total notional amount of each instrument. BHCs and IHCs must provide the "Notional Amount" regardless of whether there is an associated amount recognized in regulatory capital. For example, 100% of subordinated debt nearing maturity with limited or no recognition in regulatory capital should be included. For "Amount Recognized in Regulatory Capital" report the portion of the notional amount that is recognized in regulatory capital.

BHCs and IHCs should use the "Comments" field to provide identification of individual instruments that have changed in value. Respondents should also include any other characteristics that impact the investment value. BHCs and IHCs must provide a page reference in their Capital Plan in which the stated activities are captured in the "Page Reference in the Capital Plan" fields for field for any line item with "Comments"; this information is not required for the capital balance sections of the schedule. If page references are not available for the entries in the 'Quarterly Activity – Other than Issuances, Repurchases, or Redemptions' section, then the BHC or IHC is required to provide detailed comments explaining the entry in the "Comments" field. All BHCs and IHCs must report

quarter ending balances under the “Actual As of Date” and projected balances under Projection Quarters PQ1, PQ2, PQ3, PQ4, PQ5, PQ6, PQ7, PQ8, and PQ9 for both the “Notional Amount” and the “Amount recognized in regulatory capital”.

For any instrument type the BHC or IHC has not issued and does not project to issue, BHCs or IHCs must leave the field blank.

For both the “Notional amount” and “Amount recognized in regulatory capital” within the “Revised regulatory capital treatment section,” BHCs and IHCs must provide the actual and projected aggregate dollar amounts (\$Millions) for each line item under the revised regulatory capital rule. Submissions must reflect the necessary transition provisions for non-qualifying capital instruments with their quarter ending actual balances reported.

For “Quarterly Redemption/Repurchase Activity,” report the actual and projected aggregate dollar amount (\$Millions) of planned redemptions and repurchases to be conducted in each quarter for each type of capital instrument. All redemptions and repurchases must be reported as negative values. “Quarterly Redemption/Repurchase Activity” must include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation.

For “Quarterly Issuance Activity,” report the actual and projected aggregate dollar amount (\$Millions) of planned issuances to be conducted in each quarter for each instrument type. “Quarterly Issuance Activity” must include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for the employee stock compensation.

Conversion of preferred stock to common stock should be reported as a redemption of preferred stock and an issuance of common stock in the same quarter.

For “Quarterly Activity – Other than Issuances, Repurchases, or Redemptions,” report the actual and projected aggregate dollar amount (\$Millions) of planned changes in regulatory capital instruments that are not the direct result of issuances, repurchases, or redemptions, including but not limited to: (1) Maturities of capital instruments; and (2) Equity contributions from a parent that do not involve the issuance of common stock.

For “Capital Balances,” report the actual aggregate balances (\$Millions) of each type of capital instrument for the as-of quarter end date, reflecting the impact of planned capital actions. “Capital Balances” “Notional Amount” the actual must be completed, even if the instrument is not recognized in regulatory capital. Projection quarters are calculated based on the activity reported in the “Quarterly Redemption/Repurchase Activity”, “Quarterly Issuance Activity”, and “Quarterly Activity – Other than issuances and repurchases” and the reported “Actual”.

### ***Quarterly Redemption/Repurchase Activity***

#### **Line Item 1 Common Stock (CS) (Revised regulatory capital rule treatment – Common Equity Tier 1)**

(1)"Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the ~~revised~~ regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;

(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;

(3) PLUS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c) (only warrants in (2) surplus should be subtracted); and

(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b). Line 1 should exclude amounts reported in line 2 as described below.

#### **Line Item 2 Common Stock (CS) - Employee Stock Compensation (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report the carrying amount of common stock as defined in the FR Y-9C, Schedule HC, line item 24 issued as part of an employee stock ownership plan (ESOP) and included in equity capital on the balance sheet. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for employee stock for employee stock compensation.

#### **Line Item 3 CS Warrants (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

#### **Line Item 4 CS USG Investment (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b).

#### **Line Item 5 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4. To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

#### **Line Item 6 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report all other Common Equity Tier 1 instruments issued that are not included in the FR Y-9C, Schedule HC-R, Part I, line items 1, 2, 4 and 5.

**Line Item 7 Non-Cumulative Perpetual Preferred (NCPP) (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 8 NCPP Convertible (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of NCPP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 9 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 10 MCP USG Preferred (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank and intermediate holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3, and Schedule HC-M, line item 24(a).

**Item 11 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

**Line Item 12 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of all other capital instruments, other than those included in line items 7 through 11 that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 13 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 14 CPP TARP Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 15 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 16 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 17 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 18 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 19 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of all other capital instruments other than those include in line items 14 through 18 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 20 Subordinated Debt (Revised regulatory capital rule treatment – Tier 2)**

Report subordinated debt instruments that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

**Line Item 21 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Tier 2)**

Report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

**Line Item 22 Other Tier 2 Instruments (Revised regulatory capital rule treatment - Tier 2)**

Report all other capital instruments, other than those included in line items 20 and 21, that satisfy all eligibility criteria under the **revised** regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27.

In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For items 23 through 29, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the **revised** regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in the FR Y-9C, Schedule HC-R, line item 21.

**Line Item 23 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 24 CPP TARP Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

Report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 25 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

Report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 26 MCP USG Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 27 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 28 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 29 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of all capital instruments other than the ones included in line items 23 through 28 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

***Quarterly Issuance Activity***

**Line Item 30 Common Stock (CS) (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report (1)"Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the ~~revised~~regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;  
(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;  
(3) PLUS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c)(only warrants in (2) surplus should be subtracted); and  
(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b). Line 30 should exclude amounts reported in line 31 as described below.

**Line Item 31 Common Stock (CS) - Employee Stock Compensation (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report the carrying amount of common stock as defined in the FR Y-9C, Schedule HC, line item 24 issued as part of an employee stock ownership plan (ESOP) and included in equity capital on the balance sheet. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock for employee stock for employee stock compensation.

**Line Item 32 CS Warrants (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

**Line Item 33 CS USG Investment (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b).

**Line Item 34 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4. To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

**Line Item 35 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report as defined in the ~~revised~~-regulatory capital rule ~~(July 2013)~~.

**Line Item 36 Non-Cumulative Perpetual Preferred (NCPP) (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~-regulatory capital rules of the Federal Reserve.

**Line Item 37 NCPP Convertible (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of NCPP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~-regulatory capital rules of the Federal Reserve.

**Line Item 38 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~-regulatory capital rules of the Federal Reserve.

**Line Item 39 MCP USG Preferred (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank and intermediate holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~-regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3 and Schedule HC-M, line item 24(a).

**Line Item 40 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

**Line Item 41 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of all other capital instruments, other than those included in line items 36 through 40 that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 42 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 43 CPP TARP Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 44 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 45 MCP USG Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 46 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 47 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 48 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of all other capital instruments other than those included in line items 42 through 47 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 49 Subordinated Debt (Revised regulatory capital rule treatment – Tier 2)**

Report subordinated debt instruments that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

**Line Item 50 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Tier 2)**

Report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

**Line Item 51 Other Tier 2 Instruments (Revised regulatory capital rule treatment – Tier 2)**

Report all other capital instruments, other than those included in line items 49 and 50, that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For items 52 through 58, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the ~~revised~~ regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in Schedule HC-R, item 21.

**Line Item 52 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 53 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 54 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 55 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 56 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 57 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 58 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of all capital instruments other than the ones included in line items 52 through 57 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

***Quarterly Activity - Other than issuances or repurchases***

**Line Item 59 Common Stock (CS) (Revised regulatory capital rule treatment – Common Equity Tier 1)**

Report (1) "Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the ~~revised~~-regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;

(2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;

(3) PLUS: "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c) (only warrants in (2) surplus should be subtracted); and

(4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b). Line 59 should exclude amounts reported in line 60 as described below.

**Line Item 60 Common Stock (CS) - Employee Stock Compensation (Revised regulatory capital rule treatment - Tier 1)**

Report the carrying amount of common stock as defined in the FR Y-9C, Schedule HC, line item 24 issued as part of an employee stock ownership plan (ESOP) and included in equity capital on the balance sheet. Include increases and decreases in additional paid in capital (APIC) attributable to the amortization of employee stock compensation and any changes in APIC, treasury or common stock as a result of the actual issuance of common stock employee stock compensation.

**Line Item 61 CS Warrants (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

**Line Item 62 CS USG Investment (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b)

**Line Item 63 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4. To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

**Line Item 64 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment - Common Equity Tier 1)**

Report as defined in the ~~revised~~ regulatory capital rule ~~July 2013~~.

**Line Item 65 Non-Cumulative Perpetual Preferred (NCPP) (Revised regulatory capital rule treatment - Additional Tier 1)**

Report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 66 NCPP Convertible (Revised regulatory capital rule treatment – Additional Tier 1)**

Report the amount of NCPP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 67 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Additional Tier 1)**

Report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 68 MCP USG Preferred (Revised regulatory capital rule treatment – Additional Tier 1)**

Report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank and intermediate holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3 and Schedule HC-M, line item 24(a).

**Line Item 69 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Additional Tier 1)**

Report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

**Line Item 70 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment – Additional Tier 1)**

Report the amount of all other capital instruments, other than those included in line items 65 through 69 that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

**Line Item 71 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 72 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

Report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 73 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 74 MCP USG Preferred (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 75 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 76 USG Preferred TRUPS (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 77 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

Report the amount of all other capital instruments other than those included in line items 71 through 76 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 78 Subordinated Debt (Revised regulatory capital rule treatment - Tier 2)**

Report subordinated debt instruments that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

**Line Item 79 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Tier 2)**

Report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

**Line Item 80 Other Tier 2 Instruments (Revised regulatory capital rule treatment - Tier 2)**

Report all other capital instruments, other than those included in line items 78 and 79, that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27.

In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For items 81 through 87, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the ~~revised~~ regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in Schedule HC-R, item 21.

**Line Item 81 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 82 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 83 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 84 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 85 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 86 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

**Line Item 87 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 2)**

Report the amount of all capital instruments other than the ones included in items 81 through 86 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

***Capital Balances***

**Line Item 88 Common Stock (CS) (Revised regulatory capital rule treatment – Common Equity Tier 1)**

For the actual as-of date, report

- (1)"Common Stock" as defined in the FR Y-9C, Schedule HC, line item 24, provided it meets the criteria for common equity tier 1 capital based on the ~~revised~~ regulatory capital rules of the Federal Reserve. Include capital instruments issued by mutual banking organizations that meet the criteria for common equity tier 1 capital;
- (2) PLUS: "Surplus" as defined in the FR Y-9C, Schedule HC, line item 25;
- (3) PLUS "Other equity capital components" as defined in the FR Y-9C, Schedule HC, line item 26(c)(only warrants in (2) surplus should be subtracted); and
- (4) LESS: "Issuances associated with the U.S. Department of Treasury Capital Purchase Program: Warrants to Purchase Common Stock" as defined in the FR Y-9C, Schedule HC-M, line item 24(b). Line 88 should exclude amounts reported in line 89 as described below.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 1, 2, 30, 31, 59, 60 and actual as-of date item 88. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 1, 2, 30, 31, 59, 60 and the prior projection period's item 88.

**Line Item 89 CS Warrants (Revised regulatory capital rule treatment – Common Equity Tier 1)**

For the actual as-of date, report the carrying amount of warrants to issue common stock as defined in the FR Y-9C, Schedule HC, line item 24 and included in equity capital on the balance sheet.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 3, 32, 61 and actual as-of date item 89. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 3, 32, 61 and the prior projection period's item 89.

**Line Item 90 CS USG Investment (Revised regulatory capital rule treatment – Common Equity Tier 1)**

For the actual as-of date, report the carrying amount of warrants issued to the U.S. Department of Treasury to purchase common stock as defined in the FR Y-9C, Schedule HC, line item 24 of the reporting institution that is included in equity capital on the balance sheet included in the FR Y-9C, Schedule HC-M, line item 24(b).

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 4, 33, 62, and actual as-of date item 90. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 4, 33, 62 and the prior projection period's item 90

**Line Item 91 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Common Equity Tier 1)**

For the actual as-of date, report capital instruments issued by a fully consolidated subsidiary of the reporting institution to a third party investor that qualify for inclusion in common equity tier 1 capital as defined in the FR Y-9C, Schedule HC-R, Part I, line item 4). To qualify for inclusion in common equity tier 1 capital, the capital instruments must be issued by a depository institution or a foreign bank that is a consolidated subsidiary of a banking organization.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 5, 34, 63 and actual as-of date item 91. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 5, 34, 63 and the prior projection period's item 91.

**Line Item 92 Other Common Equity Tier 1 Instruments (Revised regulatory capital rule treatment - Common Equity Tier 1)**

For the actual as-of date, report as defined in the ~~revised~~ regulatory capital rule ([July 2013](#)).

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 6, 35, 64 and actual as-of date item 92. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 6, 35, 64 and the prior projection period's item 92.

**Line Item 93 Non-Cumulative Perpetual Preferred (NCPP) (Revised regulatory capital rule treatment - Additional Tier 1)**

For the actual as-of date, report the amount of noncumulative perpetual preferred stock and related surplus included in the FR Y-9C, Schedule HC, line item 23, and any other capital instrument and related surplus that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 7, 36, 65 and actual as-of date item 93. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 7, 36, 65 and the prior projection period's item 93.

**Line Item 94 NCPP Convertible (Revised regulatory capital rule treatment - Additional Tier 1)**

For the actual as-of date, report the amount of NCPP Convertible securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 8, 37, 66 and actual as-of date item 94. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 8, 37, 66 and the prior projection period's item 94.

**Line Item 95 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Additional Tier 1)**

For the actual as-of date, report the amount of Mandatory Convertible Preferred (MCP) securities and related surplus included in the FR Y-9C, Schedule HC, line item 23, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 9, 38, 67 and actual as-of date item 95. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 9, 38, 67 and the prior projection period's item 95.

**Line Item 96 MCP USG Preferred (Revised regulatory capital rule treatment – Additional Tier 1)**

For the actual as-of date, report the amount of mandatory convertible preferred securities issued to the U.S. Department of Treasury by bank and intermediate holding companies that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve included in the FR Y-9C, Schedule HC, line item 3 and Schedule HC-M, line item 24(a).

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 10, 39, 68 and actual as-of date item 96. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 10, 39, 68 and the prior projection period's item 96.

**Line Item 97 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment – Additional Tier 1)**

For the actual as-of date, report the amount of tier 1 minority interest not included in common equity tier 1 capital that is includable at the consolidated level as defined in the FR Y-9C, Schedule HC-R, Part I, line item 22. For tier 1 minority interest, there is no requirement that the subsidiary be a depository institution or a foreign bank. However, the instrument that gives rise to additional tier 1 minority interest must meet all the criteria for additional tier 1 capital instrument.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 11, 40, 69 and actual as-of date item 97. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 11, 40, 69 and the prior projection period's item 97.

**Line Item 98 Other Additional Tier 1 Instruments (Revised regulatory capital rule treatment – Additional Tier 1)**

For the actual as-of date, report the amount of all other capital instruments, other than those included in line items 93 through 97, that satisfy all the additional tier 1 criteria in 12 CFR 217.20(c) of the ~~revised~~ regulatory capital rules of the Federal Reserve.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 12, 41, 70 and actual as-of date item 98. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 12, 41, 70 and the prior projection period's item 98.

**Line Item 99 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of Cumulative Perpetual Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 13, 42, 71 and actual as-of date item 99. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 13, 42, 71 and the prior projection period's item 99.

**Line Item 100 CPP TARP Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of CPP TARP Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 14, 43, 72 and actual as-of date item 100. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 14, 43, 72 and the prior projection period's item 100.

**Line Item 101 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of Mandatory Convertible Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 15, 44, 73 and actual as-of date item 101. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 15, 44, 73 and the prior projection period's item 101.

**Line Item 102 MCP USG Preferred (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of MCP USG Preferred securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 16, 45, 74 and actual as-of date item 102. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 16, 45, 74 and the prior projection period's item 102.

**Line Item 103 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of Cumulative Dated Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 17, 46, 75 and actual as-of date item 103. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 17, 46, 75 and the prior projection period's item 103.

**Line Item 104 USG Preferred TRUPS (Revised regulatory capital rule treatment – Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of USG Preferred (TRUPS) securities that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 18, 47, 76 and actual as-of date item 104. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 18, 47, 76 and the prior projection period's item 104.

**Line Item 105 Other Non-qualifying Instruments in Tier 1 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 1)**

For the actual as-of date, report the amount of all other capital instruments other than those included in line items 99 through 104 that were included in tier 1 capital (FR Y-9C, Schedule HC-R, Part I, line item 21) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 19, 48, 77 and actual as-of date item 105. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 19, 48, 77 and the prior projection period's item 105.

**Line Item 106 Subordinated Debt (Revised regulatory capital rule treatment - Tier 2)**

For the actual as-of date, report subordinated debt instruments that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27. Include instruments that were (i) issued under the Small Business Jobs Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 2 capital nonqualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) under the Federal Reserve's general risk-based capital rules.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 20, 49, 78 and actual as-of date item 106. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 20, 49, 78 and the prior projection period's item 106.

**Line Item 107 Capital Instrument Issued by Subsidiary (Revised regulatory capital rule treatment - Tier 2)**

For the actual as-of date, report the amount of total capital minority interest not included in tier 1 capital, as defined in the FR Y-9C, Schedule HC-R, Part I, line item 29.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 21, 50, 79 and actual as-of date item 107. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 21, 50, 79 and the prior projection period's item 107.

**Line Item 108 Other Tier 2 Instruments (Revised regulatory capital rule treatment - Tier 2)**

For the actual as-of date, report all other capital instruments, other than those included in line items 106 and 107, that satisfy all eligibility criteria under the ~~revised~~ regulatory capital rules of the Federal Reserve and related surplus included in the FR Y-9C, Schedule HC-R, Part I, line item 27.

In addition, report tier 2 capital non-qualifying capital instruments (e.g., TruPS and cumulative perpetual preferred) that have been phased-out of tier 1 capital in the FR Y-9C, Schedule HC-R, Part I, line item 21.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 22, 51, 80 and actual as-of date item 108. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 22, 51, 80 and the prior projection period's item 108

For items 109 through 115, holding companies may include in regulatory capital debt or equity instruments issued prior to September 12, 2010, that do not meet the criteria for additional tier 1 or tier 2 capital instruments in 12 CFR 217.20 of the ~~revised~~ regulatory capital rules but that were included in tier 1 or tier 2 capital respectively as of September 12, 2010 (non-qualifying capital instruments issued prior to September 12, 2010) up to the percentage of the outstanding principal amount of such non-qualifying capital instruments as of January 1, 2014, in Schedule HC-R, item 21.

**Line Item 109 Cumulative Perpetual Preferred (CPP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 23, 52, 81 and actual as-of date item 109. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 23, 52, 81 and the prior projection period's item 109.

**Line Item 110 CPP TARP Preferred(Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of CPP TARP Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 24, 53, 82 and actual as-of date item 110. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 24, 53, 82 and the prior projection period's item 110.

**Line Item 111 Mandatory Convertible Preferred (MCP) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of Mandatory Convertible Preferred (MCP) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 25, 54, 83 and actual as-of date item 111. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 25, 54, 83 and the prior projection period's item 111.

**Line Item 112 MCP USG Preferred(Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 26, 55, 84 and actual as-of date item 112. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 26, 55, 84 and the prior projection period's item 112.

**Line Item 113 Cumulative Dated Preferred (TRUPS) (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of Cumulative Dated Preferred (TRUPS) instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 27, 56, 85 and actual as-of date item 113. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 27, 56, 85 and the prior projection period's item 113.

**Line Item 114 USG Preferred TRUPS (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of Cumulative Perpetual Preferred instruments that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 28, 57, 86 and actual as-of date item 114. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 28, 57, 86 and the prior projection period's item 114.

**Line Item 115 Other Non-qualifying Instruments in Tier 2 (Revised regulatory capital rule treatment - Non-qualifying Instrument in Tier 2)**

For the actual as-of date, report the amount of all capital instruments other than the ones included in line items 109 through 114 that were included in tier 2 capital (FR Y-9C, Schedule HC-R, Part I, line item 28) and outstanding as of January 1, 2014, and that are subject to phase out.

For projection period PQ1, the item is calculated as the sum of projection period PQ1 items 29, 58, 87 and actual as-of date item 115. For projection periods PQ2 through PQ9, the item is calculated as the sum of current projection period items 29, 58, 87 and the prior projection period's item 115.

**Line Item 116 Cash dividends declared on preferred stock**

Report planned cash dividends declared on preferred stock, as defined in FR Y-9C, Schedule HI-A, line item 10.

**Line item 117 Cash dividends declared on common stock**

Report planned cash dividends declared on common stock, as defined in FR Y-9C, Schedule HI-A, line item 11.

**Line item 118 Common shares outstanding (Millions)**

Report the number (in millions) of common shares outstanding at the time dividends on common stock are declared such that line item 119 reflects the firm's intended quarterly distribution of common dividends per share.

**Line item 119 Common dividends per share (\$)**

Report the firm's intended quarterly distribution in common dividends per share.

## **Schedule D—Regulatory Capital Transitions<sup>13</sup>**

For the purposes of the Regulatory Capital Transitions Schedule, advanced approaches BHCs and IHCs must reflect the revised regulatory capital rules on a fully phased-in basis (e.g., advanced approaches BHCs and IHCs should apply 100% of all capital deductions, not assuming the transition provisions for implementation of changes to the capital composition as in the revised regulatory capital rule).<sup>14</sup>

Non-advanced approaches firms should continue to apply, indefinitely, the risk weight and the deduction treatment applicable during 2017, as outlined in the capital rules.<sup>15</sup> In accordance with Table 7 of section 300 of the capital rules, non-advanced approaches banking organizations- shouldwould continue to:

- Deduct from regulatory capital 80 percent of the amount of any of these five items that is not includable in regulatory capital;
- Apply a 100 percent risk weight to any amounts of MSAs, temporary difference DTAs, and significant investments in the capital of unconsolidated financial institutions in the form of common stock that are not deducted from capital, and continue to apply the current risk weights under the capital rules to amounts of non-significant investments in the capital of unconsolidated financial institutions and significant investments in the capital of unconsolidated financial institution not in the form of common stock that are not deducted from capital; and
- Include 20 percent of any common equity tier 1 minority interest, tier 1 minority interest, and total capital minority interest exceeding the capital rule's minority interest limitations (surplus minority interest) in regulatory capital.

Where applicable, BHCs and IHCs should also reference the methodology descriptions outlined within the FR Y-9C Schedule HC-R, Part I and part II. Please note, however, that numbers do not need to tie to the FR Y-9C reports, given that the FR Y-14 Transitions schedule requires calculations on a fully phased-in basis except for instances as prescribed in [transitions final rule] (insert FR reference).

The Regulatory Capital Transitions FR Y-14A annual schedule collects actual (historical) data for the as-of date and projected fourth quarter data for five years. All projections in the FR Y-14A Regulatory Capital Transitions schedule should be based under the Supervisory Baseline scenario through the end of Projected Year 5 on a year-to-date basis (unless otherwise specified). All forecasts must be well-developed and well-documented, consistent with the relevant baseline scenario, and internally consistent with the BHC's or IHC's planned capital actions.

---

<sup>13</sup> Note: An initial notice was published in the Federal Register (82 FR 26793) proposing to eliminate the FR Y-14A Schedule D (Regulatory Capital Transitions, RCT). If the FR Y-14 Schedule D is eliminated, the changes outlined here will not be necessary.

<sup>14</sup> Advanced approaches BHCs and IHCs are generally firms that have \$250 billion or more in total consolidated assets or \$10 billion or more in consolidated on-balance sheet foreign exposures. See 12 CFR 217.100(b)

<sup>15</sup> See [insert transitions freeze final Federal Register notice citation] (XXX XX, 2017).

BHCs and IHCs should provide projections of capital composition, exceptions bucket calculation, risk-weighted assets, and leverage exposures through projected year 5 even if the BHC or IHC anticipates complying with the proposed fully phased-in 7% Common Equity Tier 1, 8.5% Tier 1 capital, 4% Tier 1 leverage, and 3% supplementary leverage target ratios (inclusive the capital conservation buffer, where applicable) plus any applicable surcharge for systemically important financial institutions (SIFI surcharge) by an earlier date.

Each CCAR Capital Plan must include management's best estimate of a BHC's or IHC's likely SIFI surcharge. In the process of assessing a BHC's or IHC's transition path toward compliance with the **Revised** Capital Framework, supervisors will evaluate the methodology and assumptions used by BHCs or IHCs in determining the SIFI surcharge, and may adjust such estimates as necessary when evaluating the transition path. See Appendix A: Supporting Documentation for more details about the associated information that must be submitted in addition to this report template.

In the event that a capital plan resubmission prompts a BHC or IHC to submit the FR Y-14A Regulatory Capital Transitions schedule with a date other than the as-of date, the BHC or IHC should treat all columns labeled "Actual in \$Millions as of date" as being as-of the date dictated by the capital plan resubmission. The PY1 column should be the projection 1 year from the capital plan resubmission as-of date, PY2 should be the projection 2 years from the capital plan resubmission as-of date, and so forth.

### **Relevant References**

All BHCs and IHCs are required to follow the methodologies outlined in the **revised** regulatory capital rule (78 Federal Register 62018, July October 11, 2013), the updated market risk capital rule (78 Federal Register 76521, December 18, 2013), and the supplementary final rule (September 2014) for purposes of completing the Regulatory Capital Transitions schedules for the *entire* forecast period. **Except for instances as prescribed in [insert transitions freeze final Federal Register notice citation], only advanced approaches** BHCs and IHCs should reflect the **revised** regulatory capital framework on a fully phased-in basis.

Links to these reference documents are listed below:

- Basel global systemically important banks: updated assessment methodology and the higher loss absorbency requirement (July 2013): <http://www.bis.org/publ/bcbs255.pdf>
- **Revised** Regulatory Capital Rule (78 Federal Register 62018, October 11, 2013): <http://www.gpo.gov/fdsys/pkg/FR-2013-10-11/pdf/2013-21653.pdf>
- Supplementary Leverage Final Rule (September 2014): <http://www.federalreserve.gov/newsevents/press/bcreg/bcreg20140903b1.pdf>
- Updated Market Risk Rule (December 2013): <http://www.gpo.gov/fdsys/pkg/FR-2013-12-18/pdf/2013-29785.pdf>
- **Transitions final rule [insert FR reference]**

### **Completing the Schedule**

All data should be provided in the non-shaded cells in all sub-schedules; grey shaded cells include embedded formulas and will be automatically populated.

All BHCs and IHCs, including advanced approaches BHCs and IHCs and non-advanced approaches BHCs and IHCs must complete the “Standardized RWA” sub-schedule for all reporting periods. For the purpose of completing the “Standardized RWA” sub-schedule, BHCs and IHCs are required to report credit risk-weighted assets using the methodologies under the standardized approach of the ~~revised~~-regulatory capital rule. Advanced approaches BHCs and IHCs , including the BHCs and IHCs that are considered mandatory advanced approaches institutions or that have opted-in voluntarily as an advanced approaches institution, are also required to complete the “Advanced RWA” sub-schedule for all reporting periods. **All firms should provide all data on a fully phased-in basis (i.e., not assuming any transitional or phase- out arrangements included in the ~~revised~~-regulatory capital rule) except for instances as prescribed in [transitions final rule] (insert FR reference).**

Note that for purposes of completing the FR Y-14A Regulatory Capital Transitions schedule, **BHCs and IHCs should not assume future model approval in the RWA projections for positions and models that have not yet been approved**. BHCs and IHCs that have received comprehensive risk model approval should base their projections on the comprehensive risk measure plus the surcharge for the entire planning horizon. BHCs and IHCs should not assume that the surcharge will be replaced by the floor approach in the schedule or as part of planned actions.

If a BHC or IHC does not have an exposure relevant to any particular line item in the sub-schedules (except for the Planned Action sub-schedule); it should enter zero (0) in those cells. In order for the embedded formulas to automatically populate the shaded cells in the schedule with calculated numbers, BHCs and IHCs must complete all unshaded cells in the schedule with a value. In addition, BHCs and IHCs should ensure that the version of Microsoft Excel they use to complete the schedule is set to automatically calculate formulas. This is achieved by setting “Calculation Options” (under the Formulas function) to “Automatic” within Microsoft Excel.

## **D.1—Capital Composition**

The “Capital Composition” sub-schedule and the “Exceptions Bucket Calculator” sub-schedule collect the data necessary to calculate the composition of capital under the guidelines set forth by the ~~Revised~~-Regulatory Capital Rule. Please provide all data on a fully phased-in basis (i.e., not assuming any transitional or phase- out arrangements included in the ~~revised~~-regulatory capital rule.

### ***Common Equity Tier 1***

#### **Line item 1 AOCI opt-out election**

Non-advanced approaches BHCs have the option to select either 1 for opt-out, or 0 for opt-in. Note that there are no transition provisions applied

#### **Common equity tier 1 capital**

#### **Line item 2 Common stock and related surplus (net of treasury stock and unearned employee**

**stock ownership plan (ESOP) shares**

Report common shares and the related surplus issued by BHCs and IHCs that meet the criteria of the final rules. This should be net of treasury stock and other investments in own shares to the extent that these are already not recognized on the balance sheet under the relevant accounting standards. This line item should reflect the impact of share repurchases or issuances projected in the CCAR forecast horizon. This line should also reflect the netting of any treasury stock, unearned ESOP shares, and any other contra-equity components.

**Line item 3 Retained earnings**

Retained earnings reported by BHCs or IHCs. This should reflect the impact of dividend pay-outs projected in the CCAR forecast horizon.

**Line item 4 Accumulated other comprehensive income (AOCI)**

Report the amount of AOCI as reported under generally accepted accounting principles (GAAP) in the U.S. that is consistent with the definitions included in Schedule HC-R, Part I.B., item 3, with no transition provisions.

**Line item 5 Common equity tier 1 minority interest includable in common equity tier 1 capital (report this on a fully phased-in basis)**

Report the aggregate amount of common equity tier 1 minority interest that is consistent with the definitions provided in Schedule HC-R, Part I.B., item 4. Common equity tier 1 minority interest means the common equity tier 1 capital of a depository institution or foreign bank that is a consolidated subsidiary of the holding company and that is not owned by the holding company. In addition, the capital instruments issued by the subsidiary must meet all of the criteria for common equity tier 1 capital (qualifying common equity tier 1 capital).

**Line item 6 Common equity tier 1 capital before adjustments and deductions**

This captures the sum of line items 2 through 5.

**Common equity tier 1 capital: adjustments and deductions****Line item 7 Goodwill net of associated deferred tax liabilities (DTLs)**

Report the amount of goodwill that is consistent with the definitions provided in Schedule HC-R, Part I.B., item 6, with no transition provisions.

If a holding company has significant investments in the capital of unconsolidated financial institutions in the form of common stock, the holding company should report in this item goodwill embedded in the valuation of a significant investment in the capital of an unconsolidated financial institution in the form of common stock (embedded goodwill). Such deduction of embedded goodwill would apply to investments accounted for under the equity method. Under GAAP, if there is a difference between the initial cost basis of the investment and the amount of underlying equity in the net assets of the investee, the resulting difference should be accounted for as if the investee were a consolidated subsidiary (which may include imputed goodwill).

**Line item 8 Intangible assets (other than goodwill and mortgage servicing assets (MSAs)), net of associated DTLs**

Report all intangible assets (other than goodwill and MSAs) net of associated DTLs, included in Schedule HC-M, items 12.b and 12.c, that do not qualify for inclusion in common equity tier 1 capital under the regulatory capital rules. Generally, all purchased credit card relationships (PCCRs) and non-mortgage servicing rights, reported in Schedule HC-M, item 12.b, and all other identifiable intangibles, reported in Schedule HC-M, item 12.c, do not qualify for inclusion in common equity tier 1 capital and should be included in this item.

Further, if the holding company has a DTL that is specifically related to an intangible asset (other than servicing assets and PCCRs) acquired in a nontaxable purchase business combination that it chooses to net against the intangible asset for regulatory capital purposes, the amount of disallowed intangibles to be reported in this item should be reduced by the amount of the associated DTL. However, a DTL that the holding company chooses to net against the related intangible reported in this item may not also be netted against DTAs when the holding company determines the amount of DTAs that are dependent upon future taxable income and calculates the maximum allowable amount of such DTAs for regulatory capital purposes.

**Line item 9 Deferred Tax Assets (DTAs) that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs**

Report the amount of DTAs that arise from net operating loss and tax credit carryforwards, net of any related valuation allowances and net of DTLs.

**AOCI-related adjustments**

**If Item 1 is "1" for "Yes", complete items 10 through 14 only for AOCI related adjustments.**

**Line item 10 Net unrealized gains (losses) on available-for-sale securities**

Report the amount of net unrealized holding gains (losses) on available-for-sale securities, net of applicable taxes, that is consistent with the definitions provided in Schedule HC-R, Schedule I.B., item 9a, "Accumulated other comprehensive income," With no transition provisions. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

**Line item 11 Net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures**

Report as a positive value net unrealized loss on available-for-sale preferred stock classified as an equity security under GAAP and available-for-sale equity exposures, consistent with the definitions that is included in Schedule HC-R, Schedule I.B., item 9b, with no transition provisions.

**Line item 12 Accumulated net gains (losses) on cash flow hedges**

Report the amount of accumulated net gains (losses) on cash flow hedges, consistent with the definitions that is included in Schedule HC-R, Schedule I.B., item 9c, "Accumulated other comprehensive income," With no transition provisions. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

**Line item 13 Amounts recorded in AOCI attributed to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans**

Report the amounts recorded in AOCI and is consistent with the definitions included in Schedule HC-R, Schedule I.B., item 9d, "Accumulated other comprehensive income," with no transition provisions, resulting from the initial and subsequent application of ASC Subtopic 715-20 (formerly FASB Statement No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans") to defined benefit postretirement plans resulting from the initial and subsequent application of the relevant GAAP standards that pertain to such plans.

**Line item 14 Net unrealized gains (losses) on held-to-maturity securities that are included in AOCI**

Report the amount of net unrealized gains (losses) that are not credit-related on held-to-maturity securities and are included in AOCI, consistent with the definitions as reported in Schedule HC-R, Schedule I.B., item 9e, "Accumulated other comprehensive income," with no transition provisions. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

**If Item 1 is "0" for "No", complete item 15 only for AOCI related adjustments.**

**Line item 15 Accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects, that relate to the hedging of items that are not recognized at fair value on the balance sheet.**

Report the amount of accumulated net gain (loss) on cash flow hedges included in AOCI, net of applicable tax effects that relate to the hedging of items not recognized at fair value on the balance sheet. If the amount is a net gain, report it as a positive value. If the amount is a net loss, report it as a negative value.

**Other deductions from (additions to) common equity tier 1 capital before threshold-based deductions:**

**Line item 16 Unrealized net gain (loss) related to changes in the fair value of liabilities that are due to changes in own credit risk**

Report the amount of unrealized net gain (loss) related to changes in the fair value of liabilities that are due to changes in the holding company's own credit risk. If the amount is a net gain, report it as a positive value in this item. If the amount is a net loss, report it as a negative value in this item.

Advanced approaches holding companies only: include the credit spread premium over the risk free rate for derivatives that are liabilities.

**Line item 17 All other deductions from (additions to) common equity tier 1 capital before threshold-based deductions**

Report the amount of other deductions from (additions to) common equity tier 1 capital that are not included in items 1 through 15, as described below:

**(1) After-tax gain-on-sale in connection with a securitization exposure**

Include any after-tax gain-on-sale in connection with a securitization exposure. Gain-on-sale means an increase in the equity capital of a holding company resulting from a securitization

(other than an increase in equity capital resulting from the holding company's receipt of cash in connection with the securitization or reporting of a mortgage servicing asset on Schedule HC).

**(2) Defined benefit pension fund assets, net of associated DTLs**

A BHC or IHC must deduct defined benefit pension fund assets, net of associated DTLs, held by a holding company. With the prior approval of the Federal Reserve, this deduction is not required for any defined benefit pension fund net asset to the extent the holding company has unrestricted and unfettered access to the assets in that fund.

**(3) Investments in the holding company's own shares to the extent not excluded as part of treasury stock.**

Include the BHC's or IHC's investments in (including any contractual obligation to purchase) its own common stock instruments, including direct, indirect, and synthetic exposures to such instruments (as defined in the ~~revised~~-regulatory capital rules), to the extent such instruments are not excluded as part of treasury stock.

For example, if a BHC or IHC already deducts its investment in its own shares (for example, treasury stock) from its common equity tier 1 capital elements, it does not need to make such deduction twice.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty credit risk.

The holding company must look through any holdings of index securities to deduct investments in its own capital instruments.

In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short positions in the same underlying index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions may be decomposed to recognize the hedge; and
- (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes which would have been assessed by the Federal Reserve.

**(4) Reciprocal cross-holdings in the capital of financial institutions in the form of common stock**

Include investments in the capital of other financial institutions (in the form of common stock) that the holding company holds reciprocally (this is the corresponding deduction approach). Such reciprocal crossholdings may result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments.

**(5) Equity investments in financial subsidiaries**

A BHC or IHC must deduct the aggregate amount of its outstanding equity investment, including retained earnings, in its financial subsidiaries (as defined in 12 CFR 208.77) and may not consolidate the assets and liabilities of a financial subsidiary with those of the parent institution. No other deduction is required for these investments in the capital instruments of financial subsidiaries.

**(6) Amount of expected credit loss that exceeds its eligible credit reserves (Advanced approaches institutions that exit parallel run only)**

Include the amount of expected credit loss that exceeds the eligible credit reserves.

**Line item 18 Non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that exceed the 10 percent threshold for non-significant investments**

A BHC or IHC has a non-significant investment in the capital of an unconsolidated financial institution (as defined in the ~~revised~~ regulatory capital rules) if it owns 10 percent or less of the issued and outstanding common shares of that institution.

Report the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock that, in the aggregate, exceed the 10 percent threshold for non-significant investments, calculated as described below. The BHC or IHC may apply associated DTLs to this deduction.

**Line item 19 Subtotal**

This item is a shaded cell and is derived from other items in the schedule; no input required. This is the total of common equity tier 1 prior to adjustments less all of the regulatory adjustments and deductions.

**Line item 20 Significant investments in the capital of unconsolidated financial institutions in the form of common stock, net of DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 21 MSAs, net of associated DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 22 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs, that exceed the 10 percent common equity tier 1 capital deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 23 Amount of significant investments in the capital of unconsolidated financial institutions in the form of common stock; MSAs, net of associated DTLs; and DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs; that exceeds the 15 percent common equity tier 1 capital deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 24 Deductions applied to common equity tier 1 capital due to insufficient amounts of additional tier 1 capital and tier 2 capital to cover deductions**

Report the total amount of deductions related to reciprocal cross holdings, non-significant investments in the capital of unconsolidated financial institutions, and non-common stock significant investments in the capital of unconsolidated financial institutions if the holding company does not have a sufficient amount of additional tier 1 capital and tier 2 capital to cover these deductions.

**Line item 25 Total adjustments and deductions for common equity tier 1 capital**

This is the sum of line item 20 through 24.

**Line item 26 Common Equity Tier 1**

This is the subtotal of line item 19 minus line item 25.

**Line item 27 Additional tier 1 capital instruments plus related surplus**

Report the portion of noncumulative perpetual preferred stock and related surplus as defined by Schedule HC-R, Part I.B., item 20, with zero transition provisions, that satisfy all the criteria for additional tier 1 capital in the ~~revised~~-regulatory capital rules of the Federal Reserve.

Include instruments that were (i) issued under the Small Business Job's Act of 2010, or, prior to October 4, 2010, under the Emergency Economic Stabilization Act of 2008 and (ii) were included in the tier 1 capital under the Federal Reserve's general risk-based capital rules (12 CFR part 225, appendix A, and, if applicable, appendix E) (for example, tier 1 instruments issued under the TARP program that are grandfathered permanently). Also include additional tier 1 capital instruments issued as part of an ESOP, provided that the repurchase of such instruments is required solely by virtue of ERISA for a banking organization that is not publicly-traded.

**Line item 28 Tier 1 minority interest not included in common equity tier 1 capital (report on a fully phased-in basis)**

Similar to item 5, this captures all qualifying tier 1 minority interest includable under additional tier 1 capital.

**Line item 29 Additional tier 1 capital before deductions**

This is the sum of line items 27 and 28.

**Line item 30 Additional tier 1 capital deductions**

Report additional tier 1 capital deductions as the sum of the following elements:

(1) Investments in own additional tier 1 capital instruments:

Report the holding company's investments in (including any contractual obligation to purchase) its own additional tier 1 instruments, whether held directly or indirectly.

A holding company may deduct gross long positions net of short positions in the same underlying instrument only if the short positions involve no counterparty risk.

The holding company must look through any holdings of index securities to deduct investments in its own capital instruments. In addition:

- (i) Gross long positions in investments in a holding company's own regulatory capital instruments resulting from holdings of index securities may be netted against short positions in the same index;
- (ii) Short positions in index securities that are hedging long cash or synthetic positions can be decomposed to recognize the hedge; and
- (iii) The portion of the index that is composed of the same underlying exposure that is being hedged may be used to offset the long position if both the exposure being hedged and the short position in the index are covered positions under the market risk capital rule, and the hedge is deemed effective by the holding company's internal control processes.

(2) Reciprocal cross-holdings in the capital of financial institutions.

Include investments in the additional tier 1 capital instruments of other financial institutions that the holding company holds reciprocally, where such reciprocal crossholdings result from a formal or informal arrangement to swap, exchange, or otherwise intend to hold each other's capital instruments. If the holding company does not have a sufficient amount of a specific component of capital to effect the required deduction, the shortfall must be deducted from the next higher (that is, more subordinated) component of regulatory capital.

For example, if a holding company is required to deduct a certain amount from additional tier 1 capital and it does not have additional tier 1 capital, then the deduction should be from common equity tier 1 capital.

(3) Non-significant investments in additional tier 1 capital of unconsolidated financial institutions that exceed the 10 percent threshold for non-significant investments.

Calculate this amount as follows:

- (i) Determine the aggregate amount of non-significant investments in the capital of unconsolidated financial institutions in the form of common stock, additional tier 1, and tier 2 capital.
- (ii) Determine the amount of non-significant investments in the capital of unconsolidated financial institutions in the form of additional tier 1 capital.
- (iii) If the amount in (i) is greater than the 10 percent threshold for non-significant investments then multiply the difference by the ratio of (ii) over (i).
- (iv) If the amount in (i) is less than the 10 percent threshold for non-significant investments, report zero.

(4) Significant investments in the capital of unconsolidated financial institutions not in the form of common stock to be deducted from additional tier 1 capital.

Report the total amount of significant investments in the capital of unconsolidated financial institutions in the form of additional tier 1 capital.

(5) Other adjustments and deductions.

Include adjustments and deductions applied to additional tier 1 capital due to insufficient tier 2 capital to cover deductions (related to reciprocal cross holdings, non-significant investments in the tier 2 capital of unconsolidated financial institutions, and significant investments in the tier 2 capital of unconsolidated financial institutions).

**Line item 31 Additional tier 1 capital (greater of item 29 minus item 30 or zero)**

This item is a shaded cell and is derived from other items in the schedule. This provides the total of additional tier 1 capital.

**Tier 1 Capital**

**Line item 32 Tier 1 capital (sum of items 26 and 31)**

This item is a shaded cell and is derived from other items in the schedule. This provides the total amount of tier 1 capital.

**Other (reflect all items on a year-to-date basis)**

**Line item 33 Issuance of Common Stock (Including Conversion of Common Stock)**

Captures the total issuance of common stock and related surplus in the reporting period on a calendar year-to-date basis. This figure for PY 1 and PY2 should equal the sum of "Total issuance of common stock" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

**Line item 34 Repurchases of Common Stock**

Captures the total repurchases of common stock in the reporting period on a calendar year-to-date basis. This figure for PY1 and PY2 should equal the sum of "Total share repurchases" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

**Line item 35 Net Income (Loss) Attributable to Bank or Intermediate Holding Company**

Refer to FR Y-9C instructions for Schedule HI-A, item 4 and report on a calendar year-to-date basis. Report losses as a negative value. This figure for PY1 and PY2 should equal the sum of "Net income (loss) attributable to BHC or IHC" reported in the FR Y-14A Summary Schedule, Income Statement sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

**Line item 36 Cash Dividends Declared on Preferred Stock**

Refer to FR Y-9C instructions for Schedule HI-A, item 10 and report on a calendar year-to-date basis. This figure for PY1 and PY2 should equal the sum of "Cash dividends declared on preferred stock" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

**Line item 37 Cash Dividends Declared on Common Stock**

Refer to FR Y-9C instructions for Schedule HI-A, item 11 and report on a calendar year-to-date

basis. This figure for PY1 and PY2 should equal the sum of "Cash dividends declared on common stock" reported in the FR Y-14A Summary Schedule, Capital sub-schedule for the applicable reporting periods that correspond on the Summary schedule.

**Line item 38 Previously Issued Tier 1 Capital Instruments (Excluding Minority Interest) that would No Longer Qualify (please report 100% value)**

Report 100% of the value of previously issued Tier 1 capital instruments that will no longer qualify as Tier 1 capital as per the ~~revised~~-regulatory capital rule (including perpetual preferred stock and trust preferred securities subject to phase-out arrangements). Report balances in full, without reflecting any phase-out arrangements included in the ~~revised~~-regulatory capital rule.

**Line item 39 Previously Issued Tier 1 Minority Interest that Would No Longer Qualify (Please Report 100% Value)**

Report 100% of the value of previously issued tier 1 minority interest that will no longer qualify as tier 1 capital as per the ~~revised~~-regulatory capital rule. Report balances in full, without reflecting any phase-out arrangements included in the ~~revised~~-regulatory capital rule.

**Line item 40 Data Completeness Check**

If "No", please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable.

## **D.2—Exception Bucket Calculator**

The Exception Bucket Calculator sub-schedule collects the data necessary to calculate the items that may receive limited recognition in Common Equity Tier 1 (i.e., significant investments in the common shares of unconsolidated financial institutions, mortgage servicing assets and deferred tax assets arising from temporary differences). These items may be recognized in Common Equity Tier 1 up to 10% of the BHC's or IHC's common equity on an individual basis and 15% on an aggregated basis after application of all regulatory adjustments.

### **Significant investments in the capital of unconsolidated financial institutions in the form of common stock**

#### **Line item 1 Gross significant investments in the capital of unconsolidated financial institutions in the form of common stock**

Aggregate holdings of capital instruments relevant to significant investments in the capital of unconsolidated financial entities, including direct, indirect and synthetic holdings in both the banking book and trading book.

#### **Line item 2 Permitted offsetting short positions in relation to the specific gross holdings included above**

Offsetting positions in the same underlying exposure where the maturity of the short position either matches the maturity of the long position or has a residual maturity of at least one year.

#### **Line item 3 Significant investments in the capital of unconsolidated financial institutions in the form of common stock net of short positions**

This item is a shaded cell and is derived from other items in the schedule; no input required.

#### **Line item 4 10 percent common equity tier 1 deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

#### **Line item 5 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

### **Mortgage servicing assets**

#### **Line item 6 Total mortgage servicing assets classified as intangible**

Mortgage servicing assets may receive limited recognition when calculating common equity tier 1, with recognition typically capped at 10% of the bank's common equity (after the application of all regulatory adjustments).

#### **Line item 7 Associated deferred tax liabilities which would be extinguished if the intangible becomes impaired or derecognized under the relevant accounting standards**

The amount of mortgage servicing assets to be deducted from common equity tier 1 is to be offset by any associated deferred tax liabilities, with recognition capped at 10% of the bank's common equity

tier 1(after the application of all regulatory adjustments). If the bank chooses to net its deferred tax liabilities associated with mortgage servicing assets against deferred tax assets (in Line 17 of the Capital Composition sub-schedule), those deferred tax liabilities should not be deducted again here.

**Line item 8 Mortgage servicing assets net of related deferred tax liabilities**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 9 10 percent common equity tier 1 deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 10 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Deferred tax assets due to temporary differences**

**Line item 11 DTAs arising from temporary differences that could not be realized through net operating loss carrybacks, net of related valuation allowances and net of DTLs**

Net deferred tax assets arising from temporary differences may receive limited recognition in common equity tier 1, with recognition capped at 10% of the bank's common equity (after the application of all regulatory adjustments).

**Line item 12 10 percent common equity tier 1 deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 13 Amount to be deducted from common equity tier 1 due to 10 percent deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Aggregate of items subject to the 15% limit (significant investments, mortgage servicing assets and deferred tax assets arising from temporary differences)**

**Line item 14 Sum of items 3, 8, and 11**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 15 15 percent common equity tier 1 deduction threshold (~~item 19 in the Capital Composition tab minus item 14, multiplied by 17.65 percent~~)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 16 Sum of items 5, 10, and 13**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 17 Item 14 minus item 16**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 18 Amount to be deducted from common equity tier 1 due to 15 percent deduction threshold**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 19 Data Completeness Check**

If "No", please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable.

### **D.3—Advanced Risk-Weighted Assets**

***Advanced approaches BHCs and IHCs, including BHCs and IHCs that are considered as mandatory advanced approaches institutions or that have opted-in voluntarily as an advanced approaches institution, are required to complete the “Advanced RWA” sub-schedule.*** All BHCs and IHCs, including advanced approaches BHCs and IHCs and non-advanced approaches BHCs and IHCs must complete the “Standardized RWA” sub-schedule.

In the “Advanced RWA” sub-schedule, BHCs and IHCs should provide risk-weighted asset estimates reflecting the ~~revised~~ regulatory capital rule (78 Federal Register 62018, October 11, 2013) and the updated market risk capital rule (78 Federal Register 76521, December 18, 2013) released by the U.S. banking agencies.

BHCs and IHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. Please refer to the ~~revised~~ regulatory capital rule (78 Federal Register 62018, October 11, 2013) and the updated market risk capital rule (78 Federal Register 76521, December 18, 2013) released by the U.S. banking agencies for details of the requirements.

Advanced approaches BHCs and IHCs that are unable to provide advanced approaches risk weighted asset estimates should send formal written notification to the Federal Reserve and specify the affected portfolios, current limitations that preclude the BHC or IHC from providing advanced approaches RWA estimates as well as management's plan for addressing those limitations. The notification should be sent to [info@CCAR.frb.org](mailto:info@CCAR.frb.org).

MDRM codes have been included in the sub-schedule (column C) and correspond to the definitions for the FFIEC 101 line items where applicable.

**Advanced Approaches Credit Risk (Including CCR and non-trading credit risk), with 1.06 scaling factor where applicable – Applicable to Advanced Approaches Banking Organizations**  
Risk-weighted assets should reflect the 1.06 scaling factor to the Internal Rating-Based Approach (IRB) credit risk-weighted assets where relevant, unless noted otherwise.

#### **Line item 1 Credit RWA**

This item is a shaded cell and is derived from other items in the schedule; no input required.  
This is the sum of Schedule D.3 line items 2, 15, 21, 25, 29, 30 and 31.

#### **Line item 2 through 30 Various**

Definition of the BHC's or IHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the ~~revised~~ regulatory capital rule (78 Federal Register 62018, October 11, 2013).

#### **Line item 2 Wholesale Exposures**

This item is derived as the sum of items 3 through 8.

#### **Line item 3 Wholesale Exposures: Corporate**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 1 column G

**Line item 4 Wholesale Exposures: Bank**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 2 column G

**Line item 5 Wholesale Exposures: Sovereign**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 3 column G

**Line item 6 Wholesale Exposures: IPRE**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 4 column G

**Line item 7 Wholesale Exposures: HVCRE**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 5 column G

**Line item 8 Wholesale Exposures: Counterparty Credit Risk**

This item is derived as the sum of items 9 through 14.

**Line item 9 Wholesale Exposures: Counterparty Credit Risk (Eligible margin loans, repostyle transactions oand OTC derivatives with cross-product netting—EAD adjustment method)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 6 column G

**Line item 10 Wholesale Exposures: Counterparty Credit Risk Risk (Eligible margin loans, repostyle transactions and OTC derivatives with cross-product netting—collateral reflected in LGD)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 7 column G

**Line item 11 Wholesale Exposures: Counterparty Credit Risk (Eligible margin loans, repo style transactions—no cross-product netting—EAD adjustment method)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 7 column G

**Line item 12 Wholesale Exposures: Counterparty Credit Risk (Eligible margin loans, repo style transactions—no cross-product netting—collateral reflected in LGD)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 8 column G

**Line item 13 Wholesale Exposures: Counterparty Credit Risk (OTC derivative—no cross-product netting—EAD adjustment method)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 9 column G

**Line item 14 Wholesale Exposures: Counterparty Credit Risk (OTC derivatives—no cross-product netting—collateral reflected in LGD)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 10 column G

**Line item 15 Retail Exposures**

This item is derived as the sum of items 16 through 20.

**Line item 16 Retail Exposures: Residential mortgage—closed-end first lien exposure**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 12 column G

**Line item 17 Retail Exposures: Residential mortgage—closed-end junior lien exposure**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 13 column G

**Line item 18 Retail Exposures: Residential mortgage—revolving exposures**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 14 column G

**Line item 19 Retail Exposures: Qualifying revolving exposures**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 15 column G

**Line item 20 Retail Exposures: Other retail exposures**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 16 column G

**Line item 21 Securitization Exposures**

This item is derived as the sum of items 22 through 24.

**Line item 22 Securitization Exposures: Subject to supervisory formula approach (SFA)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 17 column G

**Line item 23 Securitization Exposures: Subject to simplified supervisory formula approach (SSFA)**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 18 column G

**Line item 24 Securitization Exposures: Subject to 1,250% risk-weight**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 19 column G

**Line item 25 Cleared Transaction**

This item is derived as the sum of items 26 through 28.

**Line item 26 Cleared Transaction: Derivative contracts and netting sets to derivatives**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 20 column G

**Line item 27 Cleared Transaction: Repo-style transactions**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 21 column G

**Line item 28 Cleared Transaction: Default fund contributions**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 22 column G

**Line item 29 Equity Exposures**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 23, 24, and 25 column G

**Line item 30 Other Assets**

Report the amount that is consistent with the definitions provided in FFIEC 101 Schedule B line item 26, 27, and 28 column G

**Line item 31 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent)**

This item is a shaded cell and is derived from other items in the schedule; no input required. This is the sum of Schedule D.3 line items 32 and 35.

**Line item 32 Advanced Credit Valuation Adjustment (CVA) Approach**

This item is a shaded cell and is derived from other items in the schedule; no input required. This is the sum of Schedule D.3 line items 33 and 34. The amount derived is consistent with the definitions provided in FFIEC 101 Schedule B line item 31.b Column G.

**Line item 33 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent); Advanced CVA Approach: Unstressed Value at Risk (VaR) with Multipliers**

Stand-alone 10-day value-at-risk (VaR) calculated on the set of credit valuation adjustments (CVAs) for all Over-the-counter (OTC) derivatives counterparties together with eligible credit valuation adjustment (CVA) hedges. The reported value-at-risk should consist of both general and specific credit spread risks and is restricted to changes in the counterparties credit spreads. The bank must multiply the reported value-at-risk by three times, consistent with the approach used in calculating market risk capital charge (three-time multiplier). The 1.06 scaling factor does not apply.

BHC or IHC should report 0 if it does not use the advanced credit value adjustment (CVA) approach.

**Line item 34 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent); Advanced CVA Approach: Stressed Value at Risk (VaR) with multipliers**

Stand-alone 10-day stressed Value-at-risk (VaR) calculated on the set of credit valuation adjustments (CVAs) for all over-the-counter (OTC) derivatives counterparties together with eligible credit valuation adjustments (CVA) hedges. The reported value-at-risk should consist of both general and specific credit spread risks and is restricted to changes in the counterparties credit spreads. It should reflect three-times multiplier. The 1.06 scaling factor does not apply. BHC or IHC should report 0 if it does not use the advanced credit valuation adjustments (CVA) approach.

**Line item 35 Credit Valuation Adjustment (CVA) Capital Charge (Risk-Weighted Asset Equivalent): Simple CVA Approach**

Risk-weighted asset (RWA) equivalent using the simple credit valuation adjustment (CVA) approach. Report the amount consistent with the definitions provided in FFIEC 101 Schedule B line item 31.a Column G.

**Advanced Approaches Operational Risk**

**Line item 36 Operational RWA**

Report the amount consistent with the definitions provided in FFIEC 101 Schedule B line item 35 Column G per the ~~revised~~ regulatory capital rule (78 Federal Register 62018, October 11, 2013).

**Market Risk**

**Line item 37 Market RWA**

This item is a shaded cell and is derived from other items in the schedule; no input required. This is the sum of Schedule D.3 line items 38, 39, 40, 41, 46, 47, and 50. The amount derived is consistent with the definitions provided in FFIEC 101 Schedule B line item 34 Column G.

**Line item 38 Value-at-risk (VaR)-based capital requirement**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 4.

**Line item 39 Stressed VaR-based capital requirement**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 7.

**Line item 40 Incremental Risk Capital Charge (IRC)**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 18.

**Line item 41 Correlation Trading**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 45. Only if a BHC or IHC has received supervisory approval of its comprehensive risk model effectiveness report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 51.

**Line item 42 Correlation Trading: Comprehensive Risk Measurement (CRM), Before Application of Surcharge**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102, Line Item 19.

**Line item 43 Correlation Trading: 8% of Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM)**

This item is a shaded cell and is derived from other items in the schedule; no input required. This is 8% of the max of Schedule D.3 line items 44 and 45 and should equal the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 39.

**Line item 44 Correlation Trading: Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM) - Net long**  
Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 27

**Line item 45 Correlation Trading: Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM) - Net Short**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 35.

**Line item 46 Non-modeled Securitization**

Report the risk-weighted asset amount consistent with the definitions for FFIEC 102 Line Item 13.

**Line item 47 Specific Risk add-on (excluding securitization and correlation)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 48 Debt**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 8.

**Line item 49 Equity**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 9.

**Line item 50 Other Market Risk**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 54.

**Line item 51 Assets subject to the general risk-based capital requirements**

Definition of the BHC's or IHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report per the ~~revised~~-regulatory capital rule (78 Federal Register 62018, October 11, 2013).

**Line item 52 Other RWA**

If the BHC or IHC is unable to assign RWA to one of the above categories, even on a best-efforts basis, they should be reported in this line.

**Line item 53 Excess eligible credit reserves not included in tier 2 capital**

Include excess eligible credit reserves not included in tier 2 capital, consistent with the ~~revised~~ regulatory capital rule (78 Federal Register 62018, October 11, 2013). Definition of the BHC's or IHC's projections should correspond to the definitions outlined by the corresponding MDRM code (shown in column C) of the FFIEC 101 report.

**Line item 54 Total Risk-Weighted Assets**

This item is a shaded cell and is derived from other items in the schedule, no input required. This is the sum of Schedule D.3 line items 1, 36, 37, 51, and 52, minus Schedule D.3 line item 53.

**Line item 55 Data Completeness Check**

This item is a shaded cell to check that all nonshaded cells have been completed. If "No" appears, please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable. Please ensure that "Yes" appears across all cells.

#### **D.4—Standardized Risk-Weighted Assets**

*All BHCs and IHCs, including advanced approaches BHCs and IHCs and non-advanced approaches BHCs and IHCs must complete “Standardized RWA” sub-schedule. In addition, advanced approaches BHCs and IHCs are required to complete “Advanced RWA” sub-schedule due to the floor requirement per the Collins Amendment under Section 171 of the DFA.*

For the purpose of completing the “Standardized RWA” sub-schedule, BHCs and IHCs are required to report credit risk- weighted assets using the methodologies in the standardized approach of the ~~revised~~ regulatory capital rule ~~(78 Federal Register 62018, October 11, 2013)~~.

Advanced approaches firms must apply a 250 percent risk-weight to mortgage servicing assets (MSAs), deferred tax assets arising from temporary differences that could not be realized through net operating loss carrybacks, and significant investments in the capital of unconsolidated financial institutions in the form of common stock that are not deducted from capital. For all reporting quarters, a non-advanced approaches firm should apply a 100 percent risk weight to any amounts of MSAs, deferred tax assets arising from temporary differences that could not be realized through net operating loss carrybacks, and significant investments in the capital of unconsolidated financial institutions in the form of common stock that are not deducted from capital, and continue to apply the ~~2017~~ current risk weights under the capital rules to amounts of non-significant investments in the capital of unconsolidated financial institutions and significant investments in the capital of unconsolidated financial institution not in the form of common stock that are not deducted from capital.

BHCs and IHCs that are subject to market risk capital requirements at the as of date are required to complete the market risk-weighted asset section within the sub-schedule. However, if a BHC or IHC projects to meet the trading activity threshold that would require it to be subject to the market risk capital requirements during the forecast period, then the BHC or IHC should complete the market risk-weighted asset section within the sub-schedule. Please refer to the ~~revised~~ regulatory capital rule (78 Federal Register 62018, October 11, 2013) and the ~~updated~~ market risk capital rule (78 Federal Register 76521, December 18, 2013) for details of the requirements.

Where possible, please reference the definitions on Standardized RWA that is provided in the draft version of the HC-R, Part II, on a fully phased-in basis.

#### **Standardized Approach Credit Risk**

##### **Line item 1 Cash and balances due from depository institutions**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 1.

##### **Securities**

###### **Line item 2a Held-to-maturity (Excluding securitization)**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 2a.

###### **Line item 2b Available-for-sale (Excluding securitization)**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 2b.

**Line item 3 Federal funds sold**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 3a.

**Loans and leases on held for sale**

**Line item 4a Residential Mortgage exposures**

Report the risk-weighted asset amount consistent with the definition for the FR Y-9C, Part II, Line item 4a.

**Line item 4b High Volatility Commercial Real Estate**

Report the risk-weighted amount consistent with the definition for the FR Y-9C, HC-R, Part II, Line item 4b.

**Line item 4c Exposures past due 90 days or more on nonaccrual**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line item 4c.

**Line item 4d All other exposures**

Report the risk-weighted asset amount consistent with the definition for the FR Y-9C, HC-R, Part II, Line item 4d.

**Loans and leases, net of unearned income**

**Line item 5a Residential mortgage exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5a.

**Line item 5b High Volatility Commercial Real Estate**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5b.

**Line item 5c Exposures past due 90 days or more on nonaccrual**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5c.

**Line item 5d All other exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 5d.

**Line item 6 Trading assets (excluding securitizations that receive standardized charges)**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 7.

**Line item 7a All other assets**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 8.

**Line item 7b Separate account bank-owned life insurance**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 8a.

**Line item 7c Default fund contributions to central counterparties**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 8b.

**On-balance sheet Securitization exposures****Line item 8a Held-to-maturity**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9a.

**Line item 8b Available-for-sale**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9b.

**Line item 8c Trading assets that receive standardized charges**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9c.

**Line item 8d All other on-balance sheet securitization exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 9d.

**Line item 9 Off-balance sheet securitization exposures**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 10.

**Line item 10 RWA for balance sheet asset categories (sum of items 1 through 8d)** This item is shaded and is derived from other items in the schedule, no input required.

**Derivatives and Off-Balance Sheet Items****Line item 11 Financial standby letters of credit**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 12.

**Line item 12 Performance standby letters of credit and transaction related contingent items**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 13.

**Line item 13 Commercial and similar letters of credit with an original maturity of one year or less**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 14.

**Line item 14 Retained recourse on small business obligations sold with recourse**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 15.

**Line item 15 Repo-style transactions**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 16.

**Line item 16 All other off-balance sheet liabilities**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 17.

**Line item 17a Unused Commitments: Original maturity of one year or less, excluding ABCP conduits**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 18a.

**Line item 17b Unused Commitments: Original maturity of one year or less to ABCP**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 18b.

**Line item 17c Unused commitments: Original maturity exceeding one year**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 18c.

**Line item 18 Unconditionally cancelable commitment**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 19.

**Line item 19 Over-the-counter derivatives**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 20.

**Line item 20 Centrally cleared derivatives**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 21.

**Line item 21 Unsettled transactions (failed trades)**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 22.

**Line item 22 RWA for Assets, Derivatives and off-balance sheet asset categories**

This item is derived as the sum of items 9 through 21.

**Line item 23 RWA for purposes of calculating the allowance for loan and lease losses 1.25 percent threshold**

Report the risk-weighted asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 26.

**Market Risk**

**Line item 24 Market RWA**

This item is shaded and is derived from other items in the schedule; no input required.

**Line item 25 Value-at-risk (VaR)-based capital requirement**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 4.

**Line item 26 Stressed VaR-based capital requirement**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 7.

**Line item 27 Incremental risk charge (IRC)**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 18.

**Line item 28 Correlation Trading**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 42. Only if a BHC or IHC has received supervisory approval of its comprehensive risk model effectiveness report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 48.

**Line item 29 Correlation Trading: Comprehensive Risk Measurement (CRM), Before Application of Surcharge**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102, Line Item 19.

**Line item 30 Correlation Trading: 8% of Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM)**

This item is shaded and is derived from other items in the schedule; no input required. This item should equal the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 37.

**Line item 31 Correlation Trading: Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM) - Net long**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 26.

**Line item 32 Correlation Trading; Standardized Measurement Method (100%) for Exposures Subject to Comprehensive Risk Measurement (CRM) - Net Short**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 34.

**Line item 33 Non-modeled Securitization**

Report the risk-weighted asset amount consistent with the definitions for FFIEC 102 Line Item 10.

**Line item 34 Specific risk add-on (excluding securitization and correlation)**

This item is shaded and is derived from other items in the schedule; no input required.

**Line item 35 Debt**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 8.

**Line item 36 Equity**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 9.

**Line item 37 Other market risk**

Report the risk-weighted asset amount consistent with the definition for FFIEC 102 Line Item 54.

**Other**

**Line item 38 Excess allowance for loan and lease losses**

Report the asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 29.

**Line item 39 Allocated transfer risk reserve**

Report the asset amount consistent with the definition for FR Y-9C, HC-R, Part II, Line Item 30.

**Line item 40 Total Risk-Weighted Assets**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 41 Data Completeness Check**

This item is a shaded cell to check that all nonshaded cells have been completed. If "No" appears, please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable. Please ensure that "Yes" appears across all cells.

## D.5—Leverage Exposure

All BHCs and IHCs must complete the portion of the sub-schedule relevant to “Leverage Exposure for Tier 1 Leverage Ratio” (lines 1 - 4). Advanced approaches BHCs and IHCs must also complete the portion of the sub-schedule relevant to “Leverage Exposure for Supplementary Leverage Ratio” (lines 5 - 24).

The exposure measure for the tier 1 leverage ratio is based upon methodology in the ~~revised~~ regulatory capital rule. The exposure measure for the supplementary leverage ratio has been revised from the 2014 CCAR instructions to reflect the changes to the definition of leverage exposure, per the final rule on the Supplementary Leverage Ratio issued by the banking agencies on September 3, 2014 (final rule).<sup>16</sup> The final rule modifies the definition of “total leverage exposure,” which is the denominator in the supplementary leverage ratio, in a manner consistent with the recent changes agreed to by the Basel Committee on Banking Supervision in January 2014. The revisions in the final rule would apply to all advanced approaches banking organizations.

Consistent with the final rule, an advanced approaches banking organization should calculate its supplementary leverage ratio as the ratio of its tier 1 capital to total leverage exposure. The proposed rule would have required banking organizations to use daily averages to calculate both on- and off-balance sheet items in total leverage exposure. However, under the final rule, institutions are required to calculate total leverage exposure as the mean of the on-balance sheet assets calculated as of each day of the reporting quarter, plus the mean of the off-balance sheet exposures calculated as of the last day of each of the most recent three months, minus the applicable deductions under the 2013 ~~revised~~ capital rule. For purposes of calculating projections for the supplementary leverage ratio denominator, BHCs and IHCs that are unable to calculate averages based on the averages of daily or monthly data may report exposures as of the quarter end.

### **Leverage Exposure for Tier 1 Leverage Ratio (applicable to all BHCs and IHCs)**

#### **Line item 1    Average total consolidated assets**

Report average total on-balance sheet assets as reported in the FR Y-9C, Schedule HC-K, item 5.

#### **Line item 2    LESS: Deductions from Common Equity Tier 1 and Additional Tier 1 Capital (report as a positive number)**

Regulatory deductions from common equity tier 1 and additional tier 1 capital. Deductions should be calculated as defined in the FR Y-9C, Schedule HC-R, Part I.B., item 37.

#### **Line item 3    LESS: Other Deductions from (Additions to) Assets for Leverage Ratio Purposes (report as a positive number if a net deduction or a negative value if a net addition )**

Other deductions from or additions to assets for purposes of the leverage ratio as defined in the FR Y-9C, Schedule HC-R, Part I.B., item 38.

#### **Line item 4    Total Assets for the Leverage Ratio (item 1 less the sum of items 2 and 3)**

---

<sup>16</sup> See <http://www.federalreserve.gov/newsevents/press/bcreg/bcreg20140903b1.pdf>.

This item is a shaded cell and is derived from other items in the schedule; no input required

**Leverage Exposure for Supplementary Leverage Ratio (applicable to advanced approaches BHCs only)**

Refer to section 217.10 (c)(4)(ii) (A) of the final rule.

**Line item 5 On-Balance Sheet Assets (excluding on-balance sheet assets for repo-style transactions and derivative exposures, but including cash collateral received in derivative transactions)**

On-balance sheet assets (excluding on-balance sheet assets for repo-style transactions and derivative exposures, but including for the qualifying cash collateral received in derivative transactions, in accordance with *section 217.10 (c)(4)(ii)(C)*).

**Line item 6 LESS: Deductions from common equity tier 1 capital and additional tier 1 capital (report as a positive number)**

Regulatory deductions from common equity tier 1 and additional tier 1 capital, as applicable to advanced-approaches BHCs and IHCs per the ~~revised~~ capital rules under section 217.22(a),(c), and (d)..

**Line item 7 Total On-Balance Sheet Exposures (excluding on-balance sheet assets for repo-style transactions and derivative exposures, but including cash collateral received in derivative transactions) (item 5 less item 6)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Derivative exposures**

*Refer to sections 217.10 (c)(4)(ii) (B), (C), (D), or (I) of the final rule as appropriate.*

**Line item 8 Replacement cost for derivative exposures (net of qualifying cash variation margin).**

Report the total amount of the replacement cost for all derivative exposures, generally consistent with the US GAAP balance sheet numbers for derivative assets, and adjusted for cash variation margin that does not meet the criteria described in section 217.10 (c)(4)(ii)(C) of the final rule.

**Line item 9 Add-on amounts for potential future exposure (PFE) for derivatives exposures**

Report the total amount of PFE for each derivative contract, including for cleared transactions except as provided in section 217.10 (c)(4)(ii)(I) of the final rule, to which the banking organization is a counterparty (or each single-product netting set of such transactions), as described in section 34 of the ~~revised~~ regulatory capital rule, but without regard to section 217.34(b). Specifically, a banking organization may not use cash variation margin to reduce the net current credit exposure or the gross current credit exposure in calculation of the net-to-gross ratio.

**Line item 10 Gross-up for cash collateral posted if deducted from the on-balance sheet assets, except for cash variation margin**

Report cash collateral posted to a counterparty in a derivative transaction if a banking organization

offsets a negative mark-to-fair value of a derivative contract by the amount of cash collateral posted to the counterparty and does not include such cash collateral in its on-balance sheet assets (as permitted under the GAAP offset option), but the posted cash collateral does not meet the final rule's requirements for cash variation margin in section 217.10 (c)(4)(ii)(C).

**Line item 11 LESS: Deductions of receivable assets for cash variation margin posted in derivatives transactions, if included in on-balance sheet assets (report as a positive value)**  
Report the value of cash collateral that is posted to a counterparty to a derivative contract and that has been included on the banking organization's balance sheet as a receivable if the posted cash collateral satisfies the requirements described in section 217.10 (c)(4)(ii)(C) of the final rule. If not applicable, report zero.

**Line item 12 LESS: Exempted CCP leg of client-cleared transactions (report as a positive value)**

A clearing member banking organization that does not guarantee the performance of a CCP with respect to a transaction cleared on behalf of a clearing member client may exclude its exposure to the CCP for purposes of determining its total leverage exposure (if such exposure is included in the on-balance sheet items).

A clearing member banking organization that guarantees the performance of a CCP with respect to a transaction cleared on behalf of a clearing member client must treat its exposure to the CCP as a derivative contract for purposes of determining its total leverage exposure.

**Line item 13 Effective notional principal amount of sold credit protection**

The effective notional principal amount (that is, the apparent or stated notional principal amount multiplied by any multiplier in the derivative contract) of a credit derivative, or other similar instrument, through which the banking organization provides credit protection (for example, credit default swaps or total return swaps that reference instruments with credit risk, such as a bond).

**Line item 14 LESS: Effective notional principal amount offsets and PFE adjustments for sold credit protection (report as a positive value)**

A banking organization may reduce the effective notional principal amount of sold credit protection by a reduction in the mark-to-fair value of the sold credit protection if the reduction is recognized in common equity tier 1 capital.

A banking organization may further reduce the effective notional principal amount of sold credit protection by the effective notional principal amount of a credit derivative or similar instrument through which the banking organization has purchased credit protection from a third party (purchased credit protection) if the requirements of section 217.10 (c)(4)(ii)(D) of the final rule are satisfied. When a banking organization reduces the effective notional principal amount of sold credit protection by purchased credit protection in accordance with section 217.10 (c)(4)(ii)(D)(1), the banking organization must reduce the effective notional principal amount of purchased credit protection by the amount of any increase in the mark-to-fair value of the purchased credit protection that is recognized in common equity tier 1 capital.

If a banking organization purchases credit protection through a total return swap and records the net payments received as net income but does not record offsetting deterioration in the mark-to-fair value of the sold credit protection on the reference exposure (either through reductions in fair value

or by additions to reserves) in common equity tier 1 capital, the banking organization may not reduce the effective notional principal amount of the sold credit protection.

A banking organization may also adjust PFE for sold credit protection as described in section 217.10 (c)(4)(ii)(B) of the final rule, to avoid double-counting of the notional amounts of these exposures.

**Line item 15 Total derivative exposures (sum of items 8, 9, 10, and 13, minus items 11, 12, and 14)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Repo-style transactions**

*Refer to sections (c)(4)(ii) (E), (F), or (G) of the final rule as appropriate.*

**Line item 16 On-balance sheet assets for repo-style transactions**

Report the on-balance sheet assets for repo-style transactions, except include the gross value of receivables for reverse repurchase transactions. Exclude from this item the value of securities received in a security-for-security repo-style transaction where the securities lender has not sold or re-hypothecated the securities received. Include in this item the value of securities sold under a repo-style arrangement.

**Line item 17 LESS: Reduction of the gross value of receivables in reverse repurchase transactions by cash payables in repurchase transactions under netting agreements (report as a positive value)**

Where a banking organization acting as a principal has more than one repo-style transaction with the same counterparty and has applied the GAAP offset for repo-style transactions, report the reduction of the gross value of receivables in reverse repurchase transactions if the criteria in section 217.10(c)(4)(ii)(E), (1) through (3) of the final rule are satisfied.

**Line item 18 Counterparty credit risk for all repo-style transactions**

To determine the counterparty exposure for a repo-style transaction, including a transaction in which a banking organization acts as an agent for a customer and indemnifies the customer against loss, the banking organization would subtract the fair value of the instruments, gold, and cash received from a counterparty from the fair value of any instruments, gold and cash lent to the counterparty. If the resulting amount is greater than zero, it would be included in total leverage exposure. For repo-style transactions that are not subject to a qualifying master netting agreement or that are not cleared transactions, the counterparty exposure measure must be calculated on a transaction-by-transaction basis. However, if a qualifying master netting agreement is in place, or the transaction is a cleared transaction, the banking organization could net the total fair value of instruments, gold, and cash lent to a counterparty against the total fair value of instruments, gold and cash received from the counterparty for those transactions.

**Line item 19 Exposure for repo-style transactions where a banking organization acts as an agent**

Where a banking organization acts as agent for a repo-style transaction and provides a guarantee (indemnity) to a customer with regard to the performance of the customer's counterparty that is greater than the difference between the fair value of the security or cash lent and the fair value of the security or cash borrowed, the banking organization must include the amount of the guarantee

that is greater than this difference.

**Line item 20 Total exposures for repo-style transactions (sum of items 16, 18, and 19 minus item 17)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Other off-balance sheet exposures**

*Refer to section (c)(4)(ii) (H) of the final rule.*

**Line item 21 Off-balance sheet exposures at gross notional amounts**

The notional amount of all off-balance sheet exposures (excluding off-balance sheet exposures associated with securities lending, securities borrowing, reverse repurchase transactions, and derivatives).

**Line item 22 LESS: Adjustments for conversion to credit equivalent amounts (report as a positive value)**

The final rule retains the 10 percent CCF for unconditionally cancellable commitments, but it would replace the uniform 100 percent CCF for other off-balance sheet items with the CCFs applicable under the standardized approach for risk-weighted assets in section 217.33 of the *revised* regulatory capital rule.

**Line item 23 Off-balance sheet exposures (item 21 less item 22)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Line item 24 Total Leverage Exposure (sum of items 7, 15, 20 and 23)**

This item is a shaded cell and is derived from other items in the schedule; no input required.

**Data Completeness Check**

**Line item 25 Leverage Exposure for Tier 1 Leverage Ratio (applicable to all BHCs and IHCs)**

Check to ensure sub-schedule is complete. Please ensure that "Yes" appears across all cells.

**Line item 26 Leverage Exposure for Supplementary Leverage Ratio (applicable to advanced approaches institutions only)**

This item is a shaded cell and to check that all nonshaded cells have been completed. If "No" appears, please complete all non-shaded cells until all cells to the right say "Yes." Do not leave cells blank; enter "0" if not applicable. Please ensure that "Yes" appears across all cells.

## D.6—Planned Actions

The FR Y-14A Planned Action sub-schedule collects information on all material planned actions that management intends to pursue to address the ~~revised~~ regulatory capital rule. BHCs and IHCs are required to factor the combined quantitative impact of all planned actions into the projections reported on all other relevant sub-schedules of the Regulatory Capital Transitions submission. Such actions might include, but are not limited to, the roll-off or sale of an existing portfolio; development/implementation of risk-weighting models; data remediation to facilitate the use of lower risk weights for existing exposures; the issuance of regulatory capital instruments; or other strategic corporate actions. Planned actions should be attributable to a specific strategy or portfolio; BHCs and IHCs are not expected to cite period-over-period changes in the balances of exposures as a planned action unless those changes are attributable to a specific and identifiable strategy (e.g., citing “reduction in credit risk-weighted assets” would not be considered a valid planned action, but citing sale or runoff of a particular portfolio (which would have the effect of reducing credit risk-weighted assets) would be a valid planned action).

For each reporting period, BHCs and IHCs should report the incremental quantitative impact of each action on:

- Common equity tier 1 capital
- Tier 1 capital
- RWA\_Standardized
- RWA\_Advanced
- Average Total Assets for Leverage Capital Purposes (relevant to the tier 1 leverage ratio; to be completed by all BHCs and IHCs)
- Total Leverage Exposure for the Supplementary Leverage Ratio (to be completed by advanced approaches BHCs and IHCs only); and
- Balance sheet.

The quantitative impact of planned actions submitted by BHCs and IHCs should represent the stand-alone, incremental immediate impact of the action relevant to the time period in which it is planned to be executed. For example, if a planned action were forecasted to reduce the BHC’s or IHC’s risk-weighted assets by \$200 million as of Q4 in the current year and an additional \$100 million as of Q4 of the following year (for a total reduction of \$300 million), the BHC or IHC should report “(200)” for PY1, “(100)” for PY2, and “0” for subsequent periods. BHCs are required to factor the combined quantitative impact of all planned actions into the projections reported on all other relevant sub-schedules of the Regulatory Capital Transitions submission.

### Additional Information Required for Each Planned Action

In addition to the information provided within the Planned Action sub-schedule, BHCs and IHCs are also required to submit additional details of each of its planned actions. This information should be provided in a separate attachment.

### Column Instructions

Note that certain columns include an option of “other” in the drop down list that can be used if the listed action cannot be described using the listed selections.

**Column B Description**

Brief description of the planned action.

**Column C Action Type**

Select from a list of available actions provided in the schedule. BHCs and IHCs should select the type of action that best describes the planned action.

**Column D Exposure Type**

Select from a list of available exposure types provided in the schedule. BHCs and IHCs should select the type of exposure that is most impacted by the planned action.

**Column E RWA Type**

Selection from a list of available RWA exposure types provided in the schedule. For planned actions that have an impact on RWAs, the BHC or IHC should report the type of RWA (i.e., Counterparty Credit, Other Credit, Market, or Operational) that is most impacted by the planned action.

**Columns F-AU Projected impact (for periods PY 1 though PY 6) on:**

- **Common Equity Tier 1**
- **Tier 1**
- **Standardized Risk-Weighted Assets (RWA) (impact on the RWA projections shown on Standardized RWA sub-schedule)**
- **Advanced RWA (impact on the RWA projections shown on Advanced RWA sub-schedule)**
- **Average Total Assets for Leverage Capital Purposes**
- **Total Leverage Exposure for Supplementary Leverage Ratio**
- **Balance Sheet**

Projected incremental impact year-over-year on the BHC's or IHC's common equity tier 1 capital, Tier 1 capital, risk-weighted assets, leverage exposures and balance sheet in \$Millions as of year-end. For PY 1 only, report the incremental impact projected between the as of date and fourth quarter period corresponding to PY 1.

**Columns F-L PY1**

Report the projected impact at year-end (PY 1) for each of the seven capital and balance sheet items listed above.

**Columns M-S PY2**

Report the projected impact at year-end (PY 2) for each of the seven capital and balance sheet items listed above.

**Columns T-Z PY3**

Report the projected impact at year-end (PY 3) for each of the seven capital and balance sheet items listed above.

**Columns AA-AG PY4**

Report the projected impact at year-end (PY 4) for each of the seven capital and balance sheet items listed above.

**Columns AH-AN PY5**

Report the projected impact at year-end (PY 5) for each of the seven capital and balance sheet items listed above.

**Columns AO-AU Total**

These are shaded cells, no input is required. These items capture the projected cumulative impact of for each of the seven capital and balance sheet items listed above.

**Column AV**

Enter the file name and page number of the separate document in which a detailed description is provided for each planned action.

Please note:

**Total impact of planned actions** is provided at the bottom of the sub-schedule. This is auto-calculated and is the summation of each individual column aligned with the applicable category impact for the relevant reporting period.

**Reported changes from prior period** is the last row on the sub-schedule. This field captures the change between each reporting period on the change in impact for the applicable category (e.g., "Common Equity Tier 1," "Tier 1 capital," etc).

## **Schedule E—Operational Risk**

### **E.1—BHC or IHC Legal Reserves Reporting**

The BHC or IHC Legal Reserves Reporting sub-schedule must be completed by all institutions. For each year, report the total dollar values of the institution's legal reserve balance, representing the total legal reserve balance that was included on the institution's financial statements for the as-of date. The BHC's or IHC's submission should contain annual legal reserve balances for at least five years through to the reporting quarter.

**On a voluntary basis, report the total dollar value of the institution's legal reserves pertaining to repurchase litigation which was included on the institution's financial statements as part of the total legal reserve on the as-of date. Also please indicate the subset of this amount which is related only to contractual Representation and Warranty (R&W) claims (excluding any amounts set aside for damages, penalties, fees, etc).**

### **E.2—Material Risk Identification**

Note: This sub-schedule is only to be reported by firms subject to SR Letter 15-18.

In the table in the report form, provide a list of the firm's material operational risks included in the loss projections, along with the risk names, risk segment, and loss contribution. Material operational risks are those which are considered material according to the BHC's risk management framework. Also identify any material risks that were excluded from the loss projections.

### **E.3—Operational Risk Scenarios**

This sub-schedule is only to be reported by firms subject to SR Letter 15-18.

In the table in the report form, provide a list of the firm's Operational Risk scenarios included in the BHC Baseline and BHC Stress Operational Risk loss projections including the scenario name and loss contribution for each scenario. Note the methodology for applying scenario results to the loss projections, such as model inputs, overlays, or other methods.

## **Schedule F – Business Plan Changes**

This schedule is used to estimate the effect of a material change in business plan on a BHC's or IHC's asset, liability, and capital projections.<sup>17</sup> Examples of a material change in business plan could include a planned merger, change in a key business strategy, a significant investment, or a divestiture, provided that the divestiture has been completed or contractually agreed to prior to the submission deadline of FR Y-14A, Schedule A. Divestitures planned as part of a merger must also be

---

<sup>17</sup> A BHC or IHC is required to include in its capital plan a discussion of any expected changes to the BHC's or IHC's business plan that are likely to have a material impact on the BHC's or IHC's capital adequacy or liquidity. See 12 CFR 225.8(e)(2)(iv).

In this discussion, the BHC or IHC should consider not just the impacts of these expected changes, but also the potential adverse consequences should the actions not result in the planned changes—e.g., a merger plan falls through, a change in business strategy is not achieved, or there is a loss on the planned significant investment.

contractually agreed to prior to the submission deadline.

BHCs and IHCs that include a material business plan change in their capital plan must report this schedule. Respondents should refer to the CCAR instructions for a given year for a discussion of materiality. Schedule F should **only** be used to report material business plan changes that will derive from contractual agreements with another party. Overall projections of balances, liabilities, and capital, which include the assumed effects of run-off, growth, and contractual agreements, should be reported in the FR Y-14A Summary schedule. Schedule F seeks to isolate the projected effects of business plan changes from overall projections of these items for the BHC or IHC and from projected growth. The data reported in Schedule F reflect the quarter-over-quarter changes in reported Summary schedule items that are attributable to business plan changes. Generally, BHCs and IHCs should not report items on Schedule F as they appear in the FR Y-14A Summary schedule.

Unless instructed otherwise, firms with material business plan changes are only required to complete Schedule F for the supervisory baseline, supervisory adverse, and supervisory severely adverse scenarios. Schedule F is an annual schedule and need not be completed for the mid-cycle stress test.

Schedule F mirrors the structure of the FR Y-14A Summary schedule. Using that structure, for a given supervisory scenario, report in Schedule F the dollar amount of the incremental effect of a material change in business plan on the balance sheet, income statement, RWA, retail balance and loss projections, and capital worksheets (both CCAR and DFAST) items which are reported on the Y-14A Summary schedule. The data submitted in Schedule F should include only "Day 1" effects of the business plan change. Any "Day 2" projections, including profit and loss projections for the remainder of the quarter after the business plan change takes place, should be excluded from submitted data. In quarters in which no change in business plan occurs, report zero for all fields.

Separately report this information for each of the supervisory scenarios (Supervisory Baseline, Supervisory Adverse, and Supervisory Severely Adverse). BHCs and IHCs should complete one submission per scenario, with all expected business plan changes for a given scenario included in the same template. If a BHC or IHC reports more than one business plan change in any quarter of the projection horizon, the Federal Reserve may ask for additional information, which could include a more granular breakdown of change in asset, liability and capital projection by individual business plan change.

The following items, which are derived by the Federal Reserve on the FR Y-14A Summary schedule, cannot be derived for business plan changes. BHCs and IHCs should report the incremental effect of a material business plan change on these items directly in Schedule F.

For more information on these items, refer to Schedule A.1.a for Income Statement variables and Schedule A.1.d.1 for Capital Worksheet variables.

#### **Summary, Income Statement (Schedule A.1.a)**

- Item 63, Other Losses: Goodwill Impairment
- Item 64, Other Losses: Valuation Adjustment for firm's own debt under fair value option (FVO)
- Item 68, Allowance for Loan and Lease Losses: ALLL Prior Quarter
- Item 117, Pre-provision net revenue: Net interest income

- Item 118, Pre-provision net revenue: Noninterest income
- Item 119, Pre-provision net revenue: Noninterest expense
- Item 120, Pre-provision net revenue: Pre-provision net revenue
- Item 126, Condensed income statement: Realized gains (losses) on available-for-sale securities, including OTTI
- Item 127, Condensed income statement: Realized gains (losses) on held-to-maturity securities, including OTTI
- Item 136, Repurchase Reserve/Liability for Mortgage Reps and Warranties: Reserve, prior quarter
- Item 137, Repurchase reserve/liability for mortgage reps and warranties: Provisions during the quarter
- Item 138, Repurchase reserve/liability for mortgage reps and warranties: Net charges during the quarter

#### **Summary, Capital (Schedule A.1.d.1)**

- Item 1, Schedule HI-A—Changes in Bank or Intermediate Holding Company Equity Capital: Total bank or intermediate holding company equity capital most recently reported for the end of previous QUARTER

BHCs and IHCs should provide supporting documentation that includes any information relating to portfolio risk characteristics that has been collected during the BHC's or IHC's due diligence process. This supporting documentation should be uploaded to the IntraLinks collaboration site and categorized as:

#### **Supporting Document → FR Y-14A – Sch F – Bus Plan Changes**

If a BHC or IHC reports more than one business plan change in any quarter of the projection horizon, then the two business plan changes should be included in the BHC's or IHC's capital plan. In this case, the Federal Reserve may ask for additional information, which could include a more granular breakdown of change in asset, liability, and capital projection by individual business plan change. A firm's capital plan should include combining pro forma financial statements if the firm has projected a merger, and should include fair value adjustments applied to each acquired portfolio in order to arrive at its projected carry value if the firm has projected an acquisition.

**Example of What to Report:** Suppose that, as of 4Q16 (the data as of date for CCAR 2017), a BHC or IHC has a US first lien mortgage portfolio of \$100 million which is projected to grow by \$5 million per quarter over the planning horizon. In the first quarter of the planning horizon (1Q17 for CCAR 2017) the BHC or IHC completes a divestiture of a \$20 million portfolio and enters an agreement to acquire a \$40 million portfolio, estimated to close in the fourth quarter of the planning horizon (4Q17 for CCAR 2017). Further suppose that all of the projections mentioned above correspond to projections under the Supervisory Severely Adverse scenario.

On its FR Y-14A Summary schedule for the Supervisory Severely Adverse scenario, the BHC or IHC would report the projected balances of its US first lien mortgage portfolio on Item 1 of the Retail Balance and Loss Projections worksheet (RBLP) (MDRM number CPSRP381). These balances would correspond to column in Exhibit 1, below.

The BHC or IHC would also be required to submit a Y-14A Business Plan Changes schedule for the supervisory scenarios. In that submission, for the Supervisory Severely Adverse scenario, the BHC

or IHC would report the dollar amount of the effect that the acquisition and divestiture would have on the projected balances of its US first lien mortgage portfolio on Item 1 of the RBLP (MDRM number CBPRP381). These balances would correspond to column (4) in Exhibit 1, below.

(1) Projection Quarter	(2) Y-14A Summary RBLP, Line 1	(3) Portfolio Growth	(4) FR Y-14A BPC RBLP, Line 1	
<b>4Q15</b>	100			
<b>1Q16</b>	85	5	-20	<b>&lt;- Divestiture</b>
<b>2Q16</b>	90	5	0	
<b>3Q16</b>	95	5	0	
<b>4Q16</b>	140	5	40	<b>&lt;- Acquisition</b>
<b>1Q17</b>	145	5	0	
<b>2Q17</b>	150	5	0	
<b>3Q17</b>	155	5	0	
<b>4Q17</b>	160	5	0	
<b>1Q18</b>	165	5	0	

Note: Column (3) of exhibit 1 is not explicitly reported in either the Y-14 Summary or Business Plan Changes schedules. It is included in exhibit 1 for illustration only.

## **Schedule G – Retail Repurchase Exposures**

This Retail Repurchase schedule collects data on point in time exposures of loans sold by the BHC or IHC that may be subject to repurchase risk due to breaches of representations and warranties made during the sale of the loans, as defined in the FR Y-9C, Schedule HC-P, item 6. It also collects data on loans insured by the US Government for which the insurance coverage could be denied or indemnification required if loan defects are identified.

This schedule has two sections for information on loans sold by the BHC or IHC that may be subject to repurchase risk. Section 1 collects loans for which the outstanding unpaid principal balance (UPB) and delinquency information requested is available. Section 2 collects loans for which the outstanding UPB or delinquency information is incomplete or not available. Due to the missing data associated with loans reported in Section 2, loans in this population will be treated with conservative assumptions. Data collected in Sections 1 and 2 should be mutually exclusive.

This schedule is to be submitted semi-annually and is due seven calendar days after the FR Y-9C due date (on the FR Y-14Q submission date).

### **Table Information:**

Information reported in this schedule will be collected in Tables A through F and H. Please report information aggregated by Vintage for each table and corresponding data fields below. The Vintage of each column refers to the calendar year that the loan was sold (i.e., 2004 through the current year).

In cases where the data may not be available by Vintage, report the data in the Unallocated column. Loans sold prior to 2004 should be excluded from all data fields. It is expected that use of the Unallocated column will be very limited. Any loans sold data reported in the Unallocated column will be treated with conservative assumptions by the Federal Reserve.

If Outstanding Balance and Delinquency information is available but Realized Net Credit Losses is not known, the BHC or IHC should report in tables A.1 through F the available information and provide an explanation as to why credit loss information is not known.

If no information or incomplete information on the credit performance of the loans sold with repurchase agreements and warranties, the BHC or IHC should report in tables A.2 through F “BHC or IHC Unable to Report Outstanding UPB or Delinquency Information” to report Original UPB and Projected Losses information. Report in tables A.2 through F the Original UPB and Projected Future Losses of assets sold with servicing released where the BHC or IHC is unable to report Outstanding UPB and Credit.

Loans that have been sold, repurchased and then sold again should be reported in the most recent year of sale.

### **Row Variable Information:**

For row variables described in sections 1 and 2 with the note Excluding Exempt Population, the data submitted should exclude any loans for which the BHC or IHC has no risk of repurchase liability. For settlements, only finalized settlements should be considered Exempt; any loans subject to a pending settlement should be included on this sub-schedule. Loans paid in full are not

part of the exempt population unless they satisfy the defined exemption criteria. When addressing exclusions that may exist in any settlement agreement BHCs or IHCs should isolate the population of loans for which material exclusions exist and report these as 'loans with remaining liability' on Table H. In the event that a settlement has eliminated the vast majority of the contractual representation and warrant liability for certain loans, these should be categorized as exempt on Tables A-F. However, firms should provide details on settlement exclusions that may exist for those settled populations in Table H and in the supporting documentation, including specifics of any finalized settlements (exposures and timeframes covered by these settlements and the date the settlements were finalized). The firm should also explain any material changes in historical vintage exposure compared to prior year.

**Examples of Exempt Population:** The exempt population includes all loans for which the BHC or IHC does not have contractual representation and warranty liability. Such loans should be excluded for row variables described with the note *Excluding Exempt Population*. Examples of the exempt population include the following:

- Loans for which a final judgment has been entered or final settlement has been reached<sup>18</sup>.  
Loans subject to finalized settlements should be reported on Table H and should be exempt on Tables A-F. Any residual liability on settled loans should be reported in Table H in loans with remaining liability. Settled loans reported in Table H should remain in the Original UPB of Tables A-F, but should be excluded from Original UPB (Excluding Exempt Population).
- Loans that have been repurchased.
- FHA loans originated by Correspondents that HUD has approved as mortgagee with designated underwriting authority (Table C).
- Loans where servicing was acquired under a Bifurcation agreement with Fannie Mae or Freddie Mac (Tables A,B)
- Securitizations with non-US mortgage collateral (Tables D,E)
- Loans for which the BHC's or IHC's contractual representation and warranty liability has been terminated by the statute of limitations, and no tolling agreement is in place (Tables D, E, and F). <sup>19</sup>
- Loans sold to Fannie Mae and Freddie Mac that have achieved Representations and Warranties Relief by meeting the criteria set forth under their ~~revised~~ Representations and Warranties frameworks (Tables A, B).

**Examples of Non-Exempt Population:** The non-exempt population includes all loans where the BHC or IHC has contractual representation and warranty liability. These loans should be reported in Tables A-F. Examples of the non-exempt population include the following:

- Loans subject to a pending litigation (including appeals) or ongoing settlement negotiations. This includes any settlements which have not yet been paid. BHCs or IHCs may report any reserves for pending settlements on Schedule E – Operational Risk (E.2 —BHC or IHC Legal Reserves Reporting).

---

<sup>18</sup> For these purposes, a judgment is final when the court of competent jurisdiction has entered judgment and any available appellate rights have been exhausted or waived. A settlement is final when any required payment has been made and any associated litigation claims have been withdrawn.

<sup>19</sup> We emphasize that firms must reach an independent legal determination as to which loan sale agreements are subject to the [2015 New York Court of Appeals ruling](http://www.courts.state.ny.us/ctapps/Decisions/2015/Jun15/850pn15-Decision.pdf) (<http://www.courts.state.ny.us/ctapps/Decisions/2015/Jun15/850pn15-Decision.pdf>).

- Loans with cured or rescinded repurchase requests.
- Loans paid in full unless they satisfy the exemption criteria defined above.
- USDA underwritten loans (Table C).

**Tables A through F:** For Tables A through F, data will be represented in two sections.

**Section 1: BHC OR IHC ABLE TO REPORT OUTSTANDING UPB AND DELINQUENCY INFORMATION REQUESTED**

The row variables for Section 1 identified in Tables A through F should be completed using the following categories:

**Original UPB:**

Report the original UPB of all of the loans, including closed loans.

**Original UPB (Excluding Exempt Population):**

Report the original UPB of the loans, including closed loans but excluding the exempt population.

**Outstanding UPB (Excluding Exempt Population):**

Report the outstanding UPB as of the reporting date, excluding the exempt population.

**Delinquency Status as of the reporting date (Excluding Exempt Population):**

Report the data as of the reporting date, excluding the exempt population as defined above. The table collects delinquency categories as defined above. The sum of the four delinquency categories listed below should equal the outstanding UPB reported for that age.

As part of Section 1 for Tables A through F, when reporting the row variable for this item, the following delinquency categories will be utilized:

- Current: The UPB of loans less than 30 days past due
- Past due 30 to 89 days: The UPB of loans 30-89 days past due
- Past due 90 to 179 days: The UPB of loans 90-179 days past due
- Past due 180+ days: The UPB of all loans that are 180 days or more past due and have not yet been fully charged-off

**Net Credit Loss Realized to-date (Excluding Exempt Population):**

Report cumulative net credit losses realized by investors in the loans through the as-of date, excluding the exempt population as defined above. Cumulative net credit losses are defined as cumulative collateral loss incurred to date. Refer to the FR Y-9C, Schedule HC-P, item 6 for a further definition of "credit loss".

**Repurchase Requests Outstanding (Excluding Exempt Population):**

Report Repurchase Requests Outstanding, which is the total UPB of the loans which the investor has requested a repurchase of the loan or indemnification for any losses but a resolution had not been reached as-of the reporting date. Note that this variable is by definition exclusive of the exempt population as defined above.

**Loss to-date Due to Denied Insurance and/or Indemnification (applicable to Table C.1 only):**

Report losses realized through the reporting date due to insurance claims denied by the US

Government due to an identified defect on the loan in question. Also include any losses incurred due to indemnification agreements that were established with the US Government on loans with identified defects.

## **Section 2: BHC OR IHC UNABLE TO REPORT OUTSTANDING UPB OR DELINQUENCY INFORMATION REQUESTED**

The row variables for Section 2 identified in Tables A through F should be completed using the following categories:

### **Original UPB:**

Report the original UPB of all of the loans, including closed loans.

### **Original UPB (Excluding Exempt Population):**

Report the original UPB of the loans, including closed loans but excluding the exempt population.

### **Outstanding UPB (Excluding Exempt Population):**

Report the outstanding UPB as of the reporting date, excluding the exempt population.

Data collected in Sections 1 and 2 should be mutually exclusive.

## **Table Instructions**

### **Tables A—Loans Sold to Fannie Mae (FNMA)**

### **Tables B—Loans Sold to Freddie Mac (FHLMC)**

### **Tables C—Loans Insured by the US Government**

Loans insured by the US Government include loans insured by the Federal Housing Administration (FHA) or the Farmers Home Administration (FmHA) or guaranteed by the Veterans Administration (VA) that back Government National Mortgage Association (GNMA) securities, i.e., “GNMA loans.” Include all loans insured by the US Government including those on balance sheet (including any GNMA buyouts or on-balance sheet FHA exposures) or sold into a GNMA security.

### **Tables D—Loans Securitized with Monoline Insurance**

Include loans packaged into a securitization and wrapped with monoline insurance. If it cannot be identified whether a given loan is monoline insured, include the loan in this category.

### **Tables E—Loans Securitized without Monoline Insurance**

Include loans packaged into a securitization but not wrapped with monoline insurance;

### **Tables F—Whole Loans Sold**

Include loans sold as whole loans to parties other than Fannie Mae or Freddie Mac, even if the whole loans were subsequently sold to Fannie Mae or Freddie Mac.

**Table H—Sold Loans Subject to Completed Settlements<sup>20</sup>**

Include original UPB of loans subject to completed settlements, by vintage and investor. Only include loans subject to settlements finalized on or before the 'as of' date. Loans reported in Schedule H should be reported as exempt on Tables A-F. Any loans subject to a pending settlement or a settlement occurring after the 'as of' date should not be included in Table H and should be included in Tables A-F. Table H and Tables A-F should be mutually exclusive. Please bifurcate the Original UPB of settlement exposures on Table H into loans with no remaining contractual representation and warranty (R&W) liability and loans with remaining R&W liability. Please also indicate the total settlement dollars paid by investor type, as well as the subset of total settlement dollars paid that is directly related to contractual R&W claims (excluding any penalties, fees, damages, etc).

---

<sup>20</sup> Completed Settlements are defined as settlements for which final judgment has been entered or final settlement has been reached. A judgment is final when the court of competent jurisdiction has entered judgment and any available appellate rights have been exhausted or waived. A settlement is final when any required payment has been made and any associated litigation claims have been withdrawn.

## **Appendix A: Supporting Documentation**

This appendix sets forth requirements and supervisory expectations related to supporting documentation for all BHCs and IHCs subject to the Y-14 reporting requirements. This document is primarily focused on helping to ensure that BHCs and IHCs subject to Y-14 reporting requirements provide accurate and comprehensive information for their Y-14 reports.

Large and complex firms and LISCC firms should provide the information set forth in this appendix A with their capital plan submission. In contrast, large and noncomplex firms should not provide this information in connection with their capital plan submission, but they may be required to produce these material upon request by the Federal Reserve.

In certain cases, this document describes additional expectations for certain capital planning practices to help support BHCs' and IHCs' Y-14 reporting. However, this document is not intended to describe the full set of expectations for capital planning. The full set of capital planning expectations have been consolidated in two Federal Reserve supervisory letters, SR Letters 15-18 and 15-19, issued in December 2015. Importantly, those two SR letters clarify that the capital planning expectations for LISCC and large and complex firms (as defined in those letters) are higher than the expectations for large and noncomplex firms (as defined in those letters). A BHC or IHC should refer to SR Letter 15-18 or SR Letter 15-19, as applicable, for the capital planning expectations applicable to that BHC or IHC (depending on the BHC's or IHC's size and complexity), as this document applies to all BHCs and IHCs subject to Y-14 reporting and does not differentiate between Large and Complex vs Large and Noncomplex Firms. To the extent that this appendix references expectations that may not applicable to a large and noncomplex firm pursuant to SR Letter 15-19, a large and noncomplex firm will not be held to those expectations but should instead refer to the expectations in SR Letter 15-19.

### Schedule A – Summary

For each part of the Summary Schedule, BHCs and IHCs must submit supporting documentation that clearly describes the methodology used to produce the BHC's or IHC's projections. The supporting documentation should include the following:

#### **Policies and Procedures**

BHCs and IHCs should submit all policies and procedures related to the capital adequacy process, including the BHC's or IHC's model risk-management policies. The model risk management policies should provide the BHC's or IHC's general framework for model development, implementation and use; model validation, and governance policies and controls (consistent with supervisory guidance on model risk management), including oversight by specifying criteria and controls across various stages of the model lifecycle (Identification; Inventory/ Tracking; Development and Documentation; Independent Validation; Approval for Implementation; Ongoing monitoring; Model Retirement).

#### **Documentation of Risk Measurement Practices**

Capital plan submissions should include documentation of key risk identification and measurement practices supporting the BHC-wide or IHC-wide stress testing required in the capital plans. BHC and IHC submissions should also include internal documentation describing the BHC's or IHC's

framework for development, calibration, estimation, validation, oversight, and escalation of key risk identification and measurement practices. As noted above, an assessment of the robustness of these practices is a critical aspect of the supervisory assessment of capital planning processes as outlined in SR 15-18 and 15-19.

### **Model and Methodology Inventory Mapping to FR Y-14A**

BHCs and IHCs should submit an inventory of all models and methodologies used to estimate losses, revenues, expenses, balances, and risk-weighted assets (RWAs) and the status of validation/independent review for each. The inventory should include mapping that clearly conveys the methodology used for each FR Y-14A product line under each stress scenario.

### **Methodology Documentation**

BHCs and IHCs should include in their capital plan submissions thorough documentation that describes and makes transparent key methodologies and assumptions for performing stress testing on their portfolios. This documentation should describe how the BHC or IHC translated the macroeconomic factors (or market shock for the Trading and Counterparty Risk sections) associated with the scenario into the BHC's or IHC's projections and technical details of any underlying statistical methods used, including information on model validation and independent review. Where judgment is an essential part of the projection, the methodology documentation should demonstrate the rationale and magnitude, as well as the process involved to ensure consistency of projections with scenario conditions. Methodology documentation should include, at a minimum, the following documents:

- **Methodology and Process Overview**

BHCs and IHCs should provide documentation that describes key methodologies, processes, and assumptions for performing stress testing on the BHC's or IHC's portfolios, business, and performance drivers. Documentation should clearly describe the model-development process, the derivation of outcomes, and validation procedures, as well as assumptions concerning the evolution of balance sheet and RWAs under the scenarios, changing business strategies, and other impacts to a BHC's or IHC's risk profile. Supporting documentation should clearly describe any known model weaknesses and how such information is factored into the capital plan.

- **Model Technical Documents**

BHCs and IHCs should submit model technical documentation for key models used to performing stress testing on the BHC's or IHC's portfolios. The documentation should include:

- A description of the model methodology;
- An explanation of the theory, logic, and design underlying the model methodology and support from published research and sound industry practice;
- A discussion of historical data set construction, including data sources, adjustments to the data set, and documentation validating the use of any external data;
- The rationale for portfolio segmentation and a discussion on how a particular methodology and model captures the key characteristics and the unique risk drivers of each portfolio segment;
- A description of model selection and specification, variable choice, and estimation methodology, including the statistical results used to arrive at the selected model;

- An analysis of the model output, including the congruence of inputs with the assumed economic scenario, the justification of any qualitative adjustment, along with the statistical analysis used to support the model output; and
- A model inventory log specifying, at a minimum, the model's version, the date of model approval, the date of its last revision, its intended use, the name of its model owner and developer, the model's priority, the date of the model's last independent validation, and the date of the model's next expected independent validation.

If third-party models are used, the documentation should describe how the model was constructed, validated, and any known limitations of the model. Documentation should clearly describe assumptions concerning new growth and changes to credit policy.

Supporting documentation should transparently describe internal governance around the development of comprehensive capital plans. Documentation should demonstrate that senior management has provided the board of directors with sufficient information to facilitate the board's full understanding of the stress testing used by the firm for capital planning purposes.

- **Model Validation and Independent Review**

Models employed by BHCs and IHCs (either developed internally or supplied by a vendor) should be independently validated or otherwise reviewed in line with model risk management expectations presented in existing supervisory guidance, including Supervisory Letter SR 11-7. Institutions should provide model validation documentation on the following elements: conceptual soundness, inputs, transparency, implementation, reporting, model robustness and limitations, use of expert judgment, exception reports, outcomes analysis (back testing and/or benchmarking) and qualitative adjustments.

Validation documentation should include the BHC's or IHC's assessment of the vulnerability of their models to error, an understanding of any of their other limitations, and consideration of the risk to the BHC or IHC should estimates based on those models prove materially inaccurate. Specifically, validation reviews should examine the efficacy of model use in both base case and stress scenarios. While the use of existing risk measurement models and processes provides a useful reference point for considering stress scenario potential loss estimates, validation efforts should consider whether these processes generate outputs that are relevant in a stressful scenario or if the use of models should be supplemented with other data elements and alternative methodologies. To the extent available, the above items should also be provided for any vendor supplied models used by the BHC or IHC, along with any third party validation documentation available for the vendor supplied model.

- **Audit Reports**

BHCs and IHCs should submit audit reports from their internal audit of the capital adequacy process including reviews of the models and methodologies used in the process. (See *"Capital Planning at Large Bank Holding Companies: Supervisory Expectations and Current Range of Practice"*).

- **Results Finalization and Challenge Materials**

BHCs and IHCs should ensure that they have sound processes for review, challenge and aggregation of estimates used in their capital planning processes. BHCs and IHCs should

submit documentation providing transparency into the review, challenge, and aggregation processes and the finalization of results.

Within this methodology documentation, BHCs and IHCs should provide credible support for all assumptions used to derive loss estimates, including assumptions related to the components of loss, severity of loss, and any known weaknesses in the translation of assumptions into loss estimates. BHCs and IHCs should demonstrate that these assumptions are clearly conditioned on the stated macroeconomic scenario, are consistent with stated business strategies, and reflect the competitive environment of each business line. If firm-specific assumptions (other than broad macroeconomic assumptions) are used, also describe these assumptions and how they relate to reported projections. If the BHC or IHC models rely upon historical relationships, provide the historical data and clearly describe why these relationships are expected to be maintained in each scenario. The impact of assumptions concerning new growth or changes to credit policy on forecasted loss estimates relative to historical performance should be clearly documented.

While judgment is an essential part of risk measurement and risk management, including for loss forecasting, BHCs and IHCs should not be over-reliant on judgment to prepare their loss estimations without providing documentation or evidence of transparency and discipline around the process. BHCs and IHCs should adequately support their judgments and should ensure that judgments are in line with scenario conditions. BHCs and IHCs should be consistently conservative in the assumptions they make to arrive at loss rates. Where appropriate, documentation should quantify the impact of qualitative adjustments from modeled output.

Furthermore, within this methodology documentation, BHCs and IHCs should include a thorough discussion of any material deviations from the instructions and how the materiality of such deviations was decided upon.

*Additional information to be included in the methodology documentation is described in more detail in sections A.1 – A.7 below.*

### **Consolidated Pro Forma Financials Methodology**

BHCs and IHCs should submit documentation that describes (1) how the various balance sheet and income statement line items were developed and reported, (2) the specific assumptions used to calculate regulatory capital, including a discussion of any proposed capital distributions, and (3) any other information necessary to understand the BHC's or IHC's capital calculations (e.g., calculations related to the projections of the deferred tax asset or servicing assets that may be disallowed for regulatory capital purposes). *Additional information to be provided as part of this documentation is outlined in section A.1 below for the FR Y-14A Income Statement, Balance Sheet, and Capital sub-schedules.*

### **Governance**

BHCs and IHCs should include in their submission supporting documentation that transparently describes internal governance around the development of stress testing models and methodologies, and discuss how the stress testing methodologies have been implemented in the BHC's or IHC's existing firm-wide risk management practices. Furthermore, documentation should include a discussion of the stress testing outcomes in terms of the nature of the portfolio and the modeled scenario. The BHC or IHC should demonstrate that senior management provided the board of directors with sufficient information to facilitate the board's full understanding of the stress testing

used by the firm for capital planning purposes and allow for the appropriate level of challenge of assumptions and outcomes.

### **A.1 – Income Statement, Balance Sheet, and Capital**

#### **Income Statement, Balance Sheet, and Capital Sub-schedules**

BHCs and IHCs should submit supporting documentation that clearly describes the methodologies used to make the loss, reserve change, and revenue projections that underlie the pro forma projections of equity capital. BHCs and IHCs may submit separate documents for different models/methodologies. Each BHC or IHC should include in its supporting documentation a clear description of how the various balance sheet and income statement line items were reported.

Provide information on the specific assumptions used to calculate regulatory capital, including a discussion of any proposed capital distributions. When appropriate, clearly state assumptions related to the corporate tax rate and the evolution of the deferred tax assets. In situations where the BHC or IHC chooses not to project components of the balance sheet, those components should be held constant at the last current level and the BHC or IHC should explain why the zero delta assumption is appropriate in the given scenario.

BHCs and IHCs should submit any other information and documentation necessary to support or understand its capital calculations. For example, a BHC or IHC could show the calculations related to the projections of the deferred tax asset or servicing assets that may be disallowed for regulatory capital purposes. Where applicable, BHCs and IHCs should link the additional supporting documentation to the Summary Memo of Capital Methodology and Assumptions and the Capital sub-schedule.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as follows using the metadata tags provided:

**Supporting Materials → Consolidated Pro Forma Financials Methodology → General**

If a BHC or IHC submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

### **A.2 – Retail**

BHCs and IHCs should submit separate documentation for their Retail-related projections. A BHC or IHC may submit separate documents for different models and/or methodologies. Documentation should be submitted for all aspects of the retail portfolio, including purchased credit impaired loans and mortgage repurchase risk. Mortgage repurchase documentation should include descriptions of all important assumptions made in each scenario, including, but not limited to, assumptions about legal process outcomes and counterparty behavior. All retail documentation should include documentation of assumptions, governance, validation and independent review as outlined in the Supporting Documentation section of the Overview.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Retail**

**Supporting Materials → Methodology Technical Document → Retail**

**Supporting Materials → Model Validation → Retail**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field

### **A.3 – Wholesale**

BHCs and IHCs should submit separate documentation for their Wholesale (Corporate and CRE) loan balances and loss projections. A BHC or IHC may submit separate documents for different models and/or methodologies. BHCs and IHCs should include supporting documentation that describes the key methodologies and assumptions for performing stress testing on each wholesale portfolio. Documentation should include an index of documents submitted, a general overview document providing a broad summary of the stress testing methodologies utilized, and detailed supporting documentation that clearly describe the model development process, the derivation of outcomes, and validation procedures as outlined below. The methodologies' formulaic specification, assumptions, numerical techniques, and approximations should be explained in detail with particular attention to both their merits and limitations.

Specifically, documentation should include:

- Discussion of historical data set construction, including data sources, adjustments to the data set, and documentation validating the use of any external data.
- Time period of model calibration.
- Rationale for portfolio segmentation and a discussion on how a particular methodology and model captures the key characteristics and the unique risk drivers of each portfolio segment.
- A description of how the loss estimates appropriately capture the severity of the macroeconomic scenario, reflecting both industry and borrower characteristics. Documentation should include a justification for explanatory variables selected, including coefficients from statistical models, measures of their statistical significance, and qualitative assessments where appropriate. Where relevant, descriptive statistics, including their mean, median, minimum, maximum, and standard deviation should be outlined.
- Step-by-step examples of loss calculation, including a transparent breakdown of all components of forecasted loss (i.e., probability of default, severity of loss, exposure at default) and how each component is adjusted for the given macroeconomic scenario.
- Discussion of how losses were distributed to each quarter in the forecasted period as it relates to changes in the macroeconomic factors within the modeled scenario.
- Qualitative or quantitative adjustment to main model output. Firms should perform pre-

adjustment/post-adjustment loss analysis and supply that analysis for material disparity.

Where the current total balances in the wholesale line items do not tie directly to the corresponding category on the FR Y-9C, BHCs and IHCs should provide a reconciliation which accounts for all wholesale balances. To the extent that loss projection line items include the consolidation of various loan portfolios which have different risk characteristics, supporting documentation should break out the relevant sub- portfolio losses. Furthermore, BHCs and IHCs should provide supporting documentation and forecasts for any wholesale loan portfolios acquired after the beginning quarter of the stress scenario and/or for loans covered by loss sharing agreements with the FDIC.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Wholesale**

**Supporting Materials → Methodology Technical Document → Wholesale**

**Supporting Materials → Model Validation → Wholesale**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

#### **A.4 – Loans Held for Sale and Loans Accounted for Under the Fair Value Option**

BHCs and IHCs should submit separate documentation for their Fair Value Option and Held for Sale retail and wholesale loans. A respondent may submit separate documents for different models and/or methodologies. The documentation should include:

- Total loss and outstanding fair market value balances segmented by Commercial/Wholesale, Commercial Real Estate and Retail along with explanation as to the main drivers of loss for each category noted above.
- Please document the amount of funded and non-funded commitments for wholesale loans and for retail loans please include the average amount of loans that had been rejected or were in not in conformance with agency standards.
- An attestation to completeness: describe the process and governance & oversight for ensuring the full set of positions were accounted for and included,
- Documentation should clearly make note of instances where different methodologies were used across different business lines with like assets,
- Documentation should make note where judgment was used in defining and allocating exposure,
- Where shocks were used that differed from prescribed shocks,
- Document approach and asset coverage under these approaches,
- Describe any additional broadening or simplification of the scenario done to get the requisite amount of granularity needed to run to scenario,
- Scenario design and choice for BHC or IHC scenario and method of application compared to the FRB scenario.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Wholesale or Retail**

**Supporting Materials → Methodology Technical Document → Wholesale or Retail**

**Supporting Materials → Model Validation → Wholesale or Retail**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

## **A.5 – AFS/HTM Securities**

Supporting documentation should clearly addresses the OTTI and OCI methodologies used by BHCs and IHCs to complete the FR Y-14A Summary schedule. The documentation should, at a minimum, address the questions outlined below by major product/portfolio type (e.g., non-agency residential mortgage-backed securities (RMBS), commercial mortgage-backed securities (CMBS), auto asset-backed securities (ABS), corporate bonds, etc.).

### **Projected OTTI for AFS Securities and HTM Securities by CUSIP**

#### **OTTI Methodology**

- Describe the model/methodology used to develop stressed OTTI losses. Please state whether a vendor or proprietary model was used.
- If a vendor model was used, please provide the name of the vendor model. If a vendor model was used, has the BHC or IHC performed an independent review of the vendor model?
- What data source(s) was used to estimate the model?
- What were the key inputs/variables and how were these determined? (e.g., how were default, severity, and other elements determined? What were the key inputs in determining default, severity, and other elements? What were the key assumptions and how were these assumptions determined?)
- If using a cash flow model, was a vendor or proprietary model used? If using a vendor model, please provide the name of the vendor and model.
- How did the model/methodology (whether vendor or proprietary) incorporate macroeconomic assumptions?
- If relevant, how were macroeconomic assumptions (as prescribed under the supervisory stress scenario) used to determine projected collateral default and severity?
- Were all securities reviewed for impairment? If not, describe the rationale, decision rule, or filtering process.
- If the threshold for determining OTTI on structured products was based on a loss coverage multiple, describe the multiple used.
- If OTTI was estimated for multiple quarters, describe the process for determining OTTI in each period of the forecast time horizon.
- Is the BHC or IHC using shortcuts or rules of thumb to recognize the OTTI charges for this analysis or going through the BHC's or IHC's normal process for recognizing OTTI charges?

If using shortcuts or rules of thumb, state how this process differs from the normal process for recognizing OTTI charges.

### **Fair Market Value Determination**

- If more than one third-party vendor is used as the principal pricing source for a given security, what are the criteria for determining the final price? (e.g., is a mean, median, weighting scheme or high/low price taken?) Is there a hierarchy of sources? If appropriate, describe responses by major product or portfolio type (e.g., non-agency RMBS, CMBS, Consumer ABS).
- If an internal model is used as the principal pricing source for a given security, are prices (from an internally created model) compared with third party vendor prices? If so, which vendors are used? If prices are not compared with third party vendors, state the reason. If appropriate, describe responses by major product/portfolio type (e.g., non-agency RMBS, CMBS, Consumer ABS.).
- Describe any additional adjustments made to prices determined by internal model(s) and/or third parties. How is the ultimate price determined?
- If an internal model is used as the principal pricing source for a given security, what are the primary market pricing variables used for fair value estimation?
- Describe briefly the BHC's or IHC's price validation and verification process. Provide readily available documentation related to the BHC's or IHC's price validation and verification process.

### **Projected OCI and Fair Market Value for AFS Securities**

- Describe the model/methodology used to develop stressed OCI losses. If appropriate, describe responses by major product or portfolio type (e.g., non-agency RMBS, CMBS, Consumer ABS). State whether the same model was used to derive OTTI losses. If not, detail the specific model/methodology and rationale for utilizing a different model.
- Detail if a vendor or proprietary model was used. If a vendor model was used, provide the name of the vendor model. If a vendor model was used, has the BHC or IHC performed an independent review of the vendor model?
- What data source(s) was used to estimate the model?
- What were the key inputs/variables and how were these determined? (e.g., how were fair value losses, and other elements determined?) What were the key inputs in determining OCI loss and how were they determined?
- If using a cash flow model, was a vendor or proprietary model used? If using a vendor model, please provide the name of the vendor and model.
- How did the model/methodology (whether vendor or proprietary) incorporate macroeconomic assumptions? How were macroeconomic assumptions (as prescribed under the supervisory stress scenario) used to determine projected OCI?
- Were all securities reviewed for OCI? If not, describe the rationale, decision rule, or filtering process. If OCI was estimated for multiple quarters, describe the process for determining OCI in each period of the forecast time horizon.
- Is the BHC or IHC using shortcuts or rules of thumb to recognize the OCI charges for this analysis or going through the BHC's or IHC's normal process for recognizing OCI charges? If using shortcuts or rules of thumb, state how this process differs from the normal process for recognizing OCI charges.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Securities**

**Supporting Materials → Methodology Technical Document → Securities**

**Supporting Materials → Model Validation → Securities**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

#### **A.6 – Trading**

- Documentation should include supporting details explaining the main drivers and attribution of loss for the overall trading and MTM loss estimate, and for each respective primary risk/business unit area details on the loss attribution by the primary risk factors.
- Documentation should provide a complete and technical definition of second and higher order risk factors (cross gamma, vanna, etc.) and describe the methods undertaken by the firm to estimate the cross gamma and higher order effects.
  - Estimate the contribution to total losses from higher-order risks.
- Describe the evolution of risk per each risk area two weeks before and after the submission date, i.e. make note of positions that may expire or terminate within this time frame that significantly alters a risk profile.
- Describe the process and governance & oversight for ensuring the full set of positions were accounted for and included and also please make note of differences in the products and/or exposures included in the FR Y-14Q vs. the FR Y-14A.
- A detailed and technical description of modeling methods (including pricing models) used,
  - Documentation should clearly make note of instances where different methodologies were used across different business lines with like assets.
  - Document approach (full revaluation vs. grid based approach, e.g.) and asset coverage under these approaches,
  - Please identify those products or exposures where the firm used models or systems that were outside of the normal routine stress testing framework for the FRB stress scenario and indicate if they were reviewed or validated by an independent Model Review function.
- The decision-making used for allocating exposures according to risk area. Documentation should make note where judgment was used in defining and allocating exposure per each risk area.
- Where shocks were used that differed from prescribed shock
- Describe any additional broadening or simplification of the scenario done to get the requisite amount of granularity needed to run to scenario,
- Scenario design and choice for BHC or IHC scenario and method of application compared to the FRB scenario.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Trading**

**Supporting Materials → Methodology Technical Document → Trading**

**Supporting Materials → Model Validation → Trading**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

#### **A.7 – Counterparty Credit Risk**

Instructions related to supporting documentation requirements for FR Y-14A Schedule A.5 can be found in the Supporting Documentation appendix of the FR Y-14Q instructions.

#### **A.8 – Operational Risk**

The reporting institution should provide any supporting information including statistical results, data, summary tables, and additional descriptions in a separate document and cross reference the document to the respective question/item. BHCs and IHCs may submit separate documents for different models and/or methodologies.

##### **Documentation**

Generally, a BHC or IHC should have robust internal controls governing its operational risk loss projection methodology and process components, including sufficient documentation, model validation and independent review. Supporting documentation should cover all models, loss and resource forecasting methodologies and processes. Adequate documentation includes comprehensive and clear policies and procedures. For models, adequate documentation includes specific delineation of all key assumptions for projecting operational losses under each scenario, a description of the underlying operational risk data used to determine projected losses and the approach for translating the data into loss projections. If a budgeting process was used, the BHC or IHC should describe the budgeting process and provide specific detail on how operational losses are estimated. Adequate documentation includes articulating the models' vulnerability to error, and estimates of an error's impact should parameter specifications prove inaccurate. Documentation of all models should clearly identify the exact statistical process employed by the BHC or IHC including:

1. How the current set of explanatory factors was chosen, what variables were tested and then discarded, and how often the set of possible explanatory factors is reviewed and, if appropriate, **revised**;

2. If applicable, description of work the BHC or IHC has done to assess relationships between macroeconomic factors and operational risk losses, including relationships that were found to have the highest level of dependency, a summary of statistical results, and how these results were incorporated in the estimates;
3. A discussion of how pending litigation and reserves for litigation were incorporated into operational loss projections for all requested scenarios;
4. A detailed, transparent, and credible description of the foundation, approach, and process for making management adjustments to modeled results;
5. A description of the methodology for allocating an operational loss amount to a particular quarter;
6. An explanation summarizing the reasonableness of results, how they differ from expectations, and what the BHC or IHC does when the results are deemed "unreasonable";
7. A description of internal controls that ensure the integrity of reported results and that all material changes to the process and its components are appropriately reviewed and approved. BHCs and IHCs should ensure that change control principles apply to forecasting models used in the stress scenario analysis program, including processes that rely on management judgment;
8. An assessment of how effective or accurate the model is;
9. Identification of possible drawbacks and limitations of the selected approach.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Operational Risk**

**Supporting Materials → Methodology Technical Document → Operational Risk**

**Supporting Materials → Model Validation → Operational Risk**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology in the Comment field.

#### **A.9 – Pre-Provision Net Revenue (PPNR)**

Each methodological memo should clearly describe how a BHC or IHC approached the PPNR projection process and translated macro-economic factors into the reported projections. Separate documents may be submitted for different models and/or methodologies.

#### **Projected Outcomes**

- 1) Provide an explanation summarizing the reasonableness of projected outcomes relative to the stated macroeconomic scenario, business profile, as well as regulatory and competitive environment. Especially in the more adverse scenario(s), include substantial supporting evidence for PPNR estimates materially exceeding recently realized values.
- 2) BHCs and IHCs should discuss linkages between PPNR projections and the balance sheet as well as other exposure assumptions used for related loss projections.

- 3) Include discussion of PPNR outcomes by component (i.e. Net Interest Income, Non Interest Income, and Non Interest Expense) and by major source of each component (e.g. by major balance/rate category, type of revenue/expense, and/or business activity).
- 4) Consideration should be given to how changes in regulation will impact the BHC's or IHC's revenues and expenses over the projection period. The memo should include a section that addresses how recent or pending regulatory changes have impacted projected figures and business strategies and in which line items these adjustments are reflected.

## **Models and Methodology**

- 1) The documentation should include a full list of all models and parameters used to generate projections of PPNR components for CCAR purposes and whether these models are also used as part of other existing processes (e.g. the business-as-usual budgeting and forecasting process). Where existing processes are leveraged, discuss how these are deemed appropriate for stress testing purposes, including any modifications that were necessary to fit a stressful scenario.  
Also discuss those items that are particularly challenging to project and identify limitations and weaknesses in the process.
- 2) Thorough discussion of use of management/expert judgment, including information about rationale and process involved in translation of macroeconomic scenario variables into projections of various PPNR components should be provided. Where a combination of a modeled approach and management judgment was used to project an item, quantify the impact of qualitative adjustments to modeled output.
- 3) Provide support for all key assumptions used to derive PPNR estimates, with a focus on the link of these assumptions to projected outcomes and whether the assumptions are consistent with the stated macroeconomic scenario, regulatory and competitive environment as well as business strategies for each of major business activities.  
Document the impact of assumptions concerning new growth, divestitures or other substantial changes in business profile on PPNR estimates. In cases where there is a high degree of uncertainty surrounding assumptions, discuss and reference sensitivity of projections to these assumptions. Also ensure that all relevant macro-economic factors used for PPNR projections are also reported on the firm submitted Scenario Schedule.
- 4) In addition to broad macro-economic assumptions that will guide the exercise, it is expected that more specific assumptions will be used by BHCs and IHCs in projections of PPNR, including macro-economic factors other than those provided by the Federal Reserve System as well as BHC and IHC specific assumptions. Such assumptions and their link to reported figures, standardized and/or BHC/IHC business segments and lines should be discussed in the methodology memo.
- 5) Where historical relationships are relied upon (e.g. ratios of compensation expense to total revenues), BHCs and IHCs are expected to document the historical data used and describe why these relationships are expected to hold true in each scenario, particularly under adverse conditions.
- 6) Projecting future business outcomes inevitably relies on the identification of key relationships between business metrics and other explanatory variables. Key limitations and difficulties encountered by the BHC or IHC in the process to model these relationships should be identified and discussed in the memo.

7) Highlight changes in various aspects of BHC's or IHC's PPNR forecasting models and methodology, primarily focusing on the changes that occurred since the last CCAR submission.

### **Projections Governance and Data**

- 1) BHCs and IHCs are asked to describe governance aspects for the PPNR projections development. This includes but is not limited to a description of:
  - a. The roles of various business lines and management teams involved in the process
  - b. How the projections are generated. Particular attention should be given to how the BHC and IHC ensures that assumptions are consistent across different business line projections, how assumptions are translated into projections of revenue and expenses, and the process of aggregating and reporting the results.
  - c. Senior management's involvement of the process and the process in which the assumptions are vetted and challenged.

Also note whether established policies and procedures are in place related to this process.

- 2) Also include a separate section devoted to any divergence from the instructions in completing the PPNR sub-schedules in the FR Y-14A and FR Y-14Q Schedules. Use this section to explain any data that is missing or not provided as requested. Use this section to discuss major instances where judgment was used to interpret PPNR instructions.
- 3) Discuss general data validation and reconciliation practices here as they pertain to FR Y-14Q/A submissions. PPNR is defined as the sum of net interest income and non-interest income net of non-interest expense, with components expected to reconcile with those reported in the FR Y-9C when adjusted for certain items (see "Commonly Used Terms and Abbreviations" section of FR Y14-Q/A PPNR instructions for guidance for such items). BHCs and IHCs are encouraged to include information allowing confirmation that the data were reported per the PPNR definition. Documentation should discuss consistency of a given schedule with the BHC's or IHC's external reporting and internal reporting and forecasting. Provide a description of broadly-defined types of business models currently used (e.g. Asset/Liability, Relationship, Business Product/Services/Activity as defined or named by the BHC or IHC). Provide reconciliation between BHC or IHC reporting used to manage and forecast operations and a standardized business segment/line view required for FR Y-14A reporting. Note if allocation methodologies were used when providing data for PPNR sub-schedules in FR Y-14A/Q Schedules.
- 4) Highlight changes in various aspects of BHC's or IHC's PPNR forecasting governance and data, primarily focusing on the changes that occurred since the last CCAR submission.

### **Other**

- 1) BHCs and IHCs are also expected to address items requested in the Supporting Documentation portion of the Overview section (beginning on page 4) as applicable to PPNR if not already addressed per PPNR documentations guidance as stated above.
- 2) Other sections of the FR Y-14A and FR Y-14Q PPNR Instructions request additional information and supporting documentation. Please ensure that these items are also

referenced and described in this memo. For example, include a discussion of small/medium/large business segmentation, as noted in section "B. PPNR Projections Sub-schedule."

3) BHCs and IHCs are encouraged to submit any other information and documentation (including data series) that would support the BHC's or IHC's PPNR projections. One example of such information would be identification and discussion of major deviations of BHC or IHC historical performance from forecasted figures, focusing on the last four quarters and noting items that the BHC or IHC regards as non-recurring and/or non-core. Where applicable, it would be useful to reference this additional supporting information in the memo outlined above

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → PPNR/Balance Sheet**

**Supporting Materials → Methodology Technical Document → PPNR/Balance Sheet**

**Supporting Materials → Model Validation → PPNR/Balance Sheet**

If a respondent submits separate documents for different models and/or methodologies, please identify the model and/or methodology as one of the following types in the Comment field:

1. Net interest income and banking book balances,
2. Trading and investment banking revenue and related balances, and
3. All other non-interest income, non-interest expense, and other balances.

## **A.10 – MSR Projection Documentation**

Supporting documentation should address the questions outlined below.

### **1. Models and Methodologies**

- Describe the models and related submodels that were used to complete the submission, and please state whether the model is a third-party vendor or proprietary model.
  - Income/Expense/Valuation Engine
  - Prepayment Model
  - Default Model
  - Delinquency Model
  - Hedging Simulation
- If a vendor model was used, please provide the name of the vendor model. If a vendor model was used, has the BHC or IHC performed an independent review of the vendor model?
- Has the model undergone rigorous model validation, with results reviewed independently of the business line?
- Has any performance testing been conducted on the model? If so, what type of performance testing has been conducted?
- What data sources were used to calibrate each model?

- What were the key inputs/variables and how were these determined?
- How did the model (whether vendor or proprietary) incorporate macroeconomic assumptions?

## 2. Assumptions

- For each quarter, what new loan capitalizations and amortizations are assumed over both the baseline and supervisory stress scenarios?
  - How were the new loan capitalization forecast assumptions developed?
  - What excess spread assumptions were made with respect to new loan capitalizations in each scenario and how was this assumption derived (e.g., historical buy-up/buy-down grids, etc.)?
  - How were HARP assumptions, if any, estimated?
  - What market share is assumed, and does this change within the stress scenario?
  - Does the submission include any MSR sales or purchases under the supervisory stress? If yes, please provide detail.
- What is the composition of the underlying portfolio of loans serviced for others with respect to the following, and how does this composition change (if at all) during the supervisory stress scenario?
  - i. Loan type
  - ii. Geographical region
  - iii. FICO score
- How were macroeconomic assumptions as prescribed under the supervisory baseline and stress scenarios used to determine the respective projected loan prepayment, delinquency, and default experience for each quarter?
- How were macroeconomic assumptions that were not prescribed under the supervisory baseline and stress scenarios (for example, interest rate volatility, option adjusted spreads, primary to secondary spreads) used to determine the respective projected loan prepayment, delinquency, and default experience for each quarter?
- What are the voluntary prepayment speeds (e.g., conditional prepayment rates (CPRs) associated with refinancing) assumed for each quarter in the respective baseline and supervisory stress scenarios? Do not include constant default rates (CDRs).
- What are the factors that drive or explain the level and trend in prepayment speeds through the nine quarters over the baseline and supervisory stress scenarios?
- What are the default rates assumed for each quarter in the respective baseline and supervisory stress scenarios?
- What are the factors that drive or explain the level and trend in default rates through the nine quarters over the baseline and supervisory stress scenarios?
- How were the assumptions regarding cost of service with respect to both the baseline and stressed scenarios derived?
- Was inflation incorporated into the projection?
- What is the servicing cost structure on a per loan basis on a base and incremental basis for each level of delinquency? What are the foreclosure costs per loan?
- Does the cost structure per loan stay the same throughout the nine quarters with the number of delinquent loans changing, or do both change?
- What foreclosure time frames are used in the baseline scenario? Do these lengthen or contract in the supervisory stress?
- Is late fee income included in the submission?
  - If so, what is the BHC's or IHC's actual late fee income structure, as well as waiver policy if applicable?

- What is the late fee income assumed in the baseline and stress scenarios?
- Is it assumed that late fees are 100% collectable in the stress scenario?
- Are earnings on escrow and other balances included in the submission?
  - If yes, how are the balances forecasted, and what is the crediting rate?
- Is cost to finance advances to investors relating to delinquent loans incorporated in the submission?
  - If yes, how is the borrowing rate determined?

### 3. Hedging and Rebalancing

- Are MSR hedges assumed to be rebalanced or rolled-over at any time during the nine quarter CCAR horizon? How often are hedges assumed to be rebalanced or rolled-over? What is the timing of such rebalancing or roll-over trades?
- What are the hedge rebalancing and/or roll-over rules applied during the baseline and stress scenarios?
- Are the hedge rebalancing and/or roll-over rules applied in the baseline and stress scenarios consistent with the firm's risk appetite statement and Board/management approved limit structure?
- To what degree does hedge effectiveness decline in the stress scenarios? How was this estimated?
- How is the impact of hedging instrument bid-ask spreads captured in the submission? To what degree does the bid-ask spread widen in the stress scenario? How was this estimated?
- How does the firm account for the liquidity risk from concentrated hedge positions?
- What is assumed regarding collateral requirements?
- What are the current risk tolerance limits with respect to MSR hedging

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → PPNR/Balance Sheet**

**Supporting Materials → Methodology Technical Document → PPNR/Balance Sheet**

**Supporting Materials → Model Validation → PPNR/Balance Sheet**

In the Comment field, please identify the document as "MSR".

## A.11 Documenting Consideration of Certain Off-Balance Sheet Risks

Supporting documentation should clearly highlight how each institution (i) identified unconsolidated entities and sponsored products to which the Firm has potential exposure, (ii) evaluated those entities / sponsored products under stressed scenario conditions, and (iii) projected and reported any associated financial losses – whether in the form of non-contractual support or reflected elsewhere in PPNR (e.g., foregone revenue).

1. *Identification:* The submission should include a complete inventory of all off-balance sheet entities and sponsored products. Those assessed collectively may be aggregated for the purposes of reporting the information requested below, except that all investment

management products that seek to maintain a stable net asset value (NAV) should be listed separately. Please include, at a minimum, the following information related to unconsolidated entities / sponsored products:

- Product category. For example, Asset-Backed Commercial Paper conduits, Real Estate Investment Trusts, Hedge Funds, SEC-registered mutual funds, Collective Investment Funds, etc.
- Total assets by product or category (for those that are aggregated).
- Revenues earned by product or category for the most recent four quarters and a description of the nature of such revenues.
- Product name and/or unique identifier for those listed separately
- For stable NAV funds only, the regulatory framework by which each product is offered. For example, Investment Company Act of 1940, Rule 12 CFR 9.18, etc.

Each firm should also include a brief description of the process utilized to develop the inventory.

2. *Evaluation Methodology:* Clearly describe the methodology that was applied to the inventory in order to determine the unconsolidated entities / sponsored products for which there is a potential for non-contractual support, for example based on client expectations. This should include even those entities / sponsored products which the firm may choose not to support but such a decision could lead to lost revenues and/or other costs. Indicate the resulting decision for each product or category.
3. *Determination of Related Losses:* For each unconsolidated entity / sponsored product for which it was determined that a client expectation of non-contractual support may exist:
  - a) Describe the expected impact of macroeconomic and/or idiosyncratic stress factors to these entities / sponsored products.
    - This might include, but is not limited to, market value shocks, increased redemption activity, rollover risk, counterparty-default-related losses, etc.
    - Critical assumptions such as assumed counterparty LGD rates, velocity of redemptions amid stress, and nature of market shocks should be highlighted.
  - b) Describe the decision framework applied in determining whether non-contractual support would be provided and include a discussion of the identified costs/benefits related to each decision by major category and/or product.
  - c) Quantify and provide calculations of any related financial losses expected to be borne by the firm either in the form of non-contractual support or lost revenues and legal/operational costs and provide related calculations of those losses.
    - This should include both direct impacts (e.g., product closure and/or potential litigation costs) and indirect (i.e., second-order) impacts, such as lost revenue in other products that results from client attrition, where a decision to not support has been applied.
  - d) Clearly indicate the line items within the Y-14A summary schedule where such projected financial losses have been recorded.

### **Schedule B – Scenario**

No supporting documentation is required for this schedule.

### **Schedule C – Regulatory Capital Instruments**

No supporting documentation is required for this schedule.

### **Schedule D – Regulatory Capital Transitions**

#### **Additional Information Required for SIFI Surcharge**

In November 2011, the Basel Committee on Banking Supervision (BCBS) published its methodology for assessing an additional loss absorbency requirement for global systemically important banks (SIFI surcharge) that effectively serves as an extension of the capital conservation buffer. **As part of the FR Y-14A filing, each BHC and IHC must submit a separate document that includes management's best estimate of the likely SIFI surcharge that would be assessed under this methodology, along with an explanation of assumption used when determining the estimate.** Any BHC or IHC not currently designated as a global systemically important financial institution (G-SIFI) should include a SIFI surcharge assessment if management expects changes to its business model that would potentially lead to the BHC's or IHC's designation as a G-SIFI. Supervisors will evaluate the methodology and assumptions used by BHCs and IHCs in determining the SIFI surcharge, and may adjust such estimates as necessary when evaluating the **Revised** Capital Framework transition path.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as one of the following three document types (defined in the CCAR 2016 Summary Instructions and Guidance) using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Regulatory Capital**

**Supporting Materials → Methodology Technical Document → Regulatory Capital**

**Supporting Materials → Model Validation → Regulatory Capital**

In the Comment field, please identify the document as "SIFI surcharge".

Note that if this information is already included the BHC's or IHC's CCAR Capital Plan, then the BHC or IHC has the option of simply including text that clearly describes location of this information (e.g. file name, document page number, section title, etc.). If the BHC or IHC uses this option, the document should still use the naming convention described above.

#### **Additional Information Required for Each Planned Action (Tied to Sub-schedule 6) for FR Y-14A submission**

BHCs and IHCs are required to provide a detailed description of each planned action in a separate attachment(s). The description of each planned action should include:

- Discussion of how each planned action aligns with the BHC's or IHC's long term business strategy and risk appetite on a going concerns basis;
- Assessment of each planned action's impact on the BHC's or IHC's capital and funding needs, earnings, and overall risk profile;
- Assessment of market conditions and market capacity around each planned action (e.g., planned sale size and the availability and appetite of buyers and other potential sellers);
- Assessment of any potential execution risks to each planned action (e.g., contractual, accounting or structural limitations). The estimation of execution risk should be well documented for each planned action that are to occur;

Discussion of any recent transactions conducted either by the BHC or IHC or by other institutions that would demonstrate or support the BHC's or IHC's ability to execute each planned action at the level of impact projected.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as follows using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Regulatory Capital**

In the Comment field, please identify the document as "Planned Capital Action" and include the appropriate "Action #" in column A of the Planned Actions Sub-schedule.

Included below are examples of other supporting documentation which should be included along with the description of each planned action:

- Detailed information on planned sales such as risk profile and size of the positions, indicative term sheets and contracts; potential buyer information; current marked to market (MTM), support for the execution price; potential associated loans, financing, or liquidity credit support arrangements; potential buy back commitments; and impact on any offsetting positions. If similar recent transactions have taken place, BHCs and IHCs should provide information as a point of reference. BHCs and IHCs should also describe any challenges that may be encountered in executing the sale.
- Detailed information on planned unwinds, such as risk profile and size of the positions, profit and loss (P&L) impact at execution or in the future; funding implications; impact on any offsetting positions; and trigger of consolidation or on-boarding of the underlying assets.
- Detailed information on planned run-offs, such as risk profile and size of the positions, impact on any offsetting positions; details on trades; and maturity dates.
- Detailed information on planned hedging, such as indicative term sheets and contracts; P&L impact at execution or during life of the hedges; and impact on counterparty credit RWA.
- Detailed information on changes to risk-weighted assets calculation methodologies, such as which data or parameters would be changed, whether the firm has submitted model application to its supervisors, and remaining work to be completed and expected completion date.
- Detailed information on expanded use of clearing houses, such as types of products to be cleared and central counterparties to be used.

BHCs and IHCs should also provide detailed information on any alternative Regulatory Capital Transitions action plans in the event the firm falls short of the targets outlined in the Capital Plan, and trigger events that would result in a need to pursue any alternative action plans.

**IntraLinks Instructions:** When uploading the supporting documentation to the IntraLinks collaboration site, supporting documents for this specific area should be categorized as follows using the metadata tags provided:

**Supporting Materials → Methodology and Process Overview → Regulatory Capital**

In the Comment field, please identify the document as "Regulatory Capital Transitions action plan".

**Schedule E – Operational Risk**

No supporting documentation is required for this schedule.